Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE)¹⁻⁵

Daniel J Raiten,⁶ Fayrouz A Sakr Ashour,⁶ A Catharine Ross,⁷⁻⁹ Simin N Meydani,¹⁰ Harry D Dawson,¹¹ Charles B Stephens,¹² Bernard J Brabin,¹³,¹⁴ Parminder S Suchdev,¹⁵ Ben van Ommen,¹⁶ and the INSPIRE Consultative Group

¹Essence Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD; Departments of ¹²Nutritional Sciences and ¹ Veterinary and Biomedical Science and ¹³Center for Molecular Immunology and Infectious Disease, Pennsylvania State University, University Park, PA; ¹⁴Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA; ¹⁵USDA–Agricultural Research Service, Beltsville Human Nutrition Research Center, Diet, Genomics, and Immunology Laboratory, Beltsville, MD; ¹⁶Agricultural Research Service, Western Human Nutrition Research Center, USDA, Davis, CA; ¹¹Child and Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdoms; ¹⁶Global Child Health Group, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; ¹³Department of Pediatrics and Global Health, Emory University, Atlanta, GA; and ¹⁶TNO, Zeist, The Netherlands

Abstract

An increasing recognition has emerged of the complexities of the global health agenda—specifically, the collision of infections and noncommunicable diseases and the dual burden of over- and undernutrition. Of particular practical concern are both 1) the need for a better understanding of the bidirectional relations between nutritional status and the development and function of the immune and inflammatory response and 2) the specific impact of the inflammatory response on the selection, use, and interpretation of nutrient biomarkers. The goal of the Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE) is to provide guidance for those users represented by the global food and nutrition enterprise. These include researchers (bench and clinical), clinicians providing care/treatment, those developing and evaluating programs/interventions at scale, and those responsible for generating evidence-based policy. The INSPIRE process included convening 5 thematic working groups (WGs) charged with developing summary reports around the following issues: 1) basic overview of the interactions between nutrition, immune function, and the inflammatory response; 2) examination of the evidence regarding the impact of nutrition on immune function and inflammation; 3) evaluation of the impact of inflammation and clinical conditions (acute and chronic) on nutrition; 4) examination of existing and potential new approaches to account for the impact of inflammation on biomarker interpretation and use; and 5) the presentation of new approaches to the study of these relations. Each WG was tasked with synthesizing a summary of the evidence for each of these topics and delineating the remaining gaps in our knowledge. This review consists of a summary of the INSPIRE workshop and the WG deliberations. J Nutr 2015;145:1039S–108S.

Keywords: nutrition biomarkers, inflammation and nutrition, immune function and nutrients, BOND and inflammation/infection, assessment of micronutrient biomarkers

PART I: EXECUTIVE SUMMARY OF THE INSPIRE PROJECT

A. Introduction

The recent publication of the 2010 Global Burden of Disease (GBD)¹⁷ analyses (1) and the launch of the new series on maternal and child nutrition (2) highlight the current trends in global health, particularly as they affect the “1000 day” period of pregnancy through an infant’s first 2 y of life. As itemized in Text Box 1, the following is apparent:

¹Presented at The Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE) meeting, held at the NIH in Bethesda, MD, 28–30 November 2012. INSPIRE is housed under the parent Iron and Malaria Project, which receives its core funding from the Bill and Melinda Gates Foundation and the Office of Dietary Supplements, NIH. The views expressed are those of the authors. The Supplement Coordinator for this supplement was Fayrouz A Sakr Ashour. Supplement Coordinator disclosures: no conflicts of interest. This supplement is the responsibility of the Guest Editor to whom the Editor of the Journal of Nutrition has delegated supervision of both technical conformity to the published regulations of The Journal of Nutrition and general oversight of the scientific merit of each article. The Guest Editor for this supplement was Kevin L. Schalinske. Guest Editor disclosure: no conflicts of interest. Publication costs for this supplement were defrayed in part by the payment of page charges. This publication must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, Editor, or Editorial Board of The Journal of Nutrition.
Great strides have been made in reducing the impact of undernutrition on child health, but stunting and undernutrition remain major targets for the global health community.

An alarming trend has emerged in the global prevalence of overweight and obesity (10) across the life course.

This trend has extended into low-/middle-income countries (LMICs), historically the focus of efforts to address undernutrition.

The prevalence of noncommunicable diseases (NCDs), cardiovascular diseases (CVDs), cancers, chronic respiratory diseases, and diabetes is increasing globally and prominently in LMICs.

Communicable infectious diseases (CIDs), including HIV, malaria, tuberculosis, and diarrheal disease, remain daunting public health concerns, again hitting LMICs hardest.

2 Supported by the parent grant The Iron and Malaria Project, which is funded by the Bill and Melinda Gates Foundation, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the NIH Division of Nutrition Research Coordination, and the Office of Dietary Supplements. This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/license/) that permit unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3 Author disclosures: DJ Raiten, FA Sakr Ashour, AC Ross, SN Meydani, HD Dawson, CB Stephens, BJ Brabin, PS Suchdev, and B van Ommen, no conflicts of interest.

4 The contents of this article are the result of the deliberations and work of the INSPIRE Thematic Working Group members and chairs and do not necessarily reflect the opinions of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the NIH, or the Department of Health and Human Services. In addition, individual members of the Working Group may not endorse all statements in this report.

5 Supplemental Figures 1–3 and Supplemental Tables 1–9 are available from the “Online Supporting Material” link in the online posting of the article and from the same link in the online table of contents at http://jn.nutrition.org.

6 To whom correspondence should be addressed. E-mail: raitend@mail.nih.gov.

7 Abbreviations used: ACT, α-acid glycoprotein; apABG, α-acid glycoprotein; apAAG, α2-acid glycoprotein; APC, antigen-presenting cell; APP, acute phase protein; APr, acute phase response; ATRA, all trans retinoic acid; BOND, Biomarkers of Nutrition for Development; CAMP, cathelicidin antimicrobial peptide; CEBPB, cCAAT/enhancer binding protein β; CD, cluster of differentiation; CDK4/5, cyclin-dependent kinase inhibitor 1A/1B; CID, communicable infectious disease; CMI, cell-mediated immunity; COPD, chronic obstructive pulmonary disease; CPg, cytokine-phosphatase-guanine; CRP, c-reactive protein; CRP, C-reactive protein; CYP, cytochrome P450; CXCL8, C-X-C motif chemokine 8; Ddx5, distal-less homeobox 5; DTH, delayed-type hypersensitivity; EE, environmental enteropathy; EGF, estimated glomerular filtration rate; EOA, external quality assessment; EP, erythrocyte protoporphyrin; ESR, erythrocyte sedimentation rate; FoxP3, forkhead box P3; GSTP1, glutathione S-transferase pi 1; HDX, homeobox; HPA, hypothalamic-pituitary-adrenal; ID, iron deficiency; IFABP, intestinal fatty acid binding protein; IFNγ, interferon γ; INSPIRE, Inflammation and Nutritional Science Programs/Policy and Interpretation of Research Evidence; kDa, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; KDM6B/JMJD3, lysine (K)-specific demethylase 6B; LINE, long interspersed element; LMIC, low-/middle-income country; MCP, monocyte chemoattractant protein; MFO, mixed function oxidase; MIF, migration inhibitory factor; MIP-1α, macrophage inflammatory protein 1α; mRNA, messenger RNA; MLLS, methyltransferase 5; MMA, methylmalonic acid; MRDR, modified relative dose response; NCD, noncommunicable disease; NFκB1, Nuclear factor NF κB p50 subunit; NICHD, National Institute of Child Health and Human Development; OLD, obstructive lung disease; pABG, p-amino-phenylglycylate; PBMC, peripheral blood mononuclear cell; PCT, procalcitonin; PEM, protein-energy malnutrition; poly-2F, poly-zinc-finger; RA, retinoic acid; RARE, retinoic acid receptor; RARE, retinoic acid receptor-ε; RBP, retinol binding protein; RDR, relative dose response; REL, v-rel avian reticuloendotheliosis viral oncogene homolog; RELA, v-rel avian reticuloendotheliosis virus oncogene homolog; RET, ret proto-oncogene; ROS, reactive oxygen species; RRX, retinoid X receptor; SAA, serum amyloid A; SAP, serum amyloid P component; SCMM, subclinical mastitis; SES, socioeconomic status; SET, Sulvah/3–9, Enhancer of Zeste, Trithorax; SNS, sympathetic nervous system; SSC, Scientific Steering Committee; sTIR, soluble transferrin receptor; Th, T-helper; TLR, Toll-Like receptor; TNFA, tumor necrosis factor α; Treg, T-regulatory; VAD, vitamin A deficiency; VDD, vitamin D deficiency; VDR, vitamin D receptor; VDRE, vitamin D response element; VEGF, vascular endothelial growth factor; WBC, white blood cell; WG, working group; 2nd, zinc deficiency; ZPP, zinc protoporphyrin; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D.

In most settings, a collision is occurring of CIDs, NCDs, food insecurity, and malnutrition within the same population and, in many settings, in the same individuals [malnutrition = over- and/ or undernutrition, reflecting an imbalance of total energy, macronutrients (protein, fat, carbohydrate), vitamins, and/or minerals].

This collision, including the dual burden of over- and undernutrition, is just beginning to be addressed in any meaningful manner (11-14). All of these trends have significant implications both in terms of their impact on the population and the health systems designed to combat them. How to assess this complex scenario is one of the great challenges confronting the global health community.

From a biological perspective, 2 common threads run through all of these problems: the importance of nutrition and the role of inflammation. For any of these global health concerns, a strong nutrition component exists both in terms of the role of nutrition in susceptibility to and prevention and treatment of the disease, as well as an outcome of the condition, i.e., the impact of each of these on nutritional endpoints (intake, status). Inflammation is also recognized as a common feature of both CIDs and NCDs (15, 16). Moreover, we have learned that nutrition and inflammation also share a bidirectional relationship where each affects the other in ways that we are just beginning to appreciate (17).

For the purpose of this review (see Supplemental Figure 1 for a table of contents), important definitions and terminologies are provided in Text Box 2.

Our ability to delineate a clear role for nutrition in any disease is complicated by the impact of inflammation. This effect can occur as a result of the role of a given nutrient biomarker as an “acute phase protein” rising or falling in response to inflammation, or as a result of a direct impact of inflammation on nutrient absorption or homeostasis. Our understanding of the bioavailability of any of these conditions, CIDs or NCDs, and the role of either nutrition or inflammation, demands a better appreciation of these complex interactions.

Once understood, the challenge then becomes the determination of effective strategies to account for them for both individuals and populations.

Of particular concern to those attempting to determine the nature of the nutrition and health relationship is the fact that both acute and chronic inflammation may have a direct impact on the selection, use, interpretation, and use of any of the biomarkers that has thus far been problematic in understanding the bioavailability of any of these conditions, CIDs or NCDs, and the role of either nutrition or inflammation.

The complexity of this interaction continues to pose a dilemma for clinicians trying to determine the nutritional needs of their patients as well as for those planning or evaluating programs to ameliorate malnutrition at a population level. This conundrum has become a prominent driver of efforts to discover, develop, and implement new biomarkers of nutrition, including the efforts of such leading technical agencies as the CDC and the WHO charged with providing advice to those conducting surveys at regional or national levels (26).

B. Birth of INSPIRE

The challenges outlined above have also become obstacles in global policy to address specific conditions. A prominent example is the situation arising from concerns about the safety and effectiveness of interventions to prevent and treat iron deficiency (ID) in malaria-endemic areas (27). Historical concerns about iron in the context of infection were heightened in response to a study (28) reporting that universal iron supplementation during
Text Box 1  Trends highlighted in the GBD 2010 (1)

- Although the proportion of overall disease burden attributable to childhood underweight has more than halved between 1990 and 2010, it remains the eighth risk factor worldwide.
- High BMI has increased globally to become the sixth greatest risk factor worldwide.
- Among children <5 y old, childhood underweight was still the leading risk factor worldwide in 2010, followed by nonexclusive or discontinued breastfeeding and household air pollution from solid fuels.
- High blood pressure, high BMI, and high fasting blood glucose have all increased significantly in terms of their impact on global health between the 1990 and 2010 GBD analyses.
- Deaths from NCDs increased by ~8 million between 1990 and 2010, accounting for 2 of every 3 deaths (34.5 million) worldwide in 2010. Of these, 8 million people died of cancer (38% more than in 1990), 12.9 million died of ischemic heart disease and stroke collectively [1 in 4 worldwide compared with 1 in 5 in 1990; 1.3 million deaths were due to diabetes, twice as many as in 1990 (1)].

Additional global health data

- More than 35 million people now live with HIV/AIDS; 3.3 million of them are under the age of 15 (3).
- In 2012, 2.3 million people were newly infected with HIV; 260,000 were under the age of 15.
- In 2012, 1.6 million people died of AIDS; 210,000 of them were under the age of 15 (4).
- In 2012, malaria caused an estimated 627,000 deaths (with an uncertainty range of 473,000–789,000), mostly among African children (5).
- In 2012, there were ~207 million cases of malaria with ~80% of cases limited to 17 countries, most prominently in Africa.
- The tuberculosis death rate decreased by 45% between 1990 and 2012 (6). Nevertheless, in 2012 there were ~8.6 million new cases of tuberculosis and 1.3 million deaths (7).
- More than 95% of tuberculosis deaths occur in LMICs, and it is among the top 3 causes of death for women aged 15 to 44 (7).
- Diarrhea kills 2195 children every day—more than AIDS, malaria, and measles combined (8).
- Diarrheal diseases account for 1 in 10 child deaths worldwide (~760,000/y), making diarrhea the second leading cause of death among children under the age of 5 (9).

Text Box 2  Definitions and terminology

Acute phase response (APR):

- An innate body defense that triggers a sequence of physiologic changes in response to a myriad of stressors, including microbial invasion, tissue injury, immunologic reactions, and inflammatory processes (18–20).
- Begins when activated macrophages, primed by IFN-γ, release a complex network of cytokines such as TNF-α, IL-1, and IL-6. Cytokines then stimulate hepatocytes in the liver to produce the acute phase proteins (see Working Group 1) (21–23).

Acute phase proteins:

- More than 200 plasma proteins are modulated by the APR (18).
- Functions include anti-proteinase activity, coagulation properties, transport functions, immune response modulation, and/or miscellaneous enzymatic activity to restore the delicate homeostatic balance disturbed by trauma or infection.

Classification:

- Positive or negative, reflecting their respective increase or decrease in response to the APR.
- Early, intermediate, or late, reflecting differential time course and differential magnitude of change in response to the APR.
- Type 1, stimulated by TNF and/or IL-1, or type 2, stimulated by IL-6.

Acute inflammation:

- A physiologic response to infection or tissue injury that is usually self-limiting and resolves rapidly, allowing the body to remain healthy and maintain homeostasis.

Chronic inflammation:

- Inflammatory responses that fail to regulate themselves become chronic and contribute to the continuation of the “disease” condition in the body; conditions of chronic inflammation include NCDs (cancer, CVD, diabetes, obesity, autoimmune diseases).

Clinical inflammation:

- Based on whether the individual has clear symptoms of the inciting cause of inflammation (e.g., clinical disease or trauma), for example, fever. It can be either acute (e.g., active malaria) or chronic (e.g., latent infection with tuberculosis).

Subclinical inflammation:

- Has 2 phases and is characterized as follows:
  - Initial phase: there is a short (24–48 h) incubation period during which the pathogen can multiply or invade tissues; this initial phase may or may not be followed by clinical symptoms.
  - Second phase: occurs during convalescence after an acute illness.
- Inflammation may be covert if the infection is minor or the body’s immunity is particularly effective in preventing the disease and able to isolate the cause of the infection, preventing clinical inflammation.
- In both phases, subclinical inflammation may only be detected biochemically (24). The biochemical changes in inflammatory biomarkers during subclinical inflammation strongly relate to alterations in many nutrient biomarkers. Hence, detecting the presence of subclinical inflammation using inflammatory biomarkers in apparently healthy people is important in population studies.
early childhood increased the risk of severe morbidity and mortality from malaria and other infections, particularly when supplements were given to individuals who were not iron-deficient. In response to these concerns, the WHO/CDC amended existing guidance with regard to use of iron supplements to include the caveat that, in areas of endemic malaria, iron status should be assessed before interventions (26). Aside from obvious challenges of invasive blood sampling and capacity needs for such a large undertaking, the predominant method for assessing iron nutrition, serum ferritin measurement, is affected by the presence of inflammation.

In response to the specific issues around the iron and malaria question, a collaboration was initiated between the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the US NIH and the Bill and Melinda Gates Foundation, Clinical Nutrition Development (NICHD) to address the following objectives: 1) identification and clarification of biological mechanisms affecting iron metabolism (in both host and infectious organisms) in malaria-endemic areas and 2) development of biomarkers/indicators to assess iron status in women, infants, and young children, including biomarkers of exposure, status, and function that can be used in the context of inflammation/infection.

In addition, the NICHD has also partnered with the Bill and Melinda Gates Foundation and others to initiate the Biomarkers of Nutrition for Development (BOND) Program (29). The goal of the BOND program is to service the food and nutrition community by providing evidence-based advice about the best choice of biomarkers for specific uses and to address key gaps in our knowledge about how best to assess the role of nutrition in health. Phase I of the BOND program included an evaluation of 6 nutrients—zinc, iron, folic acid, vitamin B-12, vitamin A, and iodine—chosen on the basis of input from the SSC. These WGs met via teleconference 2 to 3 times to further refine the suggested outline and to begin the process of drafting the WG reports. A content-focused INSPIRE workshop was convened in Bethesda, MD, 28–30 November 2012. This focused INSPIRE workshop was convened in Bethesda, MD, 28–30 November 2012. This provided WG members with the opportunity to invite others in areas identified as relevant to the WG deliberations as well as experts to provide additional insights about specific issues in need of in-depth coverage. To address overlapping and cross-cutting issues, the WGs were encouraged to closely collaborate in order to avoid redundancy and to maintain a logical train of thought across the WGs. The objectives of the workshop were as follows: 1) to present preliminary results of WG deliberations, 2) to discuss cross-cutting issues to avoid overlap, and 3) to exchange ideas and obtain experts’ perspectives on specific topics identified by the WG.

Deliberations from the INSPIRE workshop supported the process of developing the final WG summary reports. Discussions reinforced the notion of this effort as a progression of thought from an understanding of the basic biology of inflammation/infection and nutrition and culminating in suggestions about how best to account for these interactions in making clinical and programmatic

---

### Text Box 3 INSPIRE WG themes

<table>
<thead>
<tr>
<th>WG theme 1: overview of the role of nutrition in immune function and the inflammatory response</th>
</tr>
</thead>
<tbody>
<tr>
<td>WG theme 2: specific relations between nutrients, immune function, and inflammatory response—impact of nutrition on the immune response</td>
</tr>
<tr>
<td>WG theme 3: specific relations between nutrients, immune function, and inflammatory response—impact of the immune response on nutrition</td>
</tr>
<tr>
<td>WG theme 4: translating evidence to practice—approaches to addressing the nutrition and inflammation relations</td>
</tr>
<tr>
<td>WG theme 5: methodologies and new technologies including the potential use of systems biology and new “omics” technologies for discovery of new biomarkers</td>
</tr>
</tbody>
</table>
decisions based on the interpretation of extant data. Finally, attention was paid to the identification of new technologies and science that might be applied to further our understanding of these relations.

These proceedings include a brief summary of the INSPIRE workshop, manuscripts provided by invited speakers, and the final WG reports. The summaries of deliberations of WGs 1–4 are presented in detail below. Highlights of WG 5 are found in the text below the description of that section of the workshop.

**III. Summary of the INSPIRE workshop.** The INSPIRE workshop opened with an overview provided by the SSC co-chairs, Drs. Catharine Ross and Simin Meydani, and the NICHD Secretariat, Dr. Daniel Raiten. The first session included presentations by Stephen Hursting who reviewed the current knowledge with regard to the relation of inflammation and chronic disease (31). This was followed by a review of immunology, mucosal immunobiology, innate immunity, and response to pathogens provided by Dr. Kelsall’s review which included a coverage of key elements of the immune response including the biology and factors affecting the induction of IgA (32), an introduction to various aspects of the role of the gut microbiota in immune function (33, 34), and a brief discussion of inflammatory bowel disease as an exemplar of how these factors may interact in a clinically relevant manner (35). See Supplemental Figure 2 for the complete meeting agenda.

Each session that followed focused on the INSPIRE themes. The theme 1 session began with an overview of “the role of nutrition in immune function and the inflammatory response” by Dr. Harry Dawson who emphasized several key elements to consider including the following: 1) contributory factors to the inability to translate research findings into clinical practice, 2) the importance of the choice or choices of species used to model human responses, 3) challenges associated with defining nutrient status in the context of the APR and its impact on selection and interpretation of biomarkers of nutrient status, and 4) recognition that the effect of nutrition on specific immune response pathways is related to many factors, including the severity of deficiency, presence of other deficiencies, presence of other infections, age, genetics, etc. Dr. Kate Claycombe followed with an overview of the role of nutrition in the genetics and epigenetics of inflammation (36).

The next set of content sessions focused on the bidirectional relations between nutrition and inflammation. Dr. Zulficar Bhutta began the discussion with an overview of nutrition, immune function, inflammation, and infant health from a global perspective (37) followed by an overview of the current understanding of the relations between nutrition, the microbiome, gastrointestinal immunity, and inflammation (38). In addition to providing coverage of the extant knowledge regarding these relationships, Dr. Duffy (38) highlighted some seminal questions for future attention including 1) can functional “meta-omics” approaches lead to informed understanding of microbial roles in digestion and metabolism, 2) will understanding how foods shape the microbiota lead to healthier lifestyles across generations, and, 3) what roles will the biological action of small molecules produced by probiotic strains play in health and disease?

The following session addressed the converse of the relation, i.e., the impact of inflammation on nutrition. The opening presentation was provided by Dr. Patrick van Rheenen, who covered the clinical utility of currently available biomarkers of gut wall integrity. He provided insights about the general relations between malnutrition, gastrointestinal integrity, and inflammation. This was followed by a discussion of the utility of 3 specific biomarkers in that context: measurement of citrulline as a reflection of intestinal integrity (39, 40); intestinal FA binding protein (I-FABP) (41), also a marker of gastrointestinal integrity; and fecal calprotectin, a potential early signal for intestinal inflammation (42).

Clinical implications of the relations between nutrition and metabolic correlates of inflammation were the subjects of the presentation by Dr. Liza Makowski (43). Dr. Makowski and colleagues explored the interactions between oxidative stress, inflammation, and such clinical outcomes as obesity and diabetes. Their article is a summary of their work indicating that certain obesogenic dietary patterns drive a tissue-specific increase in oxidative damage that may affect functionality. Their animal models offer potential mechanisms by which oxidative stress via activation of inflammatory responses can affect insulin signaling, glucose intolerance, and diabetes (43).

As outlined above, the goals of the INSPIRE initiative are to present the extant knowledge with regard to what we know about the relations between nutrition, immune function, and inflammation but also to evaluate best ways to translate that information into practical application. The session on translation included 2 presentations that addressed the latter.

In the field of clinical nutrition, much attention has been generated by the observations linking inflammation to performance and the interpretation of available biomarkers used to assess of specific nutrients (25). One of the leaders in the effort to address this conundrum is Dr. David Thurnham who provided an overview of the state of the science and strategies for addressing this complex dilemma in nutrition (25). The second talk in this session was a discussion of mathematical/statistical approaches to addressing inflammation/nutrition provided by Dr. Ravi Varadhan.

One of the highlights of all of the presentations was a discussion of the exciting new developments in approaches to studying these complex interactions. The final session of the workshop included presentations that highlighted some of these new innovative approaches. Beginning with an overview by Ben van Ommen of how best to apply systems biology to the question of nutrition and inflammation, the session concluded with coverage of the current understanding of proteome dynamics presented by Dr. Mark Hellerstein. These presentations and the subsequent deliberations were seminal in stimulating discussions about the application of these new technologies to the study of nutrition and inflammation and to reinforce the notion that the evaluation of the role of nutrition must be conducted in a more physiologic context that moves away from the “siloed” single-nutrient approach that has predominated the field to date. The deliberations of the last WG included listing a series of core questions that might be addressed by using a “systems biology” approach outlined in Text Box 4.

To move this agenda forward, this WG described a 2-step process that includes the following:

- **Research phase focusing on the development of the systems “model” that can utilize existing and emerging approaches including various “-omics” approaches (proteomics, genomics, metabolomics) and computational systems approaches.** The WG highlighted the need to explore relations at various levels of complexity and integration (e.g., intracellular, local tissues, and systemic, including signaling processes) and can develop a complex bioinformatics infrastructure. The essential elements of this infrastructure consist of 3 essential components:
PART II: WG REPORT SUMMARIES

The following are reports summarizing the deliberations of the 4 WGs. The INSPIRE Secretariat drafted these reports on the basis of the deliberations of each of the WGs, with the goal of presenting a progression of thought beginning with an overview of the basic biology describing the relations between nutrition, immune function, and inflammation (WG 1), followed by overviews of the bidirectional nature of these relations [i.e., the impact of nutrition on immune function/inflammation (WG 2) and the impact of inflammation, both acute and chronic, on nutrition (WG 3)], and concluding with a focus on the translation of the extant knowledge to develop some potential approaches to addressing these relations specifically as they pertain to clinical/population-based assessment (WG 4). Accompanying each summary is a list of research priorities identified by the WGs. The INSPIRE organizers and Secretariat gratefully acknowledge the efforts and input of the WGs in the development of these reports.

II. Innate immune and barrier function.

Much is known about the intimate and inextricable role of nutrition in immunity and/or inflammation (44); however, few studies describe nutrient-mediated immunomodulation in humans. This review contains an overview of several key elements of the nutrition-inflammation nexus including the following: an examination of the roles of specific micronutrients and their interactions in dependent pathways, the potential effects of genetics and epigenetics in determining the effects of nutrition on immunity and inflammation, and coalescing all of this knowledge into a description of the nature and impact of the APR. This overview is intended to provide context for the subsequent discussions by the other WGs involved in the INSPIRE review and concludes with a summary of suggested research priorities. The case study nutrients covered in this review are vitamin A, iron, zinc, vitamin D, folate acid, and selenium and were chosen on the basis of their public health importance and because they provide the most relevant evidence with regard to their known effect on immunity.

A. WG theme 1: overview of immune function, inflammation, role of nutrition, and considerations for further study

Objective: The objective was to review the basic biology that characterizes the relations between nutrition, immune function, and inflammation and the relative strengths and weaknesses of current approaches to research. WG 1 summary and conclusions are provided in Text Box 5.

I. Introduction. Much is known about the intimate and inextricable role of nutrition in immunity and/or inflammation (44); however, few studies describe nutrient-mediated immunomodulation in humans. This review contains an overview of several key elements of the nutrition-inflammation nexus including the following: an examination of the roles of specific micronutrients and their interactions in dependent pathways, the potential effects of genetics and epigenetics in determining the effects of nutrition on immunity and inflammation, and coalescing all of this knowledge into a description of the nature and impact of the APR. This overview is intended to provide context for the subsequent discussions by the other WGs involved in the INSPIRE review and concludes with a summary of suggested research priorities. The case study nutrients covered in this review are vitamin A, iron, zinc, vitamin D, folate acid, and selenium and were chosen on the basis of their public health importance and because they provide the most relevant evidence with regard to their known effect on immunity.

II. Innate immune and barrier function. Innate immunity, also referred to as nonspecific immunity, is the first line of defense against invading pathogens and consists of anatomic barriers and humoral and cellular components (Text Box 6).
Tables 1 and 2 summarize data from animal and human models, respectively, with regard to the impact of specific nutrients on aspects of innate immunity. The key points from animal studies include the following:

- Protein-energy malnutrition (PEM) has its largest effect in reducing barrier function, both epithelial (47–52) and physiologic (53–55), followed by the function of macrophages (56–59), neutrophils (60–65), and to a lesser extent, NK cell activity (66).
- Vitamin A and zinc deficiencies have effects similar to PEM (67–77), with the exception that NK cell (but not macrophage) function is reduced by VA deficiency (VAD) (78, 79). Physiologic barrier function is not markedly affected by either vitamin A or zinc.
- Vitamin D deficiency (VDD) has modest effects on innate immunity, with the greatest effect seen on macrophage function (80–86).
- ID primarily affects neutrophil function with less significant effects on macrophage bacteriocidal function (see “Potential Points of Interaction between Micronutrients Involved in Dependent Pathways” below).

The key points from human studies include the following:

- PEM has the largest effect on aspects of innate immunity than do any of the nutrients covered. PEM reduces epithelial (87–92) and physiologic (93–97) barrier function as well as the function of macrophages (95, 98) and neutrophils (62, 99–101). NK cell activity is also affected to a lesser extent (66).

Text Box 1 summary and conclusions
- A large body of literature documents the interactions between nutrition and the immune and/or inflammatory response.
- The nexus of much of this interaction is within the constellation of immunologic/neuroendocrinologic responses to stress referred to as the “APR.”
- The APR has profound consequences that affect both metabolism and nutritional homeostasis and the ability to assess nutrient status vis-à-vis concentrations of biomarkers mobilized during an APR.
- Specific immune and inflammatory pathways that are affected by single nutrients remain largely undefined, which limits the ability to translate the evidence into clinical use.
- Factors contributing to this inability are reviewed and include the following:
  - choice or choices of species used to model human responses,
  - difficulty in defining human nutrient status in clinical settings due to confounding effects of the APR,
  - the concurrent presence of multiple nutrient deficiencies, and
  - an emerging appreciation of interactions with the microbiome.
- This review includes information on the role of specific case study nutrients (vitamin A, vitamin D, zinc, iron, selenium, folic acid) in dependent pathways.
Conclusions: Some useful consensus exists between animal and human models as well as human-specific pathways. Suggestions are offered for a focused research agenda that includes an expanded exploration of the effects of genetics and epigenetics in these relations.

Text Box 6 Components of the innate immune system
- Anatomic barriers include the following:
  - skin
  - mouth and nose
  - gastrointestinal tract
  - respiratory tract
  - eyes
- Inflammation: stimulated by infection/injury involving the release of chemical mediators to initiate the APR, etc.
- Physiologic barriers include the following:
  - temperature
  - pH
  - oxygen tension
  - production of proteins such as lysozyme, complement and antimicrobial components of the APR such as C-reactive protein (CRP), serum amyloid A (SAA), α1-acid glycoprotein (AGP), cathelicidins, and defensins
- Complement system: responses that support both innate and adaptive/cellular immunity and consists of >30 membrane-bound and soluble plasma proteins, is activated in a cascade-like manner, and is responsible for the detection and removal of foreign entities/pathogens or marking them for attack (45, 46)
- Cellular components of the innate immune response:
  - mast cells
  - phagocytes, including macrophages, neutrophils, dendritic cells
  - basophils and eosinophils
  - NK cells
  - γδ T cells

- Vitamin D deficiency (VDD) has modest effects on innate immunity, with the greatest effect seen on macrophage function (80–86).
- ID primarily affects neutrophil function with less significant effects on macrophage bacteriocidal function (see “Potential Points of Interaction between Micronutrients Involved in Dependent Pathways” below).

The key points from human studies include the following:

- PEM has the largest effect on aspects of innate immunity than do any of the nutrients covered. PEM reduces epithelial (87–92) and physiologic (93–97) barrier function as well as the function of macrophages (95, 98) and neutrophils (62, 99–101). NK cell activity is also affected to a lesser extent (66).
VAD is primarily manifested through compromised epithelial barrier function (67, 102–105) with a minimal effect on NK cell activity (105–107).

Zinc deficiency (ZnD) primarily compromises epithelial barrier (108), macrophage (95), and neutrophil function (109–111).

VDD in humans has a modest effect on innate immunity, with the exception of macrophage function and production of cathelicidins and defensins (112).

ID primarily affects neutrophil function.

As a result of increased interest in the activities of vitamin D beyond the traditional focus on bone/calcium, an important new understanding of vitamin D’s role in immune function has emerged. Liu et al. (113) described a vitamin D–dependent pathogen-sensing axis in human macrophages that highlights the importance of vitamin D in innate immunity. They also described a potential disparity in this response that could explain differences in susceptibility to infections on the basis of racial/genetic background. In essence, they described an innate immune response involving activation of Toll-like receptors (TLRs) to trigger direct antimicrobial activity against intracellular bacteria that is mediated by NO in murine models but not in humans. In this newly observed model in human macrophages, TLR activation upregulates the expression of the vitamin D receptor (VDR) and the Vitamin D-1-hydroxylase genes, leading to induction of the antimicrobial peptide cathelicidin and killing of intracellular bacteria such as *Mycobacterium tuberculosis*. This is a primate-specific response (114) and is greatly influenced by cytokines such as IL-4 and IFN-γ. Initially, these observations were restricted to monocytes and macrophages; however, recent studies showed that cathelicidin antimicrobial peptide (CAMP) is induced by vitamin D in keratinocytes and respiratory and bladder epithelial cells (113). These data are derived from cell culture models. In vivo data are emerging that support vitamin D–dependent induction of cathelicidin in skin and peripheral blood monocytes by administration of large amounts of vitamin D to humans (115).

## III. Acquired immune function: animal and human studies.

### a. NF-κB signaling and induction and maintenance of T-regulatory cells. NF-κB function and mechanism of activation are described in Text Box 8.

#### i. Nutrients and NF-κB signaling.

Several hundred mediators of NF-κB signaling pathways have been described in the literature (117), including almost all essential nutrients and >100 bioactive food components. Some specific effects of nutrients include the following:

- **Vitamin A**: increased NF-κB occurs during experimental VAD in mice (118) that is normalized by all *trans* retinoic acid (ATRA) administration. Mechanistic evidence for in vitro vitamin A–inhibited basal and LPS, TNF-induced NF-κB activation (119) includes
  - Retinoic acid receptor (RAR) α–mediated reduction in p65 protein (118) and
  - Ligand-dependent cytoplasmic sequestration of p50/p65 by retinoi X receptor (RXR) (120).

- **Vitamin D**: mechanisms of vitamin D–mediated inhibition of NF-κB signaling include:
  - Inhibition of v-rel avian reticuloendotheliosis viral oncogene homolog (*Rel*) transcription by competitive binding of VDR/RXR binding to the Rel promoter (121),
  - Induction of *IκBα* (122) and inhibition of *IκBα* degradation (123), and
  - Hyperactivation of NF-κB occurs in VDR knockout mice (124).

### TABLE 1 Strength of evidence: impact of micronutrient deficiencies on nonspecific or innate immunity (animal studies) 1

<table>
<thead>
<tr>
<th>Micronutrient Deficiency</th>
<th>PEM Deficiency</th>
<th>Vitamin A Deficiency</th>
<th>Vitamin D Deficiency</th>
<th>Zinc Deficiency</th>
<th>Iron Deficiency</th>
<th>Folate Deficiency</th>
<th>Selenium Deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epithelial barrier function</td>
<td>++++</td>
<td>++++</td>
<td>—</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>?</td>
</tr>
<tr>
<td>Physiologic barriers</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>—</td>
<td>?</td>
</tr>
<tr>
<td>Macrophage function</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Neutrophil function</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>NK cell function</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>?</td>
</tr>
</tbody>
</table>

1 PEM, protein-energy malnutrition; —/+ mixed evidence; +, weak evidence; ++, partial evidence; +++, good evidence; ++++, strong evidence; ?, no studies.

### TABLE 2 Strength of evidence: impact of micronutrient deficiencies on nonspecific or innate immunity (human studies) 1

<table>
<thead>
<tr>
<th>Micronutrient Deficiency</th>
<th>PEM Deficiency</th>
<th>Vitamin A Deficiency</th>
<th>Vitamin D Deficiency</th>
<th>Zinc Deficiency</th>
<th>Iron Deficiency</th>
<th>Folate Deficiency</th>
<th>Selenium Deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epithelial barrier function</td>
<td>++++</td>
<td>++++</td>
<td>—</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>?</td>
</tr>
<tr>
<td>Physiologic barriers</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>—</td>
<td>?</td>
</tr>
<tr>
<td>Macrophage function</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Neutrophil function</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>NK cell function</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>?</td>
</tr>
</tbody>
</table>

1 PEM, protein-energy malnutrition; —/+ mixed evidence; +, weak evidence; ++, partial evidence; ++++, good evidence; ++++, strong evidence; ?, no studies.
**Text Box 7  Acquired or adaptive immunity**
- Is not inherited
- Can be active, resulting from the development of antibodies in response to an antigen, as from exposure to an infectious disease or through vaccination, or passive, resulting from the transmission of antibodies, as from mother to fetus through the placenta, via breastfeeding or by the injection of antiserum
- Components of the acquired immune system include T and B lymphocytes that are derived from the same hematopoietic stem cells in bone marrow and morphologically indistinguishable until after they are activated

**Antigen-presenting cells**
To distinguish between "self" and a foreign or deranged cell, certain cells, e.g., dendritic cells, B cells, and to a lesser extent, macrophages, are equipped with special "costimulatory" features that are recognized by receptors on T cells

**B cells**
- Function in the humoral immune response
- Are the source of immunoglobulins or antibodies, the function of which is to identify and neutralize foreign objects: the 5 types of antibodies are IgA, IgD, IgE, IgG, and IgM

**T cells**
- T precursors (or progenitors) migrate from the bone marrow to the thymus where they are called thymocytes and where they develop into T cells
- Cytotoxic T cells (TCs, killer T cells, or cytotoxic T lymphocyte (CTLs)) induce the death of cells that are infected with viruses (and other pathogens) or are otherwise damaged or dysfunctional
- Helper T cells (cluster of differentiation (CD) 4⁺ lymphocytes) are not cytotoxic but facilitate those processes via expression of T cell receptors (TCRs) that recognize antigens; CD4 cells require a smaller stimulus for activation than cytotoxic T cells
- The activation of a naïve helper T cell causes it to release cytokines, which influence the activity of many cell types, including the antigen-presenting cells that activated it
- Helper T cells can provide extra signals that "help" activate cytotoxic cells

**Zinc:** it can inhibit or stimulate NF-κB signaling in vitro depending on the cell type and stimulus used (125). The following zinc effects have been reported:
- Hyperactivation of NF-κB occurs in zinc-deficient mice in response to sepsis (126).
- In humans, the generation of TNF by peripheral blood mononuclear cells (PBMCs) in response to LPS is reduced by short-term zinc deprivation.
- Bioinformantics analysis indicated that NF-κB binding to its cognate element is reduced by ZnD (127).
- IL2 gene expression is decreased in zinc-deficient humans (128). Interestingly, this relation and its correction are proposed as a potential biomarker for ZnD in a manner analogous to the classic enzyme stimulation assay for vitamins (vitamin B-6, thiamin, and riboflavin). However, due to the lack of specificity (i.e., IL-2 expression is affected by several other nutrients), this is unlikely to assume a significant role as a specific zinc biomarker.

**Vitamin E:** inhibition of NF-κB by such antioxidants as vitamin E has been shown to occur via multiple mechanisms (129).

**b. Induction and maintenance of T-regulatory cells.**
T-regulatory (Treg) cells play an integral role in self-regulatory processes through their involvement in both shutting down immune responses after successful elimination of pathogens and in preventing autoimmunity (130, 131). Members of the Treg cell family are numerous, but the best-characterized are those that express CD4, CD25, and forkhead box P3 (FoxP3). Again, specific nutrients have been implicated in various aspects of Treg activity.

**i. Role of vitamin A in Treg activity.** Mouse gut dendritic cells generate ATRA in response to specific stimuli such as TLR2 ligands (132). This locally generated ATRA imparts gut homing specificity to T and B cells. ATRA is also essential for the generation of gut-homing FoxP3-expressing Treg cells (133). The generation of ATRA was originally thought to be restricted

**Text Box 8  NF-κB function and mechanism of activation**

**Function**
- Serves as a major transcription factor that coordinates the innate and adaptive immune response
- NF-κB binding is necessary, but not sufficient, to regulate the expression of several thousand genes including the proinflammatory cytokines IL-1β, TNF, and IL-6 (116)

**Mechanism**
- NF-κB is activated upon ligation of the T cell receptor, B cell receptor, or one of the many TLRs as well as in response to proinflammatory cytokines, mitogens, growth factors, and oxidants
- Activation of NF-κB is a multistep process involving the following:
  - degradation of inhibitory subunit [most commonly nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IkBa)], leading to
  - "activation" of a 2-protein complex [most commonly p50 Nuclear factor NF-kappa-B (NFκB1)/p65 rel avian reticuloendotheliosis (RELA)].

This complex migrates to the nucleus and binds to DNA in the promoter region of genes, and initiates transcription.
to gut dendritic cells. However, recent data indicate that other cytokines, such as IL-3 or IL-4, stimulate such other cells as macrophages (134), basophils (135), and stellate cells (136) to produce ATRA, leading to the generation of FoxP3-expressing Treg cells in tissues such as lung and liver.

The induction and maintenance of Treg cells by ATRA is extremely complex, and >200 studies, most using mice, have been published to date. Certain aspects of this process are species-specific. For example, the FoxP3 protein, the master regulatory transcription factor in determining Treg differentiation, is transiently induced upon human, but not mouse, T cell activation (137). The mouse FoxP3 gene contains 3 functional retinoic acid response elements (RAREs), 2 in the promoter region and 1 in the enhancer region (138). Although treatment of human T cells with ATRA or with an RAR-α agonist induces histone acetylation at the FoxP3 gene promoter and FoxP3 expression (139), demonstration of an RARE in human FoxP3 has not been reported to date. Last, only 18% of the nearly 5000 predicted FoxP3 DNA-binding sites are conserved between species (140).

**ii. Role of vitamin D in Treg activity.** The mouse and human FoxP3 promoters also contain functional vitamin D response elements (VDRs) (141, 142). Increased FoxP3 expression has been reported after in vitro treatment of human and mouse T cells with 1,25-dihydroxyvitamin D [1,25(OH)2D]. The situation in vivo may be more complex, because mice with a T cell–targeted knockdown of the VDR manifested no change in the frequency or function of peripheral FoxP3+CD4+ T cells. These observations suggest a dominant influence on Treg induction by non–T cells (143). In vivo data for vitamin A– and vitamin D–dependent induction of Tregs in humans are emerging but are extremely difficult to establish methodologically because of the likely need to obtain biopsied materials (144–146).

**iii. Role of other nutrients in Treg activity.** In addition to vitamins A and D, other nutrients may affect the induction of Tregs. Tregs in mice express high levels of the folate receptor (147), and gut Treg induction depends on dietary folate (148). The zinc finger domains of FOXP3 are required for its function, and approximately one-half of the transcription factors that regulate FOXP3 contain zinc. However, zinc-deficient animals have normal numbers of Tregs (149).

**c. Nutrients and the acquired immune system.** As outlined in Table 3 and documented in Supplemental Tables 2–8, studies in animal models have revealed the following:

- **PEM and deficiencies of vitamin A, zinc, or iron have a robust, albeit variable effect in reducing antigen-presenting cell (APC) function (150–160).**
- **PEM and vitamin A, zinc, and iron deficiencies exert their greatest effect on reducing CD4+ T cell function (79, 161, 162). Proliferation is often reduced, and polarization to a particular antigen is reduced/alterned (163–165).**
- **VAD causes reduced trafficking of T and B cells to tissues (158, 166, 167).**
- **CD8+ T cell function is the least studied of the major components of acquired immunity.**
- **VDD has a modest effect on cell-mediated and humoral immunity with the greatest effect seen on APC and T cell function (85, 168–173). In particular, NK T cell development in mice is critically dependent on vitamin D (173).**

The data from human studies, presented in Table 4, reveal the following:

- **Only PEM has evidence attesting to an effect in reducing human APC function (174).**
- **PEM and vitamin A and zinc deficiencies have their largest effect in reducing CD4+ T cell function (98).**
- **There are suggestions of reduced proliferation for all 3 and modest evidence of alteration in polarization for VAD and supplementation (106).**
- **VDD has a relatively minor effect on cell-mediated and humoral immunity in humans, with the greatest effect seen on APC and T cell function (175, 176).**
- **ID primarily affects CD4+ T cell function, with a lesser effect on B cell function and no conclusive evidence with regard to its impact on APCs (177–181).**
- **Megaloblastic anemia due to folate acid deficiency has been associated with depressed cell-mediated immunity (182).**

Parenthetically, the implications of the effect of PEM, vitamin A, zinc, and iron on CD4+ T cell counts are important in the context of interpreting the impact of nutritional interventions in conditions such as HIV in which CD4+ T cell counts are used as a primary outcome. Because we appreciate that nutrient deficiency in itself affects CD4+ T cell count, we must design studies that can distinguish between a disease (e.g., HIV pathogenesis or treatment) effect and the impacts of malnutrition or its amelioration. For example, a study that evaluates the impact of a single or multiple micronutrient intervention on HIV might include an HIV-negative control to be able to distinguish between an HIV-specific effect and the impact of ameliorating nutritional insufficiency. This distinction has obvious biological and programmatic/public health implications.

Among the limitations of the extant evidence is that most of the research to date has focused on the effect of single-nutrient deficiencies on immune response. Few studies examined the simultaneous association of multiple nutrients, or their status, with immune function (183, 184). The design of such studies in humans is challenging for several reasons, including

- **our relatively limited understanding of the nature of micronutrient interactions within biological systems,**
- **the complexities of the health context in low- to middle-income settings where multiple-micronutrient insufficiency may be common but often coexists with multiple other conditions contributing to both acute and chronic inflammation,** and
- **low prevalence of multiple-micronutrient deficiencies in otherwise healthy participants in developed countries;**

**TABLE 3 Strength of evidence: impact of micronutrient deficiencies on cell-mediated and humoral immunity (animal studies)***

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>PEM Deficiency</th>
<th>Vitamin A Deficiency</th>
<th>Vitamin D Deficiency</th>
<th>Zinc Deficiency</th>
<th>Iron Deficiency</th>
<th>Folate Deficiency</th>
<th>Selenium Deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antigen-presenting cell function</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>?</td>
<td>?</td>
<td></td>
</tr>
<tr>
<td>T cell function</td>
<td>++++</td>
<td>++++</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>B cell function</td>
<td>++</td>
<td>++++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>?</td>
<td>++</td>
</tr>
</tbody>
</table>

*PEM, protein-energy malnutrition; −/+ mixed evidence; +, weak evidence; ++, partial evidence; +++, good evidence; ++++, strong evidence; ?, no studies.*
when they do exist in certain subgroups such as adolescents, certain racial groups, or the elderly, confounders such as age, disease, etc., further complicate experimental design and data interpretation.

d. Potential points of interaction between micronutrients involved in dependent pathways. Several points of interaction among the various micronutrients seem likely and are outlined in the accompanying Text Box 9. For the purpose of this overview, the general molecular actions of 4 micronutrients (vitamins A and D, zinc, folic acid) will be the primary focus, including their specific points of convergence on the regulation of 2 major regulators of inflammation: NF-κB activity and the induction, and maintenance, of Treg cells.

IV. Role of specific micronutrients in the immune system. Tables 1–4 summarize the extant knowledge with regard to the role of PEM and micronutrient deficiencies in immune function (more details are shown in Supplemental Tables 2–8). Particular attention was devoted to studies that identified mechanisms at the cellular or molecular level. The following is a brief summary highlighting key aspects of these relations. Particular attention is given to those aspects for which congruity exists between findings from animal and human models to inform the discussion of well-characterized human-specific pathways.

a. Mechanisms of vitamin A effect on the immune system. Most of the effects of vitamin A on immune or inflammatory responses can be explained via binding of the vitamin A metabolite, ATRA, to 1 of 3 zinc-finger proteins containing members of the nuclear receptor superfamily, RAR-α, RAR-β, and RAR-γ (185). These function as ligand-dependent transcriptional regulators by binding, usually as heterodimers to RXR-α, -β, and -γ and to RARE in target genes. Apo (unliganded) RAR can also occupy regulatory elements at their target genes and repress their expression. Ligand-dependent repression of gene expression by RAR can also occur. Recent estimates, in various human cell lines, indicate that RARs are constitutively bound to ~500 genomic sites, and ATRA treatment induces RAR binding to 500–600 DNA sites (186).

The number of genes actually regulated in this manner is unknown. It has been >10 y since the last large-scale survey was done. At that time, the estimated number of genes directly regulated by retinoic acid was very large (187), whereas the number of direct targets was fewer. Although new data are needed to further elucidate the magnitude of these relations, it is clear that vitamin A has multiple genetically mediated effects on the immune response via the activities of ATRA.

b. Mechanisms of vitamin D effect on the immune system. Although some effects of vitamin D are mediated independently of VDR, the large majority of the activity of vitamin D can be explained via binding of the vitamin D metabolite [1,25 (OH)2D] to a single, zinc-finger containing, ligand-activated transcription factor, VDR. The heterodimeric partner, RXR, is required for transcriptional activity. The VDR/RXR complex binds to specific sites within the promoter region of genes known as VDRE and activates transcription (188).

The presumed number of genes containing a VDRE and/or regulated by VDR/RXR is very large. Recent human data suggest that VDR can bind to >2700 sites in the genome and directly regulates >200 genes (189). Like vitamin A, vitamin D can affect immune function through this genetic interaction. Because vitamins A and D share a nuclear receptor (RXR), compete for coactivators and corepressors, and reciprocally regulate the expression of their receptors, a wide variety of combined effects on gene regulation likely occurs (190–192).

c. Mechanisms of the zinc effect on the immune system. The molecular actions of zinc appear to be more complex than those of vitamins A and D. In humans, the zinc-containing proteome contains <3000 members (193). More than 10% of this proteome encodes enzymes, including alcohol and aldehyde dehydrogenases, involved in vitamin A metabolism (193). Zinc is also necessary to maintain the structural integrity of proteins such as zinc-finger containing transcription factors (194). Approximately 50% of all transcription factors, including the vast majority of transcription factors involved in leukocyte lineage commitment (T cell vs. B cell commitment, CD4 vs. CD8 lineage commitment, Treg commitment) and effector function,
contain zinc (195). Furthermore, 477 members of the poly-zinc-finger (poly-ZF) family of putative transcriptional repressors in humans (330 in mice) involved in epigenetic gene silencing contain zinc (195).

The ability of free zinc to act as an intracellular signaling molecule, similar to calcium ion (Ca$^{2+}$), was recently described (196). An appreciation of the molecular complexities of zinc is just emerging. It will be essential to determine what the hierarchy of functional pathway maintenance is during ZnD.

**d. Mechanisms of folic acid effects on the immune system.** The molecular actions of folic acid are also extraordinarily complex. Folic acid, along with other nutrients involved in one-carbon metabolism (e.g., methylcobalamin, choline, betaine, and methionine), is required for the synthesis of DNA and S-adenosylmethionine (SAM)–dependent methylation of DNA and histones. The number of specific sites [specifically sites on DNA where cytosine and guanine are separated by a phosphate; referred to as cytosine-phosphate-guanine (CpG) sites] in the genome that are potential targets for methylation is staggering. The recent Encyclopedia of DNA Elements (ENCODE) project has identified 1.2 million putative CpG methylation sites in the human genome (8.6% of nonrepetitive genomic CpGs) (197). The methylation pattern is unique to each cell type. The number of genes regulated by histone methylation is similar to that regulated by DNA methylation, and the pattern of histone methylation is unique to each cell type (198). The roles of folate in methylation-dependent DNA modifications will be covered in greater detail in the following section on epigenetics.

**V. Genetics and epigenetics of inflammation: role of nutrition.** Genetic variations/polymorphisms and copy number variation have been shown to have potent effects on immune function and inflammation (199). These observations were extended into studies exploring the heterogeneity of responses resulting from nutrition intervention trials.

The copy numbers of a gene typically vary as a result of duplication of the portion of the chromosome that contains the gene. This accounts for ~12% of variation found in the human genome (200). In addition to established associations between genetic variations of inflammatory cytokine genes and increased circulating levels, other genetic variation such as changes in copy number can modulate inflammation. To our knowledge, there are no studies that examined the effect of copy number variation on the effect of nutrition on immune function or inflammation, but this could be a fertile area for future research.

**a. Epigenetics.** Understanding the role that epigenetics plays in determining the plasticity and heterogeneity of human immune responses is essential for planning and interpreting data generated by nutrition intervention trials. Basic principles regarding epigenetics and immunity/inflammation are highlighted in the accompanying Text Box 10. In the following section, we will consider the role of nutritionally regulated epigenetic control of genes involved in immunity and/or inflammation.

Aside from the role of miRNA in immune development and function, and despite the surging interest in epigenetics in the past decade, surprising little is known about how immunity or inflammation is modulated via epigenetic mechanisms. The majority of epigenetic studies were conducted with the use of T cells and macrophages. Factors that control T cell development such as IL-2 are regulated via promoter demethylation in T cells (202). Naive CD4$^+$ T cells differentiate into specific and stable T-helper (Th) cell phenotypes (including, but not limited to, Th1, Th2, Th17, and Tregs). Chromatin remodeling allows increased binding of specific factors to the regulatory regions of IFNG in Th1 cells or IL4 (203) in Th2 cells.

Few studies have addressed how nutrients play a regulatory role in altering immune function or inflammation via epigenetic pathways. A small but rapidly growing literature suggests that non-nutrient, bioactive food components may regulate epigenetic pathways. Claycombe et al. discuss these in a companion article to this supplement “Epigenetics of inflammation and immune dysfunction: the role of nutrition” (36). The following is a summary of the current knowledge about nutrient control of epigenetic events in general with a focus on immune or inflammatory responses.

**b. Role of specific nutrients in genetics/epigenetics.**

1. **Role of vitamin A in epigenetic processes and the genetics of immune function.** Cell culture models and a very small number of human clinical studies indicate that nutritional factors including vitamins A and D affect numerous genes involved in chromatin remodeling or processes that are involved in epigenetic regulation.

---

**Text Box 10 Basic principles of epigenetics**

- Epigenetic modifications that lead to gene expression alterations involve transmitting heritable modifications without DNA base pair changes.
- Epigenetic changes play a role in determining immune responses to various organisms.
- Epigenetic changes can persist postmitotically or transgenerationally.
- DNA methylation is considered to be the most permanent form of epigenetic regulation and is associated with transgenerational effects, including genomic imprinting.
- Major epigenetic mechanisms include the following:
  - Methylation of CpG islands found in the regulatory regions of DNA. The number of CpG sites in the genome that are potential targets for methylation is very large (197).
  - Post-translational modification of nucleosomal histone proteins. Examples of histone modifications include:
    - methylation of histone lysine and arginine
    - histone phosphorylation
    - histone ubiquitination
    - histone acetylation activity
  - Generation of noncoding RNA, such as long intergenic noncoding ribonucleic acids (lincRNA) (201) or microRNA (miRNA), that affect mRNA translatability or stability.
Hypomethylation of hepatic DNA occurs in response to vitamin A treatment in rats (204), and hypermethylation of long interspersed element (LINE) 1 is found in peripheral blood white cells of vitamin A–deficient children (205). Genomewide DNA methylation assays demonstrated several hundred differentially methylated CpG sites between ATRA-treated human embryonic stem cells and neuroblastoma cells (206). The mechanisms for these phenomena are unknown, but ATRA induces glycine N-methyltransferase, an enzyme that regulates the provision of methyl groups. Because this mechanism has the potential to alter the global abundance of methyl donors, and because vitamin A has general actions on cell differentiation, it is unknown whether these effects are indirect or whether specific genes are targeted for epigenetic regulation by vitamin A in vivo. Emerging evidence suggests that both mechanisms are operative.

Substantial in vitro evidence exists for a role for ATRA in epigenetic regulation of stem cell or tumor cell differentiation via specific targeting of genes (Text Box 11). Evidence for effects of vitamin A on epigenetic regulation of immune function is emerging.

Because ATRA has potent growth inhibitory and differentiation actions on a wide range of leukemic cell lines, the majority of studies examined the epigenetic effects of ATRA on the differentiation of myeloid leukemia cells. Few studies have been conducted in primary cells. RARs physically associates with the H3-K4 histone methyltransferase-5 (MLL5) and promoter region of CCAAT/enhancer binding protein ε (C/EBPe), enhancing neutrophilic differentiation of the acute promyelocytic leukemia cell line HL-60 (211). Upregulation of several miRNAs occurs during ATRA-induced differentiation of the acute promyelocytic leukemia nuclear bodies (NB4) (212).

The generation of the bioactive form of vitamin A is under tight control. Studies in mice suggest that cytochrome P450 (CYP) 26A1, an enzyme involved in numerous aspects of drug metabolism, is also involved in ATRA catabolism. It is induced by ATRA and subject to a high level of epigenetic regulation. Promoter methylation may play a limited role in Cyp26a1 gene silencing in the absence of ATRA (213) but may account for lack of ATRA induction of Cyp26a1 in ATRA-resistant cells (214). In addition, high constitutive levels of methylated H3-K27 are associated with the promoter of the mouse Cyp26A gene in mouse F9 teratocarcinoma cells that are lost after treatment with ATRA (214).

Simultaneously, increased recruitment of acetylated H3-K9 and H3-K14 to the Cyp26A promoter occurs in response to ATRA treatment (214). Upon ATRA withdrawal, H3-K27 histone methylation occurs, which leads to polycomb repressive complex 2–mediated gene silencing of Cyp26a1 in mouse embryonic stem cells (215). The potential implications of these types of interactions on drug safety and efficacy has been discussed (216) and will be covered in further detail by WG 2.

ii. Role of vitamin D in epigenetic processes and the genetics of immune function. Evidence is emerging for vitamin D in epigenetic regulation of gene expression. Some of this evidence is derived from models of tumor cell differentiation in vitro. KDM6B/JMJD3 histone demethylase is induced by vitamin D, but not ATRA, in human colon cancer cells (217) and has been implicated in the regulation of cyclin-dependent kinase inhibitor 1A (CDKN1A)/p21CIP1 by 1,25(OH)2D in normal prostate cells (218). Histone acetylation controls cathelicidin gene expression by vitamin D in keratinocytes (219). Vitamin D induces the expression of miRNA in different cell types. Plasma miRNA profiles have been determined in subjects given high-dose vitamin D, but the within-subject heterogeneity and small number of subjects precluded any determination of definitive vitamin D–regulated miRNA (220).

The essentiality of vitamin D in regulating invariant invariant NK T cell development in mice is thought to be via epigenetic mechanisms (173). There is other evidence for a transgenerational effect of vitamin D on immunity. Adult mice exposed to in utero VDD developed more severe and earlier onset experimental autoimmune encephalomyelitis, but adult mice exposed to perinatal VDD developed more severe and earlier onset experimental autoimmune encephalomyelitis (221).

Like vitamin A, the generation and degradation of the bioactive form of vitamin D is under tight control. The promoter region of CYP27B1, the enzyme responsible for 1,25(OH)2D generation, is demethylated, and histones associated with the promoter deacetylated in response to vitamin D treatment in mouse kidney proximal tubule-derived mouse cortical tubular cells and the human embryonic kidney–derived cell line 293F (222). The induction of CYP24A1, the enzyme responsible for 1,25-dihydroxyvitamin D3 catabolism, by VDR is dependent on the expression of the histone demethylase KDM6B/JMJD3 (223). Inflammation can also affect the generation of 1,25-dihydroxyvitamin D3 via epigenetic mechanisms. The miRNA miR-125b, a positive regulator of inflammation in macrophages (224), negatively regulates VDR and CYP24A1 (224, 225). A greater association of KDM6B/JMJD3 to the Cyp24A1 promoter gene and induction of Cyp24A1 mRNA occurs in response to LPS in mouse macrophages (217). These data suggest that inflammation leads to decreased VDR activity and increased vitamin D catabolism.

Text Box 11  Epigenetic impact of ATRA

- DNA sequences found within genes involved in the regulation of morphogenesis (known as “homebox transcription factors”) are prototypical ATRA-regulated genes.
- ATRA causes the recruitment of the histone H3-K27 demethylase lysine (K)-specific demethylase 6A KDM6A/UTX to the promoters of the homeobox transcription factors HOXA13 and HOXB13 in human NTERA-2 clone D1 Cell Line human (NT2/D1) teratocarcinoma cells (207, 208), leading to a loss of H3-K27 methylated histone and gene transcription.
- The histone H3-K27 demethylase KDM6B/JMJD3 is an ATRA-inducible gene in mouse neural stem cells, human HeLa cells, and human U2OS osteosarcoma cells (209).
- Treatment of neural stem cells with ATRA induced recruitment of KDM6B/JMJD3 to the promoter region of the homeobox transcription factor distal-less homeobox 5 (Dlx5) (209).
- ATRA-treatment was accompanied by binding of methylated H3-K4 to the promoter region and demethylated H3-K27 to the enhancer region of the RET gene in human neuroblastoma cell line (SK-N-BE) (210).
### Text Box 12 Impact of zinc status

- ZnD induces global DNA hypomethylation in vivo (227).
- In vivo evidence exists for an epigenetic component related to the immunosuppressive effects of high and low concentrations of zinc.
- Gestational zinc deprivation in mice leads to immunodeficiency that can be observed through 3 subsequent generations (228).
- Zinc supplementation of zinc-repleted pregnant rats suppresses immune functions in their offspring (229).
- Prenatal zinc supplementation of zinc-adequate rats also adversely affects immunity in offspring (230).

### VI. The APR and the study of nutrition-inflammation interactions

The application of our basic understanding of the immune system and its implications for health are best understood by the phenomena that occur in response to many stressors, including microbial invasion, tissue injury, immunologic reactions, and inflammatory processes. The array of immunologic, neuroendocrine, and neurobiologic responses is collectively referred to as the APR (238). Because of a diversity of stimuli, differential kinetics and magnitude, and other factors that can affect the APR, establishing a single unifying definition has been difficult. Because conditions that might contribute to an APR within given study designs/descriptions have not been consistently provided, the ability to gain a full appreciation of the impact of the APR on nutrition has been challenging; however, some general concepts are understood. General characteristics and manifestations of the APR are described in Text Box 13.

Aside from the metabolic impact of the APR on substrate utilization and nutrient homeostasis, of particular relevance to the impact of the APR on nutrition are the changes in numerous plasma protein concentrations. Plasma concentrations of >200 proteins change in response to acute inflammation and are referred to as APPs (245) (the APP classification scheme can be found in Text Box 14).

Our ability to further explore the APR and characterize its impact is contingent on the models used to explore these relations. We learned what cytokines induce specific APPs, the function of specific APPs, and that the magnitude and duration of the APR can be species-specific. For example, CRP is a major positive APP in humans, pigs, and dogs, whereas SAA, serum amyloid P (SAP), and haptoglobin are the major APPs in mice (245). Human, but not rodent, CRP activates the classical pathway of complement in serum (248). Thus, care must be taken when choosing the species to model the human APR.

#### a. Nutritional/metabolic implications of the APR

The APR and accompanying changes in APP concentrations can result in profound metabolic consequences with significant nutritional implications (Text Box 15).

Although evidence exists for extrahepatic synthesis of APPs, the majority are derived from hepatocytes in higher order vertebrates. Table 5 shows a survey of the most commonly encountered human APPs along with their putative functions. Recent evidence from proteomic studies in stress-challenged mice and humans suggests the existence of several hundred more proteins that might meet this definition (249, 250).
b. Roles and impact of APPs. Approximately 50% of the major APPs are involved in nutrient transport or regulation of nutrient status. This challenges the ability to distinguish between changes in nutrient status consequent to exposure vs. the response of a nutrient-related APP to an APR. It might also compromise efforts to implement and monitor an intervention effectively in a patient experiencing an APR, because the metabolic responses to the APR may, by their nature (i.e., a physiologic override of normal metabolic/nutritional processes), be intransigent to usual approaches to mitigation (e.g., use of a dietary supplement to increase concentrations).

Conversely, it is also the case that certain aspects of the APR are blunted in severely malnourished children (251–253). Another important consideration in this context is the impact of chronic stress on the APR and consequent metabolic problems. The latter scenario is exemplified by what we have learned about the impact of HIV infection on the inflammatory response and subsequent changes in metabolism that might account for some of the chronic untoward complications of that disease and its treatment (254–256). These types of disease-mediated chronic relations will be discussed in further detail by WG 3.

Text Box 14  Different classification schemes of APPs

- Positive or negative: reflecting their respective increase or decrease in response to the APR
- Early, intermediate, or late: reflecting differential time course and differential magnitude of change in response to the APR
- Type 1 (stimulated by TNF and/or IL-1β, enhanced by IL-6) or type 2 (stimulated by IL-6) (246)
- A change of ~25% in plasma concentration of a protein in response to inflammation has been suggested as the simplest criterion to define an APP (247).

In addition to the broad impact of the APR cascade, APPs also play specific roles within the human body and are outlined in Text Box 16.

In many ways, the response to stresses such as infections may be seen as paradoxical (i.e., having a negative impact on both host and pathogen). This view is particularly evidenced by the nutritional responses to infection (e.g., nutrient sequestration, anorexia) (257). To understand how this paradox is manifested and how it is intended to defend the host, it is useful to look at what is known about specific nutrients in this context.

Sequestration of nutrients to limit the growth and function of pathogens has been proposed as one reason for the redistribution of some nutrients during the APR. This is most evident for iron (259) but may also occur with zinc (260). Another intriguing possibility is that nutrient deprivation increases the level of stress on all host cells, causing those that are subsequently stressed by intracellular pathogens or trauma to die (257). Similarly, to limit host tissue damage, sequestration of pro-oxidant nutrients and a change in the antioxidant balance in favor of the host in response to reactive oxygen species (ROS) produced during the immune response have been proposed (18). Last, compartmentalization of nutrients during inflammation may create a permissive environment for inflammation to occur via temporary removal...
of nutrients (e.g., vitamin A, zinc) that negatively regulate NF-κB activity (118, 126).

c. Case study: vitamin A and the APR. Rather than a full discussion of each of the putative APP mechanisms, a case study exploration of the various proposed scenarios using vitamin A as an example will be illuminating. Although vitamin A is absolutely required for mounting an effective immune response, it is tempting to speculate that temporarily inhibiting plasma delivery of vitamin A to tissues is beneficial to the host by creating a favorable environment for inflammation. The accompanying Text Box 17 outlines potential mechanisms that might describe how this limitation might occur and evidence for how this may manifest in the context of infection.

Several strategies have been designed to assess nutrient status in the face of the APR, including the use of a single APR to identify subjects with and without an active APR, reporting nutrient concentrations and prevalence rates of deficiency in those with and without elevated APPs, or using multiple APPs to adjust nutrient values for phase or severity of infection (271, 272). Each of these strategies may be useful, but they are limited, and identification of biomarkers of nutrient status that are not sensitive or responsive to inflammation remains an important avenue of research. This will be addressed extensively by WG 4. The application of genomic metabolomic and/or proteomic approaches to this problem may be useful (127, 273, 274).

VII. Conclusions. Considerable progress has been made toward understanding the mechanistic roles of specific nutrients in the function of leukocytes of rodent models and in human cell lines. In particular, the discovery of cell signaling networks by which nutrients regulate the differentiation and phenotype of regulatory leukocytes has been an important development. The translation of these mechanistic results in ways that improve outcomes in human diseases has been limited. Aside from the obvious inability to control the experimental environment, the complex nutritional context of at-risk human populations presents a daunting challenge. For example, although research with rodents typically examines deficiencies of a single nutrient in a diet in which all other nutrient amounts are optimal, human diets may commonly be lacking in multiple nutrients and simultaneously have certain nutrient excesses. Consequently, a key research priority is the need to examine interactions between essential nutrients with the immune and related systems to determine if they have additive, synergistic, facilitating, or unpredictable effects relative to an individual’s nutritional status.

In human populations, genetic and epigenetic differences likely account for important variations in the response of the immune system to nutrient fortification. Reliance on inbred mouse species housed in highly controlled environments may not be the most relevant model for understanding the implication of these genetic interactions in humans. New approaches for model systems that more closely duplicate the dietary, genetic, and hygienic realities of human populations should be considered.

VIII. Research Priorities. Recent estimates indicate that rats, mice, and hamsters account for ~80% of the animals used in all laboratory experimentation (275). Although some of these data

---

**TABLE 5** Function of the major acute phase reactants

<table>
<thead>
<tr>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opsonin</td>
</tr>
<tr>
<td>Opsonin</td>
</tr>
<tr>
<td>Opsonin</td>
</tr>
<tr>
<td>Opsonin</td>
</tr>
<tr>
<td>Opsonin</td>
</tr>
<tr>
<td>Coagulation</td>
</tr>
<tr>
<td>Complement activation, vitamin D transport</td>
</tr>
<tr>
<td>Fe sequestration</td>
</tr>
<tr>
<td>Fe sequestration</td>
</tr>
<tr>
<td>Fe sequestration</td>
</tr>
<tr>
<td>Fe sequestration</td>
</tr>
<tr>
<td>Bacterial pattern recognition receptor</td>
</tr>
<tr>
<td>Complement activation</td>
</tr>
<tr>
<td>Zn transport</td>
</tr>
<tr>
<td>Lipid metabolism</td>
</tr>
<tr>
<td>Retinol transport</td>
</tr>
<tr>
<td>Se transport</td>
</tr>
<tr>
<td>Thyroid hormone transport</td>
</tr>
<tr>
<td>Glucocorticoid transport</td>
</tr>
<tr>
<td>Fe transport</td>
</tr>
<tr>
<td>Thyroid hormone transport</td>
</tr>
</tbody>
</table>

\(^1\) AGP, alpha 1 acid glycoprotein; CRP, C-reactive protein; Gc, group-specific component globulin; HS, Heremans-Schmid; ORM, orosomucoid; SAP, serum amyloid P; ?, possible. \(^2\) Involved in nutrient transport.
The interaction of the effects of micronutrient status with the gut microbiota is an emerging area of research interest (283). The composition of the gut microbiota is affected by nutritional status and nutrition/eating habits. Overnutrition affects the gut microbiota, and a large number of studies have shown that caloric/fat intake influences the ratio of different phyla of bacteria within the intestinal tract (283). Humans and animals with high fat intakes tend to have more Firmicutes, a phylum of bacteria that may actually enhance fat absorption (284). With regard to undernutrition, a limited number of studies have shown that PEM is permissive for more pathogenic bacteria (90, 285). It is not clear whether malnutrition sets up conditions that are favorable for pathogenic bacterial growth and/or whether impaired immune surveillance leads to outgrowth of noncommensal bacteria. Recent studies indicate that some microorganisms actually contribute to malnutrition (91). A limited number of other studies also suggest that vitamin A (286), selenium (287), iron (288), and zinc deficiencies (289) may affect the microbiome. Text Box 18 includes a list of research priorities highlighted in this review.

B. WG theme 2: specific relations between nutrients, immune function, and inflammatory response—impact of nutrition on the immune response

Objective: Review the extant data to evaluate the impact of malnutrition on immune function and the inflammatory response. WG 2 summary and conclusions can be found in Text Box 19.

I. Introduction. The evidence with regard to the impacts of malnutrition, including both under- and overnutrition, on health across the life cycle is incontrovertible (1). As outlined by WG 1 and summarized in Table 6, many of the effects of undernutrition are mediated through the immune system, including changes in host defenses that affect resistance to or recovery from infections. In addition, overnutrition may induce chronic inflammation that increases the risk of both infectious and NCDs. Furthermore, effects can be lasting, even across generations, predisposing undernourished children in utero to the metabolic syndrome and related diseases later in life (322, 323).

This review includes examples of undernutrition, including undernutrition defined by poor growth (i.e., underweight, stunting, and wasting) and deficiencies of specific micronutrients (vitamin A, zinc, and iron) as well as overnutrition, focusing on obesity. For each example, a geographic and life cycle perspective
is offered along with a description of the clinical signs and biochemical markers that define each condition. The principal aim will be to describe the impact of malnutrition on the immune system and on the related risk of disease. The primary data sources for this review are human studies, including results from nutrition intervention trials that were either preventive (i.e., trying to prevent malnutrition and related disease risk) or therapeutic (i.e., trying to treat a particular disease, such as pneumonia, in subjects at risk of deficiency). Data from animal studies that offer unique insights were also considered. A final goal is to address how malnutrition may affect commonly used biomarkers of inflammation.

II. Vitamin A. The biology and biomarkers used for assessing vitamin A were recently reviewed (324), and are discussed in more detail in WG 3. A brief overview of the basics of vitamin A is provided in Text Box 20.

a. Epidemiology of VAD. The challenge of obtaining vitamin A, a fat-soluble vitamin, is great in many settings because preformed vitamin A is found primarily in animal-source foods including liver, eggs, and whole milk. Although it can also be obtained through precursors (β-carotene and other provitamin A carotenoids), which are found in orange-yellow vegetables and fruit and green leafy vegetables, the conversion of carotenoids to vitamin A is variable. Text Box 20 provides a summary of causes contributing to VAD.

On the basis of serum retinol concentrations <0.70 μmol/L (or 20 μg/dL), 122 countries are characterized as having moderate to severe VAD problems in preschool-aged children, whereas 88 countries fulfill this criterion with regard to pregnant women; it is estimated that a total of 190 million children and 19 million women are affected (5). The regions that are most affected by VAD are Africa and Southeast Asia (325). Preschool-aged children and pregnant women face the highest risk, reflecting high nutritional demands and high infectious disease burden (325). The principal clinical manifestation of VAD is xerophthalmia in various levels of severity, ranging from night blindness and Bitot’s spots to corneal scarring and blindness. Other consequences of VAD are anemia and a higher risk of child mortality from infectious diseases (325).

b. Effects of VAD/vitamin A supplementation on immune function and disease risk. As discussed by WG 1, VAD and vitamin A supplementation affect a range of innate and adaptive immune functions. Overall, VAD has been associated with decreased barrier function and skewing toward a Th1 response. Several human studies documented that VAD is associated with increased Th1-driven delayed-type hypersensitivity (DTH) responses and reduced Th2-driven antibody responses to vaccines; vitamin A supplementation reverses these responses (104, 105, 326). An animal study indicated that a high vitamin A intake may be linked to asthma (164), an association that remains to be studied in humans. Vitamin A supplementation has mostly been reported to have reciprocal effects of VAD (Table 6).

The important effects of vitamin A on immune function are reflected in the many community and clinical studies that showed that vitamin A affects mortality and morbidity. Large randomized trials led to meta-analyses concluding that prophylactic vitamin A supplementation of children between 6 mo and 5 y of age is effective in reducing child mortality from infectious diseases.
their APP, CRP, and AGP values in response to vomiting and supplementation on inflammation and its markers is less clear. Serum retinol and RBP concentrations, the role of vitamin A in infections, depending on the infectious pathogen (351). Also, between gut chemokine and cytokine responses and duration of 15-mo-old children differentially modified the association between vitamin A as a therapeutic agent (Table 7).

Infections, vitamin A supplementation may be beneficial effects. Although vitamin A may have a preventive effect on the incidence or severity of diarrhea and measles in community trials, it has had little or the opposite effect on respiratory infections (105). The same is seen in studies of vitamin A in neonates is still under debate; whereas some studies suggested a beneficial effect in South Asia and in boys, the results have been heterogeneous (332). One possible explanation for the apparent lack of benefit of vitamin A supplementation below 6 mo of age is that infants in such studies are protected from infection by maternally derived immune factors (e.g., serum IgG, factors in breast milk) to a greater degree than are older infants. Thus, the benefits of correcting VAD on survival are less pronounced.

Disease-specific studies have likewise not shown uniformly beneficial effects. Although vitamin A may have a preventive effect on respiratory infections (105). The same is seen in studies of vitamin A as a therapeutic agent (Table 7).

More in-depth mechanistic studies have provided clues to these conflicting results. For instance, neonatal vitamin A supplementation had a different effect on in vitro whole-blood cytokine responses depending on the sex and the vaccination status of the children (301). Vitamin A supplementation of 6- to 15-mo-old children differentially modified the association between gut chemokine and cytokine responses and duration of infections, depending on the infectious pathogen (351). Also, although it is clear that inflammation is associated with decreased serum retinol and RBP concentrations, the role of vitamin A supplementation on inflammation and its markers is less clear. Vitamin A supplementation of children <5 y of age increased their APP, CRP, and AGP values in response to vomiting and diarrhea but not in response to cough and fever (297) (Table 8).

Clearly, VAD is associated with critical impairment of immune function. However, the effects of vitamin A supplementation on the immune system may lead to variable clinical outcomes, depending on the nature of the immune response needed to combat the infecting pathogens. For this reason, vitamin A supplementation may be a double-edged sword. For some—and on the basis of the clinical trials, presumably most—infectious diseases, vitamin A supplementation may be beneficial; in other situations it may be harmful (369, 370). Important effect modifiers may be population vitamin A status, age, sex, vaccination status, season, pathogen prevalence, disease type, and disease burden. The latter is also reflected in differences in effect over region and season (332, 370).

### III. Zinc

The basics of zinc biology and biomarkers were recently reviewed (371) and are discussed in more detail by WG 4. A brief summary of zinc assessment methods is found in the accompanying Text Box 21.

Estimates of the childhood deaths attributable to zinc deficiency are based on a population-level modeling. The population-attributable fractions for ZnD for diarrhea, pneumonia, and malaria are calculated by estimating the reduction in mortality if the risk of ZnD was reduced by a theoretical minimum in children <5 y old (377).

#### a. Epidemiology of ZnD

ZnD is a global problem that contributes significantly to disease morbidity and mortality, particularly in low-income countries (372, 378). Although severe ZnD is rare, mild to moderate deficiency is common throughout the world (372) and is a predisposing factor for a range of infections, particularly diarrhea (379). ZnD is estimated to account for 450,000 deaths annually, >4% of deaths among young children, and 1% of all deaths in children globally (378).

The estimation of zinc availability in the diet in combination with childhood stunting rates to generate a likelihood of deficiency remains the accepted method for assessing population-based ZnD. The estimation of zinc availability in the diet in combination with childhood stunting rates to generate a likelihood of deficiency has been used by the International Zinc Consultative Group (380) and remains the accepted method for assessing population-based ZnD. On the basis of estimates of dietary zinc availability and the prevalence of childhood stunting, it is estimated that ~15–30% or 1–2 billion of the world’s population is zinc deficient (378, 381). The prevalence of ZnD is greatest in South and Southeast Asia, sub-Saharan Africa, and Central America (372, 382). Mild to moderate ZnD is thought to be common in low-income populations, especially in populations with a low consumption of zinc-rich animal-source foods and high intakes of foods rich in phytates, which inhibit zinc absorption (383). Children <5 y of age, pregnant women, and the elderly comprise the groups at high risk of deficiency. Within those groups, premature and small-for-gestational-age infants and preschool-aged children, predominantly those 6–23 mo of age are at greatest risk (372, 379).
Infants are particularly vulnerable because the zinc content of human milk declines sharply in the postpartum period regardless of maternal zinc status (372). Furthermore, interactions of ZnD and environmental enteropathy (EE) that plague children in developing areas may well be synergistically interactive, each worsening the other and their potential impact on impaired child development (386). Human and animal studies showed that mild ZnD can impair multiple mediators of host immunity, ranging from physical barriers of the skin to innate and acquired immunity, increasing the risk of severe infection (387, 354). Globally, these effects translate to 10% of diarrhea diseases, 16% of acute lower respiratory infections, and 18% of malaria episodes being attributed to ZnD (378). Of the 450,000 deaths attributed to ZnD, >50% result from diarrhea (378). In addition, poor zinc status has been implicated in ~7% and 10% of pneumonia and malaria deaths, respectively (378).

Neither ZnD nor zinc supplementation has an appreciable effect on responses to bacille Calmette-Guérin (301), diphtheria and tetanus toxoid (388), rabies (389), influenza (390), or measles vaccine (measles vaccine by 9 mo of age, oral polio vaccine, type 1, hepatitis B vaccine, and varicella vaccine) (386).

### Table 6: Effects of micronutrient supplementation on immune function and vaccine responses (human studies)

<table>
<thead>
<tr>
<th>Type of malnutrition and type of immune function</th>
<th>Effects of supplementation on immune system (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamin A</strong></td>
<td>High-dose VAS above 6 mo of age decreases risk of death from infections such as measles and diarrheal diseases (290)</td>
</tr>
<tr>
<td>Epithelial barrier function</td>
<td>• High-dose VAS above 6 mo of age decreases risk of death from infections such as measles and diarrheal diseases (290)</td>
</tr>
<tr>
<td>Innate physiologic barriers</td>
<td>• VAS in the context of HIV infection or lower respiratory tract infections has been associated with adverse outcomes (105, 263, 290–292)</td>
</tr>
<tr>
<td>1058S Supplement</td>
<td>• Improved barrier function (105)</td>
</tr>
<tr>
<td>Macrophage function</td>
<td>• Abnormal dual-sugar (lactulose, mannitol) intestinal permeability inversely correlated with serum retinol (293) and partially normalized by supplementation in VA-deficient individuals in some studies (294) but not others (295, 296)</td>
</tr>
<tr>
<td>Neutrophil function</td>
<td>• Increased symptomatology after high-dose VAS during acute lower respiratory tract infections reported in some studies (105) may indicate restored mucus production</td>
</tr>
<tr>
<td>NK cell function</td>
<td>• No effect of ZnD or supplementation on immune function (reference)</td>
</tr>
<tr>
<td>T cell function</td>
<td>• Zinc supplementation in children led to an improvement in the lactulose:mannitol excretion ratio in some studies (311) but not other studies (312, 313)</td>
</tr>
<tr>
<td>B cell function</td>
<td>• Zinc supplementation in children led to an improvement in the lactulose:mannitol excretion ratio in some studies (311) but not other studies (312, 313)</td>
</tr>
<tr>
<td><strong>Zinc</strong></td>
<td>• Zn supplementation led to an improvement in the lactulose:mannitol excretion ratio in some studies (311) but not other studies (312, 313) studies; ratio may improve in infected children without Zn deficiency given supplemental Zn (314)</td>
</tr>
<tr>
<td>Epithelial barrier function</td>
<td>• Zn supplementation children had higher serum complement C3 (315)</td>
</tr>
<tr>
<td>Innate physiologic barriers</td>
<td>• Children with diarrhea supplemented with Zn supplementation do not exhibit an increase in NK cells (316)</td>
</tr>
<tr>
<td>NK cell function</td>
<td>• Increased NK cell activity in the elderly (317)</td>
</tr>
<tr>
<td>T cell function</td>
<td>• Increased CD4+ cell count in AIDS patients (318)</td>
</tr>
<tr>
<td>1058S Supplement</td>
<td>• Increased thymocyte count in thymus (319)</td>
</tr>
<tr>
<td>B cell function</td>
<td>• Increased thymulin activity (320)</td>
</tr>
<tr>
<td>1058S Supplement</td>
<td>• No consistent effect of Zn supplementation on DTH to TB antigen [reviewed in (103)]</td>
</tr>
<tr>
<td><strong>Note</strong></td>
<td>• Short-term diminished cellular response to PPD in boys (103) and hospitalized children (105)</td>
</tr>
</tbody>
</table>

1. AGP, α1-acid glycoprotein; BCG, bacille Calmette-Guérin; CD, cluster of differentiation; CD45RO, cluster of differentiation antigen 45 RO; CRP, C-reactive protein; DTH, delayed-type hypersensitivity; DTP, diphtheria tetanus-pertussis; PPD, purified protein derivative; SAA, serum amyloid A; TB, tuberculosis; VA, vitamin A; VAD, vitamin A deficiency; VAS, vitamin A supplementation.
Haemophilus influenzae type b (321), and pneumococcal vaccines (389, 391). Zinc supplementation, however, may improve antibody responses to cholera vaccination in children (392). It should be noted that the influence of zinc status on vaccination has not been well studied. Most of the evidence is drawn from secondary analyses or small observational studies. Few account for the effects of age, sex, degree of deficiency, supplement dose, and duration of dosing.

Text Box 20 Basics of vitamin A: biology and assessment
- Primary causes of VAD include:
  - Poor intake/food insecurity [the limited availability/accessibility of either animal source (preformed) vitamin A or alternative sources of vitamin A] and
  - Poor absorption (e.g., fat malabsorption).
- A high infectious disease burden can lead to decreased appetite, decreased absorption, liver or kidney disease, and other factors affecting loss of retinol binding protein (RBP), and depletion of body stores through excessive metabolism and increased excretion of vitamin A (325).
- Vitamin A is stored in the liver, and the most widely used biomarkers in population studies are serum retinol and serum RBP (324).
- Retinol is transported through the serum by RBP in an ~1:1 molar ratio; thus, these markers correlate closely with one another.
- Serum retinol and RBP also correlate with liver vitamin A stores in subjects with or at risk of clinical deficiency.
- RBP is also a negative APP; thus, inflammation and infection have a negative effect on serum retinol and RBP concentrations (324).
- More quantitative assessment techniques include the following:
  - Dose-response tests that indicate the adequacy of liver stores and isotope-dilution tests that reflect the amount of vitamin A stored in the liver. Both are labor intensive and expensive compared with serum retinol and RBP (324).
  - Conjunctival impression cytology has been used as a marker for vitamin A status but has not been widely adopted (324).
- More accurate and stable biomarkers of VAD are needed.

TABLE 7 Effects of interventions (preventive and therapeutic) on clinical outcomes (human studies)

<table>
<thead>
<tr>
<th>Type of malnutrition</th>
<th>Effect of preventative intervention on clinical outcomes (reference)</th>
<th>Effect of therapeutic intervention on clinical outcomes (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A</td>
<td>Decreased overall mortality in children between 6 mo and 5 y of age (290, 327–328)</td>
<td>Decreased severity of measles infection (105, 329)</td>
</tr>
<tr>
<td></td>
<td>No effect on overall mortality in children between 1 and 5 mo of age (330)</td>
<td>No effect or even increased severity of pneumonia (105, 283, 331)</td>
</tr>
<tr>
<td></td>
<td>Conflicting evidence with regard to effect on overall mortality in neonates (332)</td>
<td>Beneficial effect of low daily doses vs. high doses on incidence and duration of respiratory infections (333)</td>
</tr>
<tr>
<td></td>
<td>Reduced incidence of measles infection (105) in infant boys but not infant girls (334)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduced incidence and severity of diarrhea severity for some pathogens (105, 335, 336)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Potentially increased incidence and severity of respiratory infections (105)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased mother-to-child transmission of HIV (105)</td>
<td></td>
</tr>
<tr>
<td>Zinc</td>
<td>Decreased mortality: diarrhea, pneumonia, and malaria episodes (337–339)</td>
<td>Decreased mortality: diarrhea (340)</td>
</tr>
<tr>
<td></td>
<td>Decreased incidence of opportunistic infections in AIDS patients (341)</td>
<td>Decreased morbidity: fewer diarrhea episodes (340)</td>
</tr>
<tr>
<td>Iron</td>
<td>Increased risk of malaria and of death in malaria-endemic areas (349, 350)</td>
<td>Fewer treatment failures in serious infections of suspected bacterial etiology in young infants (342)</td>
</tr>
<tr>
<td></td>
<td>Risk may be greater in nondeficient individuals</td>
<td>Conflicting evidence of impact in the treatment of pneumonia (343–345)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reduced duration of cold symptoms (346); increased duration of fever and inflammatory responses in treatment of gram-negative catheter sepsis in adults and childhood pneumonia (347, 348)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No clear benefits</td>
</tr>
</tbody>
</table>

INSPIRE Project 1059S
The clinical and immunologic effects of therapeutic zinc prophylaxis in children are associated with a reduction in diarrhea mortality of 13% and pneumonia mortality of 15%; however, despite the implied association of zinc status with malaria mortality (199), zinc prophylaxis does not appear to affect deaths from malaria (339), raising questions about both the value of current methods of zinc assessment and the specific role of zinc in malaria. Significant reductions in acute and persistent diarrhea morbidity were also observed in zinc-supplemented children in therapeutic trials (340). On the basis of these results, the WHO recommended in 2004 that children be given oral zinc for 10–14 d with oral rehydration salts for the treatment of diarrhea (393). Evidence of whether or not zinc supplementation provides a similar therapeutic benefit to children with severe pneumonia is conflicting (343–345). However, results from a recent trial in India indicate that zinc adjunctive therapy can reduce treatment failures in infants aged 7–120 d with severe infections of suspected bacterial etiology (342). On the other hand, some data suggest that supplementation during the clinical phase of gram-negative infections may exaggerate APRs and prolong hospitalization (347, 348, 349). The clinical and immunologic effects of therapeutic zinc supplementation on the outcome of infection are likely to depend on age, zinc dosage and frequency, degree of deficiency, region, and infectious agent. Further mechanistic studies are needed to optimize zinc therapy and to define populations most likely to benefit.

IV. Iron. The biology of iron and the available assessment tools have been reviewed extensively (27, 395) and are discussed by WG 4. Text Box 23 summarizes some of the basics.

### Text Box 21 Basics of zinc: clinical effects and assessment
- The most common effects of severe ZnD in humans include growth retardation, delayed sexual maturation, skin lesions, anorexia, alopecia, poor cognitive development, and impaired immune function (372, 373).
- The most common causes of ZnD are dietary insufficiency, limited nutrient bioavailability from local diets, and excretion during recurrent episodes of infection.
- Plasma, urinary, and hair zinc are reliable biomarkers of zinc status in healthy populations.
- Their use in deficient populations is problematic (374).
- Plasma zinc concentrations are most often used to assess zinc status at the population level and have a cutoff of <0.65 μg/dL to define ZnD in children (375).
- Plasma zinc is influenced by factors unrelated to zinc status, including inflammation and recent dietary intake, making it a poor indicator of individual zinc status (376).

### Table 8 Effects of malnutrition (or supplementation) on commonly used markers of inflammation (evidence from human studies)

<table>
<thead>
<tr>
<th>Type of malnutrition</th>
<th>CRP</th>
<th>AGP</th>
<th>IL-6</th>
<th>TNF-α</th>
<th>IL-10</th>
<th>IL-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A</td>
<td>↑1,2</td>
<td>↓1,4</td>
<td>(297)</td>
<td>—</td>
<td>↑2</td>
<td>(106)</td>
</tr>
<tr>
<td>Zinc</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Iron</td>
<td>—</td>
<td>—</td>
<td>↓(354)</td>
<td>↓(359)</td>
<td>—</td>
<td>↓(360)</td>
</tr>
<tr>
<td>Underweight, stunting, or wasting (PEM)</td>
<td>↓(361)</td>
<td>—</td>
<td>— (98)</td>
<td>↓(98)</td>
<td>—</td>
<td>— (98)</td>
</tr>
<tr>
<td>Obesity</td>
<td>↑(382–368)</td>
<td>↑(362–368)</td>
<td>↑(382–368)</td>
<td>↑(362–368)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

1 AGP, α1-acid glycoprotein; CRP, C-reactive protein; PEM, protein-energy malnutrition; ↓, decrease; ↑, increase; ↔, variable.
2 Supplementation.
3 In children with diarrhea and vomiting.
4 In children with cough and vomiting.
V. Undernutrition. For the purposes of this discussion and consistent with the work of WG 1, undernutrition will be referred to as PEM to distinguish it from single- or multiple-micronutrient deficiencies. The primary manifestations of PEM covered are underweight (low weight-for-age), stunting (low height-for-age), and wasting (low weight-for-height).

a. Epidemiology of underweight, stunting, and wasting.

The prevalence of under-5 underweight, stunting, and wasting due to undernutrition, although diminished due to aggressive public health interventions, remains high (1). The most vulnerable remain in low-income countries. Regional differences are seen, with underweight being most prevalent in Asia and eastern Africa, stunting in eastern and middle Africa as well as in South Central Asia, and wasting in South Central Asia. Severe wasting (<3 SDs) is often used as a trigger for nutritional rehabilitation programs and is most common in South Central Asia and middle Africa. The causes of PEM are diverse, but in these affected regions early childhood infections are typically associated with poor water and sanitation, poverty, food insecurity, and inadequate health care (408). In particular, a low availability of micronutrient-rich, animal-source foods is associated with the development of malnutrition (406). Repeated episodes of infection leading to impaired absorptive function also likely contribute to the development of undernutrition and may compound the problem of inadequate food intake (323).

PEM can also develop in adults and is typically defined as a BMI (in kg/m²) <18.5. Older adults are at particular risk of malnutrition, with the prevalence of low BMI increasing 4-fold above 75 y of age compared with those aged 45–64 y in the United States (409). Older adults also tend to have lower lean body mass and higher adiposity than younger adults due to loss of muscle mass with aging (410). The development of malnutrition in the elderly is complex and may include poverty, decreased ability to prepare food, depression, or the development of illness,
Overweight/obesity (BMI > 30) is increasing at alarming rates, and the recent GBD analysis (1) states that the global prevalence of overweight/obesity (BMI > 30) is increasing at alarming rates, and the recent GBD analysis (1) states that the global prevalence of overweight/obesity (BMI > 30) is increasing at alarming rates. Relevant aspects of the impact of PEM on the innate immune system are covered by WG 1. Some additional, relevant aspects of the impact and risks associated with PEM are summarized in Text Box 25. Although acquired immunity, including CMI, is most consistently affected by PEM, some aspects of innate immunity may also be affected in underweight, wasted, and stunted individuals, with effects being more pronounced in more severely malnourished patients, e.g., those 3 SD below the expected mean, or with a clinical presentation of Kwashiorkor or Marasmus. Relevant aspects of the impact of PEM on the innate immune systems are highlighted in Text Box 25.

VI. Obesity.

a. Epidemiology of obesity. According to the WHO (418) and the recent GBD analysis (1), the global prevalence of overweight/obesity (BMI > 30) is increasing at alarming rates, even in LMICs. Of particular concern is the dramatic increase in overweight/obesity in children <5 y of age. Biochemical markers of obesity include high serum leptin, low adiponectin, and elevated inflammatory makers including CRP, TNF, and IL-6 (362–365). Insulin resistance and type 2 diabetes are often comorbidities with obesity. Coincident with the increase in obesity rates has been a concurrent increase in those comorbid NCDs, including hypertension, diabetes, CVD risk, and cancer (1). It has been suggested that the development of insulin resistance and diabetes may be due to the state of chronic low-grade inflammation found in obesity (366, 367).

b. Effects of obesity on immune function and disease risk. Obesity and its concomitants (e.g., insulin resistance) have been associated with impaired immune/inflammatory responses (419, 420). A summary of the reputed effects of obesity on immune function/inflammation and disease risk are found in Text Box 26. With respect to vaccinations, there are several studies reporting impaired responses in obese adults and children including the following:

- An impaired response was found to hepatitis B vaccination (444, 445).
- A decreased anti-tetanus antibody response after tetanus vaccination was observed in obese compared with healthy-weight children (446).
- Trivalent influenza vaccination was associated with a lower antibody titer 1 y after vaccination, and impaired CD8 responses were observed against vaccine strains in obese individuals (447).

In support of the human studies, animal models of diet-induced obesity clearly demonstrated immune impairment and increased inflammation. Closely mimicking human obesity, mice with diet-induced obesity developed insulin resistance, elevated leptin, and elevated lipid TGs leading to fatty liver and increased inflammatory markers (448–450). Compared with lean mice, diet-induced obese mice had greater morbidity and mortality from primary and secondary influenza infections (451, 452), impaired resistance to Leishmania major infection (453), and increased mortality from S. aureus–induced sepsis (454).

VII. Conclusions. Nutrients affect the immune system in a variety of ways (455). We reviewed how malnutrition—due to VAD, ZnD, ID, stunting, wasting, underweight, and obesity—affect immune function and inflammation were covered by WG 1. The effects of PEM occur through both its effects on immune and inflammatory function as well as on host protective barriers and development (2). The putative mechanisms by which PEM affects immune function and inflammation were covered by WG 1. Acquired or cell-mediated immunity (CMI) is impaired by anthropometrically defined undernutrition. Infants and children with underweight, wasting, and stunting are typically also at risk of multiple-micronutrient malnutrition deficiencies; thus, it can be difficult to specifically associate particular immune deficiencies with these conditions. CMI is also specifically impaired in elderly adults with PEM. Serum antibody responses to vaccination also seem to be impaired in the elderly (256) unlike in younger malnourished subjects. Some additional, relevant aspects of the impact and risks associated with PEM are summarized in Text Box 25.

Text Box 24 Summary of the impact of iron on immune function and inflammation

- ID affects the function of phagocytes such as neutrophils and macrophages (359, 401).
- As a transition metal and because of its oxidation-reduction potential, iron is an important component of the active site of enzymes such as NADPH oxidase and myeloperoxidase, which are important in producing the oxidative burst involved in killing microorganisms ingested by phagocytes.
- Although phagocytic function is not impaired by ID, neutrophils and macrophages from iron-deficient individuals have an impaired ability to generate an oxidative burst and produce hypochlorous acid, key components of bacterial killing (402, 403).
- Defects in bacterial killing by neutrophils have also been documented in ID and recover within 2 wk of initiation of iron supplementation (404).
- Production of proinflammatory cytokines such as TNF and IL-6 by innate immune cells is also reduced by ID (359).
- In the adaptive immune system, lymphocyte function is impaired by ID because proliferation requires the activity of iron-containing enzymes including ribonucleotide reductase. ID inhibits the proliferation of T lymphocytes and, to a lesser extent, B lymphocytes (359).
- Thymic function and the number of T cells in the periphery are also diminished by ID (401, 405), but supplementation has a variable effect on restoring the number of peripheral T cells (103). ID was associated with lower production of the Th2 cytokine IL-4 and higher production of the Th1 cytokine IFN-γ (360).
function. Malnutrition in all of these forms is uniformly associated with impaired immune function, and mechanistic studies reveal effects on both the innate and adaptive immune systems. Not surprisingly, malnutrition is also associated with increased susceptibility to infectious diseases and mortality.

In mechanistic studies there is evidence that treatment of malnutrition restores immune function; and population-based intervention trials, in some cases, showed decreased morbidity and mortality with supplementation. However, some population studies also raise concerns; particularly for micronutrient supplementation there are indications of lack of effects or adverse outcomes of supplementation in some situations. As discussed above, adverse outcomes were seen during vitamin A and iron supplementation programs, and the mechanisms underlying these adverse effects may involve altered host resistance.

The nutritional state for optimal immune function appears to require balance, without stunting, wasting, and underweight on one hand, and without obesity on the other hand. Similarly, micronutrient deficiencies impair immunity, but excesses of at least some micronutrients may cause harm under some circumstances. More research is needed to refine our understanding of the mechanisms of and solutions to these circumstances.

VIII. Research priorities. A list of research priorities is provided in Text Box 27. For all of the nutritional scenarios covered in the present review, it seems clear that more studies are needed to optimize the use of supplementation in order to maximize benefit and minimize risk.

C. WG theme 3: specific relations between nutrients, immune function, and inflammatory response—impact of the immune response on nutrition and impact of inflammation/infection on nutrition

Objective: To evaluate the evidence with regard to the impact of inflammation on nutrition/nutrient status across the continuum of inflammatory conditions (from acute infection to chronic NCD states). Please see Text Box 28 for WG 3 summary and conclusions.

I. Introduction. This review follows and builds on the information presented by WGs 1 and 2 with a particular focus on the impact of acute and chronic inflammatory conditions on nutrition and, wherever possible, on nutrient biomarker selection, use, and interpretation. Commonly used inflammation and nutritional biomarkers are reported by WG 4. Of particular concern is the impact of the inflammatory APR in terms of both relevant aspects of its pathophysiology and its effects on biomarker selection and interpretation. In addition, the more generalized “acute stress response” will be discussed because it also contributes to the response to disease. The review begins with an overview of the current understanding of the clinical implications of the APR and the distinct but related acute stress response. This is followed by a summary of the critical role of gastrointestinal ecology. After an outline of general features of the infection-nutrition interaction, 6 case study nutrients are reviewed in order to explore these relations. Several case study clinical contexts are presented including the following: infectious disease exposures and EE, reflecting the implication of
derangements in intestinal integrity; chronic and NCDs; pregnancy and infancy; and a brief discussion of drug-nutrient interactions. To set the stage for this discussion, the following sections will briefly address 2 distinct but related aspects of the human response to stress, the inflammatory APR and the acute stress response.

II. Global health and the inflammatory APR. As described in detail by WG 1, an APR is a stereotypic, generalized host reaction, caused by a cascade of cytokines released by activated phagocytic cells (238). However, recent research suggests that different stimuli eliciting an APR may not only have different effects on the magnitude of the responses but also lead to the qualitatively different responses highlighted by WG 1. A range of medical, physiologic, and environmental conditions may precipitate an APR (Table 9).

In low-income countries, infectious diseases continue to be major causes of the APR, although some infections may downregulate or impair the ability to mount an APR. Moreover, as highlighted in the GBD study (1), NCDs, including obesity, are assuming a greater role in the health picture in these same resource-constrained settings. Thus, both the infectious and NCD burden is considerable, especially among the poor, due to lack of safe water and sanitation, inadequate vaccination coverage, poor health care access and delivery, and the combination of food insecurity and limited dietary diversity leading to poor nutrition. Hence, elevated serum APPs occur not only among those with acute clinical infection but also among asymptomatic individuals, reflecting subclinical, residual, unrecognized infection or chronic NCDs. In view of the increasing importance of obesity, the latter is considered as a specific inflammatory state in a later section of this review (section V.b.).

In addition to diseases, the environment has also assumed a more prominent role as a factor contributing to poor health and the manifestations of the APR. One exposure that has assumed increasing importance to the global health community is the impact of household fossil fuel use for indoor cook stoves (456). Dutta et al. (457) reported systemic inflammation (evidenced by increased serum IL-6, IL-8, TNF, and CRP) among rural Indian women cooking with biomass fuels compared with those cooking with a clean fuel such as liquefied petroleum gas.

III. The acute stress response. In addition to the APR, the body also has an exquisitely sensitive system for responding to stress, broadly referred to as the acute stress response. The acute stress response, also known as the "fight or flight response," was initially described by Cannon (458) and represents a cascade of events involving the SNS and the HPA. The stress response is distinct from the APR in that the latter is an immune/inflammatory response triggered by cytokine response to a stimulus, whereas the former is a more generalized metabolic response to stress involving multiple systems, most prominently the neuroendocrine axis. The components and physiologic implications of the APR are described by WG 1. The characteristics of the acute stress response and its links to the inflammatory response including the intimate interaction with the neuroendocrine system, mediated largely via the HPA and the sympathetic/adrenomedullary system, are described in Text Box 29.

a. Evidence that chronic stress can be harmful to the host. The link between immune function/inflammation and the acute stress response has clinical implications that have just begun to be explored. Although the acute stress response effects are temporary, such that catabolism and immunosuppression are initially beneficial, over a prolonged time period these effects can be damaging. As a result, the host could be more vulnerable to infections, neoplastic disease, and metabolic derangements. General causes and implications of chronic inflammation were reviewed by WG 4.

The impact of this type of chronic stress can result in an increase in glucocorticoids, thereby antagonizing growth hormone actions on fat tissue. Chronic episodes of stress may lead to an attenuation of growth hormone actions to induce lipolysis, which could contribute to increased visceral adiposity. In addition, enhanced glucocorticoid secretion can lead to insulin resistance and profound hyperinsulinemia (464).

Experimental basic science showed that in monosodium L-glutamate (MSG)-induced hypothalamus-damaged and hyperadipose rats, exposure to LPS resulted in HPA hyperactivity likely due to leptin resistance, hyperinsulinemia (which may precede insulin resistance), and hypertriglyceridermia (465). In addition, catecholamines can induce production of the proinflammatory cytokine IL-6 locally at the myocardium (466); IL-6 stimulates hepatic production of CRP, which can contribute to progression of atherosclerosis. Persistent elevations in catecholamines can alter hemodynamics and lead to endothelial injury.
The injured endothelium releases chemokines that attract monocytes, lymphocytes, and glucocorticoids, which could facilitate the early stages of atherosclerosis through induction of vascular cellular adhesion molecules (467).

The cascade of events associated with HIV infection exemplifies the potential detrimental effects of a chronic acute stress response. HIV-infected monocytes and macrophages are stimulated to produce IL-1, TNF, and IFN-γ, which can increase CRH release and thus potentially affect immunomodulation of cytokine production (234). Taken together, the chronic activation of glucocorticoids and catecholamines can cause changes in the inflammatory cytokine milieu to selectively alter the pattern of cytokine secretion from Th1 to Th2. This may be linked in part to the increased predominance of visceral adiposity (255), insulin resistance (256), and atherosclerosis (468) in HIV-infected patients.

IV. Overview of clinical implications of infection. The impact of infection on nutrition is incontrovertible. Text Box 30 outlines the general pathways by which this impact is manifested.

Infections and undernutrition constitute a 2-way causal interrelation, the “malnutrition-infection cycle,” whereby undernutrition generally increases risk and severity of infection and infections and/or their treatment may impair food intake and nutritional status. This scenario is played on a global scale and puts infants and children <5 y at particular risk (408). The historic approach with regard to nutrition is to develop and roll out intervention programs to address particular aspects of this situation (e.g., universal single/multiple-micronutrient interventions and/or vaccines). However, evidence continues to emerge that, in the absence of a full appreciation of the complexities of a given health context and the biology of nutrition within that context, nutritional interventions to circumvent this cycle may have deleterious effects. The elements of this complexity are highlighted in Text Box 31.

The complexities of this cycle are illustrated by the results of a large study in a highly malarious area in which daily iron supplementation in young children increased infectious adverse events, especially in those considered iron replete (28). Another

---

**Text Box 27  Research priorities**

- Accurate and stable biomarkers of VAD
- Effect of vitamin A supplementation on inflammation and inflammatory markers
- Mechanisms behind the variable clinical outcomes seen as a result of the impact of vitamin A on the different immune responses
- Effect of vitamin A supplementation on neonates and infants <6 mo
- Influence of zinc status on vaccine response
- Other confounders in the zinc–vaccine response association (age, sex, degree of zinc deficiency, etc.)
- Impact of therapeutic vs. preventive use of zinc supplementation for different clinical outcomes
- Mechanistic studies to optimize zinc therapy and to define populations most likely to benefit
- Impact of zinc status on Th17 or Treg cells

---

**Text Box 28  WG 3 summary and conclusions**

- A paradigm is presented that incorporates an appreciation of the complex global health scenario and the importance of considering the intimate and inextricable interactions between inflammation and nutrition and their impact on health status assessment.
- The multiple effects of inflammation on both inflammatory and nutritional biomarkers are presented in a variety of conditions that exemplify these effects, including various infections and NCDs (e.g., obesity, obstructive lung diseases), and from a life cycle stage perspective (pregnancy and infancy).
- Attention is given to the important role of the gastrointestinal barrier and the gastrointestinal ecology including the emerging appreciation of the importance of the microbiome.
- Additional coverage includes the immunologic and nutritional manifestations of derangements in this ecology commonly referring to as “environmental enteropathy.”
- The conditions covered illustrate both the complexity of host profiling and the need for identifying priority biomarkers that reflect status, function, and effect of interventions in individuals and at the population level.
- Context-specific examples are considered in relation to gut integrity and secondary effects of drug exposures.
- Infections and undernutrition coexist in underprivileged individuals and populations and constitute a 2-way causal interrelation, the “malnutrition-infection cycle,” whereby undernutrition generally increases the risk and severity of infection and infections and/or their treatment may impair food intake and affect nutritional status.
- Infection and inflammation influence nutritional status and biomarker selection and interpretation in multiple ways including the following:
  - altered intakes through effects on appetite
  - altered absorption through effects on mucosal integrity
  - increased caloric requirements through altered metabolism and host immune responses
- Six nutrients are considered in detail (iron; vitamins A, D, and B-12; zinc; and folate), and summary statements of extant evidence about the roles that these nutrients play in inflammation are presented.
- Research priorities are highlighted ranging from basic science to epidemiologic profiling and the identification of risk categories.
example is the observation that vitamin A supplementation, which generally lowers mortality in children, increased the risk of mother-to-child HIV transmission in pregnant and postpar- tum HIV-infected women in Tanzania (469), although not in South Africa (470) or Malawi (471). In infants of HIV-positive mothers, postpartum maternal and neonatal vitamin A supple- mentation may hasten progression to death in breastfed children who are PCR negative at 6 wk (291). The following sections cover specific examples of the infection-malnutrition cycle.

Having laid out the basic concepts underlying the potential interactions between inflammation, infection, and nutrition, it is useful to explore how these interactions affect specific aspects of nutrition. To explore this aspect of the inflammation/nutrition relation, 6 specific nutrients—iron, zinc, vitamin A, folate, vitamin B-12, and vitamin D—are examined. The following 8 questions were used to frame this discussion:

- What is the role of [nutrient] in the basic biology of immunity/inflammation? (This was extensively addressed by WGs 1 and 2.)
- What is the evidence that [nutrient] status or intervention affects inflammation/infection? (This is informed by materials presented by WG 2.)
- Is there evidence that inflammation/infection affects [nutrient] status?
- What mechanisms are responsible for altering [nutrient] status?
- Is there evidence that different infections or types and sources of inflammation have differential effects on [nutrient] status?
- Is there evidence that host genetic effects modulate the effects of infection/inflammation on [nutrient] status?
- What are the implications for host [nutrient] status?
- What are the implications for biomarker assessment of [nutrient] status?

The responses to these questions are outlined for each of the 6 nutrients in Supplemental Table 9 and Supplemental Figure 3.

a. Exposure to specific and multiple infections through the life course. It is not uncommon for individuals in low-income countries to have multiple, coexisting infections and NCDs. The scenario is best exemplified by the comorbidities associated with HIV infection (472). Although HIV is most commonly used as the example of comorbidity, the recent analysis of the GBD clearly indicates that there are various colliding epidemics of infectious diseases and NCDs occurring particularly in low-/middle-income settings (1). Other examples of comorbid conditions include latent infections (e.g., mycobacteria, cytomegalovirus), chronic helminth infections (e.g., geo- helminths, schistosomes, filariae) maintained by regular exposure, chronic viral infections (HIV; hepatitis A, B, and C), with frequent, superimposed acute respiratory, gastrointestinal, and urogenital tract infections. In childhood, diarrhea may occur 6–8 times/y.

The inflammatory drivers are multiple, especially because infection exposure occurs from birth onward. These patterns of comorbidity may be complex. Helminth infections are often established in early childhood, and the prevalence and intensity peaks in childhood, with persistent infection exposure through

### TABLE 9  Conditions that may precipitate an APR

<table>
<thead>
<tr>
<th>Medical</th>
<th>Accidents</th>
<th>Physiologic</th>
<th>Environmental</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td>Trauma</td>
<td>Gestation</td>
<td>Indoor cooking with biomass fuel</td>
</tr>
<tr>
<td>Noninfectious inflammatory diseases (diabetes, cancer)</td>
<td>Burns</td>
<td>Parturition</td>
<td>Pollution (toxin exposures)</td>
</tr>
<tr>
<td>Infarction and hemorrhage</td>
<td>Latrogenic (surgery, drugs, radiation)</td>
<td>Vaccination</td>
<td>Climate change (temperature/weather extremes)</td>
</tr>
</tbody>
</table>

1 APR, acute phase response.
adolescence. Along with effects such as EE discussed below, these infections may trigger APRs during the tissue-phase of the primary infection or during reinfection, whereas stable, low-intensity infections may not be associated with elevated levels of acute phase reactants.

The chronicity of effect depends on the nature of the infection, including its transmission patterns. Some examples include the following:

- In holoendemic malaria areas with year-round transmission, a large proportion of the population, including pregnant women, may experience asymptomatic parasitemia, concurrent elevation of serum APRs, and anemia of chronic inflammation.
- Overt tuberculosis, which affects 11 million people/y, causes a massive APR; but even latent tuberculosis, which affects one-third of the world’s population, has been associated with a slightly increased APR (H Friis, University of Copenhagen, personal communication, 2012).
- HIV continues to be a significant problem, with >34 million people now living with HIV/AIDS; 3.4 million of them are <15 y old (473). Current knowledge with regard to their nutritional needs was recently reviewed (474). Comorbid conditions (both infectious and NCDs) continue to be a common concomitant of HIV infection and may impair ability to produce an APR, thereby further increasing the risk of common and opportunistic infections that drive an APR.

The use and interpretation of nutritional biomarkers must take into account these age-specific and potentially multiple effects of infection. This also highlights the importance of clear clinical definitions of subject categories in studies of nutritional biomarkers.

b. Chronic malaria and parasitic infections. In 2010, there were 219 million cases of malaria, with ~80% of cases limited to 17 countries, most prominently in Africa with an estimated 660,000 deaths (with an uncertainty range of 490,000–836,000), mostly among African children (475). Not only does this represent a significant global health concern but its unique characteristics offer specific insights into the nature and implications of chronic exposure.

Many children, adults, and pregnant women living under conditions of perennial malaria transmission remain susceptible to malaria parasitemia. This is often asymptomatic due to the partial acquisition of malarial immunity. Chronic parasitemias lasting several months are common in such individuals unless treated with antimalarial drugs. Age differences in patterns of malaria immunity relate to this chronicity of exposure. Hepatosplenomegaly occurs with persistent infections and a chronic inflammatory state develops, often with hypergammaglobulinemia, which is attributable to reticuloendothelial and lymphoid hyperplasia. In a minority of individuals this may result in hyperreactive malaria splenomegaly with enormous splenic enlargement (476). Chronic exposures to other parasitic infections (e.g., schistosomiasis) may also cause hepatosplenomegaly, and these coexposures may further exacerbate chronic inflammation. Pathologic hepatic disease in childhood can lead to anemia, RBC production failure, and growth impairment. The association between hepatosplenomegaly, secondary to these chronic exposures, and cytokine responses has been little studied (477). Proinflammatory mechanisms are important, but there is little research relating these to nutritional correlates and biomarkers and their potential interactions (478). The following sections describe what is known about the impact of infection,

---

Text Box 30  Effects of infections on nutritional status and validity of biomarkers
- Infection may affect nutritional status directly as a result of poor appetite, local lesions, or other manifestations causing pain (e.g., oral or esophageal ulcers impairing food intake, diarrhea impairing absorption and increasing excretion of nutrients).
- The APR mediated through its cardinal manifestations may result in:
  - Fever via increases in resting energy expenditure,
  - Anorexia via reduction in the intake of energy and nutrients, and
  - Impaired absorption and increased utilization and excretion of nutrients.
- Infection and the APR also affect nutrition indirectly via the role of some nutrient biomarkers as acute phase reactants (e.g., ferritin), thereby influencing their validity if used to assess specific micronutrient status. These effects are more severe with generalized, frequent, or recurrent infections.

Text Box 31  Factors that might affect nutritional interventions
- Baseline nutritional intake and status of the individual/population including the following:
  - Impact of infection/inflammation on biomarkers used to assess status
  - Deficient vs. replete: a particular consideration for “universal”/countrywide intervention programs
- Stage of the life cycle:
  - Infants: breastfeeding
  - Children: complementary feeding
  - Pregnancy/lactation
- Bioavailability, safety, and efficacy of proposed dose, form, composition, and administration route of the intervention, particularly within the specific conditions of the region/cultural setting
- Appreciation of the nature of the concurrent infection or infections and the body’s response to infection/inflammation as outlined by WGs 1 and 2
- The nature of the biological relation between a nutrient and an infectious organism (e.g., malaria)
- The impact of other therapeutic interventions (e.g., drugs, vaccines)
NCDs, and certain physiologic states on nutrition with specific examples provided within each category.

c. Intestinal barrier integrity. Any discussion of the interaction between infection, nutrition, and health must include an appreciation of the expanding understanding of the critical roles played by the gastrointestinal environment. The importance of gastrointestinal integrity is demonstrated by numerous reports documenting a relation between increased intestinal permeability and poor growth in low-income countries (479–481). In addition, the gastrointestinal environment, including the critical influence of the gut microbiome, plays an integral role as a barrier protecting the host from invasion by pathogenic organisms found in our environment. Key features of and approaches for assessing gastrointestinal function/integrity are highlighted in Text Box 32.

Although much has been learned about the interactions between the gut microbiome, immune system, and nutrition (283), the association of measurements of inflammatory markers of gut wall integrity with nutritional profiles has not been studied extensively. This is an important research gap because enteric infections are common causes of child morbidity and mortality, particularly in low-resource settings; thus, identification of relevant biomarkers for assessing risk is a priority.

d. Environmental enteropathy. EE, also called tropical enteropathy, is a chronic subclinical condition caused by persistent fecal-oral contamination that results in colonization of the small intestine, destruction of intestinal villi, and inflammation (490, 491). The relations between EE, malnutrition, and development are complex and include impaired cognition and behavioral development in infants and young children consequent to the loss of essential nutrients integral to brain development (492, 493). EE has been implicated as a cause of stunting or chronic malnutrition; as much as 40% of stunting among under-5 children is attributed to EE in sub-Saharan Africa (494). Not only are growth and development adversely affected by EE, it also causes impaired immunologic responses to oral vaccines (495).

The epidemiology of EE is not well described, because diagnostic criteria are lacking, as are reliable point-of-care biomarkers. The intestinal permeability test using lactulose and mannitol has been used extensively to assess the integrity of intestinal barrier function, but it is limited due to its sensitivity and specificity. Candidate biomarkers currently being tested include neutrophil myeloperoxidase, fecal neopterin, citrulline, Regeneration gene 1A, Regeneration gene 1B, antibody to bacterial cell wall LPS core oligosaccharide (EndoCab antibody), and zonulin (see above section on intestinal barrier integrity) (491).

Immunologic manifestations of EE are outlined in Text Box 33.

People living in communities in poor conditions of hygiene and sanitation are not equally affected by EE, which implies the need to discover underlying factors, such as genetic predisposition, amount of exposure to pathogen, role of pre-existing malnutrition, as well as the role of immune system (490). Characterization of EE in at-risk individuals is clearly important for the interpretation of nutritional biomarkers.

V. Chronic and noncommunicable diseases. As highlighted in the recent review of the GBD (1), there are several alarming global trends that occur with regard to NCDs.

- The prevalence of high BMIs has increased globally to become the sixth greatest risk worldwide.
- 1.3 million deaths were due to diabetes in 2010, twice as many as in 1990.
- Deaths from NCDs (diabetes, CVD, cancer) increased by ~8 million between 1990 and 2010, accounting for 2 of every 3 deaths (34.5 million) worldwide in 2010.

Each of the major NCDs has been shown to have a strong inflammatory component, including cancer (498–500), CVD (501–503), and diabetes (504–506). For the purposes of this review, WG 3 chose to focus on obesity and chronic obstructive pulmonary disease (COPD) as examples of the inflammation, nutrition, and NCD nexus.

a. The double burden of malnutrition. Developed nations in the 1980s saw an upsurge in overweight and obesity among adolescents. Now, LMICs are facing the same problem of an increasing prevalence of overweight/obesity. In addition, these same settings are facing the added trend of overweight and obesity coexisting with undernutrition (associated with deficits of calories, specific single or multiple nutrients) in the same individuals, households, or communities—a condition called the double burden of malnutrition (6). This double burden is occurring in many settings, but recent data from Bangladesh offer a graphic example of the problem. In Bangladesh, where childhood stunting prevalence is one of the highest in the world (41% with height-for-age z scores ≤2, and 24% of women chronically malnourished with a BMI <18.5), overweight and obesity affect 17% women of childbearing age (507).

Among the challenges presented by the double burden are how best to develop and roll out programs to address either under- or overnutrition in settings in which both coexist. Clinically, the concern becomes how best to assess not only nutritional status broadly but how best to address potential interactions of over- and undernutrition with inflammation (i.e., with the APR). As will be outlined below, obesity (and its comorbidities) has an array of effects on the inflammatory response and vice versa. Add to that the impact of anomalies in the status of single or multiple micronutrients, and one can envision a complex scenario that can affect clinical accuracy and the development of effective interventions. Clearly, this complexity outlines an urgent research agenda.

The role and impact of selected nutrients on immune function and the inflammatory response were covered by WGs 1 and 2 and are covered in additional detail in Supplemental Table 9. The following is a brief discussion of the relations between overweight/obesity individuals and inflammation.

b. Overweight and obesity are chronic inflammatory states. Overweight and obesity are inflammatory in nature because adipose tissue releases a number of inflammatory mediators (508). The main source of the mediators is believed to be macrophages that infiltrate adipose tissue, although adipocytes also contribute to the inflammatory process. Chronic low-grade inflammation is also a risk factor for type 2 diabetes and the metabolic syndrome (a complex of symptoms that include a combination of obesity, hypertension, impaired fasting glucose, or dyslipidemia). In obese subjects, compared with those with normal weight, there is an upregulation of systemic indicators of inflammation such as total leukocyte count, serum APRs, proinflammatory cytokines and chemokines, soluble adhesion molecules, and prothrombotic mediators. Although there may be an overlap between obese and nonobese states, obese individuals may have a severalfold increase in serum concentrations of TNF, IL-6, MCP-1, IFN-γ-induced protein 10, IL-18, macrophage migration inhibitory factor (MIF), and regulated on activation, normal T cell expressed and secreted (RANTES).

These chronic inflammatory mediators occurring in overweight and obesity are considered to be involved in insulin resistance, insulin dysfunction, hyperinsulinemia, and insulin resistance, insulin dysfunction, hyperinsulinemia, and insulin resistance.
resistance and the metabolic syndrome. Adipose tissue is in fact a large endocrine organ secreting the proinflammatory hormone leptin and the hormones visfatin and resistin, which cause insulin resistance (509–511). In addition, it produces APRs, cytokines, chemokines, growth factors, components of the alternative complement system, and RBP. Ectopic deposition of adipose tissue may also occur in the absence of obesity and causes inflammation. This is particularly important in causing cardiac pathologies if the deposit is in the heart. This perhaps underlies the “thin-fat” hypothesis of increased atherosclerotic

**Text Box 32   Key features of the gastrointestinal barrier**
- The barrier between the indigenous community of bacteria comprising the “gut microbiome,” residing in the gastrointestinal lumen and the sterile bloodstream, is formed by a layer of epithelial cells closely interconnected by tight junctions. This barrier plays a significant role in protecting the hosts from a myriad of potential adverse environmental exposures (482).
- These cells produce an antimicrobial layer composed of defensins, immunoglobulins, and mucins.
- Underneath the epithelium lies a complex network of communicating dendritic and immune cells that prevent leakage of luminal contents into the systemic circulation.
- The microbiome itself forms an ecological barrier that deters pathogens. Disruption of this intestinal barrier increases gut permeability and enables luminal bacteria and microbe-associated products to enter the bloodstream, a process called “bacterial translocation” (68, 483, 484).
- Bacterial translocation has been implicated in numerous infectious [e.g., HIV (485) or malaria (486)] and noninfectious [e.g., liver (487)] diseases.

**Approaches to assessing loss of gastrointestinal barrier integrity or function**
- Dual sugar absorption test:
  - This test is based on the premise that large sugar molecules such as lactulose do not cross the intestinal barrier in the healthy patients, whereas smaller molecules such as mannitol do.
  - Loss of gut wall integrity causes lactulose to leak into the circulation and results in an increase in the urinary lactulose-to-mannitol ratio.
  - Because of its laborious nature the dual sugar absorption test is unsuitable for monitoring purposes in clinical practice in resource-poor settings.
- Citrulline test for functional enterocyte mass:
  - Citrulline is a nonessential amino acid that is produced from glutamine in small intestinal enterocytes. Loss of enterocytes results in declining circulations of citrulline in the blood and is shown in cytotoxic treatment–induced mucositis (40).
  - Serum concentrations of citrulline $\geq 20 \mu\text{mol/L}$ predict success of small bowel nutritional rehabilitation in short bowel syndrome, villous atrophy syndrome, and chemotherapy-induced mucositis.
  - The utility of this test to assess recovery of enterocyte mass in rehabilitated malnourished patients to allow transition to community care has not been established.
  - The presence of intestinal inflammation does not affect plasma citrulline concentrations.
- Calprotectin:
  - Calprotectin is a cytosolic protein with antimicrobial activity that is released from neutrophils in the gastrointestinal tract and is found in high concentrations in the stool of patients with intestinal inflammation (e.g., Crohn disease and ulcerative colitis).
  - Healthy infants and toddlers have higher stool amounts than do school-aged children, teenagers, and adults. This finding is consistent with the observation that the gut microbiome functionally matures in the first few years of life (488).
  - Calprotectin amounts may be elevated in the stool of malnourished children with EE, although this has not yet been examined.
  - Several other biomarkers have been identified, which may have utility in assessing gut inflammation (489):
    - lactoferrin
    - the enzyme biomarker, M2-PK, an early marker for colorectal polyps
    - $S100A12$ (a genetic marker that might be associated with neutrophil function and inflammation)

**Text Box 33 Immunologic/inflammatory impacts of EE**
- Mechanistically, the manifestations of EE are the result of a persistent cell-mediated inflammatory reaction in the mucosa, which leads to increased rates of cell destruction (496).
- Lamina propria T cell subpopulations (CD3, CD4, and CD8) are higher than normal, but CD8:CD4 values are normal.
- Cells expressing the CD25 activation marker are more commonly observed.
- Intraepithelial lymphocytes are common and contain perforin granules that reflect cytotoxic capability and indicate that the mucosa is under severe distress.
- The mucosa of children with EE shows increased numbers of both pro- and anti-inflammatory cytokine-producing cells, although this increase is smaller in children with malnutrition.
- Cells producing anti-inflammatory cytokines are markedly reduced in severely malnourished children, giving an upper hand to proinflammatory cytokine–producing cells (497).
heart disease among Indians who have increased visceral fat deposition that may not be associated with obesity (512). The concentration of inflammatory mediators in obesity is reduced with increased physical activity (513, 514), although whether the reduction is due to physical activity itself or to reduced body weight needs to be clarified.

c. Inflammation and nutrition in obstructive lung diseases. Persistent inflammation seen in many chronic diseases is associated with increased morbidity and mortality (515–518). Moreover, therapies aimed at reducing inflammation were found to lower overall mortality among healthy people with elevated CRP (519), reduce progression of atherosclerosis in patients with coronary artery disease (520), and improve exercise capacity (521) in patients with COPD. The topic of how inflammation affects nutrition in chronic NCDs or vice versa, however, is less well studied. In this section, obstructive lung disease (OLD) is discussed as an example of the bidirectional relation that may exist between inflammation and nutrition in chronic diseases, in order to identify potential gaps in our understanding (characteristics of OLD are shown in Text Box 34). In Figure 1, a schematic is provided of the bidirectionality of this relation identifying potential nutritional contributors and outcomes. A range of nutritional disturbances is considered, including obesity, weight loss, muscle wasting, adipose tissue accumulation, and specifically, micronutrients and vitamins A and D (Figure 1).

In chronic conditions such as asthma, inflammation and nutritional disturbances are often related to epiphenomena such as environmental exposures to tobacco smoke, air pollution, or airborne allergens. Evidence that inflammation leads to worse nutrition is reported in studies linking increased TNF production (527–530) and higher resting energy expenditure (531) with being underweight in patients with COPD. Moreover, the systemic inflammation may also be directly responsible for muscle wasting and cachexia seen in some patients with COPD (532–535). It was also reported that high-sensitivity CRP was a marker for impaired energy metabolism, lower functional capacity, and a lower St. George’s Respiratory Questionnaire score in patients with COPD (536). Previous studies showed that a low fat-free mass assessed by bioelectrical impedance analysis is an independent predictor of mortality irrespective of fat mass (534).

More recently, a placebo-controlled randomized trial in patients with COPD found that nutritional supplementation, in combination with a short course of anabolic steroids vs. nutritional supplementation alone, enhanced gain in fat-free mass and respiratory muscle function in depleted patients with COPD over an 8-wk period (537); however, a post hoc analysis did not identify a survival benefit from the intervention (538). Hence, more evidence is needed to determine if the prevention of weight loss in patients with COPD is a modifiable endpoint with nutritional interventions, and if such interventions lead to a measureable survival benefit.

i. Obesity and OLD/asthma. The importance of obesity in asthma has received increasing attention over the past decade, in part because of the striking increase in the prevalence of global obesity (550–552) change (539–541). Potential mechanisms to explain the impact of obesity on asthma are outlined in Text Box 35.

Research in a multitude of settings with the use of various study designs in children and adults has identified an association between obesity and asthma (544–551). However, there is insufficient evidence to state whether obese children have a greater risk of more severe asthma (541).

In terms of potential interventions, a few small-scale, randomized studies examined the role of weight loss in adults (552–554) but none have been conducted in children. A recent systematic review found weak evidence to support weight reduction as an intervention to improve asthma outcomes. Better evidence on the relation between weight loss and asthma outcomes will be provided by the BE WELL (Breathe Easier through Weight Loss Lifestyle) intervention, a randomized clinical trial of the efficacy of an evidence-based, comprehensive, behavioral weight-loss intervention in obese adults aged 18–70 y with suboptimally controlled, persistent asthma (555).

ii. Specific micronutrients and OLD. The role of micronutrient deficiencies in the etiology of OLD has also gained considerable attention over the past 2 decades (556). Multiple observational studies found micronutrient deficiencies to be associated with either asthma (537–565) or COPD (566, 567), although randomized supplementation trials yielded inconsistent results (558, 561, 562). Plausible mechanisms and extant evidence for 2 micronutrients, vitamins A and D, are presented in Text Box 36.

Inflammation and nutritional disturbances observed in OLD could also be epiphenomena of environmental exposures that result in allergic inflammatory responses. For example, cigarette smoke, ozone, and nitrogen oxides (primarily NO and NO2) are all rich in free radicals (597), which may not only affect overall antioxidant micronutrient concentrations but also increase local inflammatory responses in the lung. Allergic inflammation in the lungs may also occur in response to traffic-related pollutants as evidenced by observations of positive associations between traffic, ambient pollutant exposures, and both asthma and allergy outcomes in asthmatic children (598–605).

The existence of plausible mechanisms to explain possible interactions between specific or multiple micronutrients in the absence of clinical trial data to support such relations suggests either poor design or lack of attention to sound principles of nutritional assessment in such trials (e.g., the need for accurate baseline data to establish status before interventions or to explain subject status). A need also exists for better clinical characterization, including nutrient-specific biomarkers, that accounts for the potential impact of inflammation in order to address these relations. Better data are needed with regard to the role of nutrients in OLD, both in terms of etiology/risk and as potential outcomes (primary: nutrient malnutrition; secondary: metabolic derangements leading to loss of appetite, changes in body composition) of the OLD process.

VI. Pre- and postnatal conditions, outcomes, and inflammation. Pregnancy inflammation (infectious or noninfectious) is often associated with increased risk of adverse pregnancy outcomes,
and subclinical endotoxemia has been associated with systemic and adipose tissue inflammation in pregravid obese women (606). The features of noninfectious inflammation in pregnancy are highlighted in Text Box 37.

a. Oxidative stress in pregnancy and in prematurity. Tissue lipid peroxidation is increased in healthy pregnancy, but gestational increases in lipid peroxidation by-products are aggravated in overweight, obese, and diabetic pregnant women, and oxidative stress is an important consequence of pregnancy obesity that can directly affect micronutrient status. Oxidative stress associated with increased ROS and/or reactive nitrogen species has also been linked to poor reproductive outcomes (e.g., idiopathic infertility, poor semen quality, and low-quality oocytes) (619) as well as poor implantation and increased endometriosis via placental ischemia/hypoxia-mediated defects (620). Thus, it has been suggested that early-onset pre-eclampsia, spontaneous miscarriage, and intrauterine growth restriction may represent a spectrum of placental oxidative stress–related disorders (620). The role of oxidative stress biomarkers (F2-isoprostanes, oxidized low density lipoprotein, malondialdehyde, hyperhomocysteinemia, NO, peroxynitrites, 8-oxodeoxyguanosine, reduced glutathione/oxidized glutathione, 4-hydroxy-2-nonenal, tyrosine nitration) and their nutritional modification in relation to pregnancy pathogenesis requires further investigation (619).

There is good evidence that oxidative stress is associated with preterm birth complications due to an underdeveloped and highly stressed antioxidant system (621, 622). Because the activity of key antioxidant enzymes only matures in the last weeks of gestation, preterm infants have a developmentally immature antioxidant system showing generally low activity of superoxide dismutase, catalase, and glutathione peroxidase enzyme activities, thus predisposing to oxidative stress. Moreover, preterm infants demonstrate a relatively high activity of the xanthine/xanthine oxidase system that can aggravate oxidative stress via production of superoxide anion. Membrane α-tocopherol concentrations and plasma and tissue carotenoid concentrations are lower in premature infants than in full-term infants due to lack of placental transfer of lipophilic antioxidants during the late gestation (623).

b. Acute and chronic infection in pregnancy. It has been well established that pregnant women are more susceptible to some infections, and for this reason they represent a special population group (627). Systemic immune responses in pregnancy

Text Box 34 Characteristics of OLD
OLDs are a group of chronic respiratory conditions characterized by:
- airflow limitation,
- wheezing,
- dyspnea, and
- increased work of breathing (484, 522).

The spectrum of OLD ranges from:
- reversible airway disease, more commonly seen in asthma, to
- irreversible airway disease associated with emphysema and more commonly seen in COPD (523).

Inflammation occurs both locally in the lungs but also in the systemic circulation (524). In both asthma and COPD, local inflammation leads to airflow limitation either through:
- hypertrophy of mucous glands,
- excessive secretions, or
- bronchial smooth muscle hyperactivity.

In chronic OLD, the inflammation leads to either airway remodeling (525) or destruction of lung parenchyma. Chronic lung inflammation in COPD is followed by increased systemic inflammation, weight loss, and low muscle mass (526).

Text Box 35 Obesity and OLD/asthma: potential mechanisms
- Reduced lung volumes (542)
- Greater airway responsiveness (543)
- Increased local and systemic inflammation that may be associated with an exaggerated response to environmental triggers (541)
- An increase in abdominal fat mass associated with a chronic elevation of the circulating concentrations of inflammatory mediators including CRP and pro- and anti-inflammatory cytokines and chemokines, leading to a state of low-grade inflammation (508)
are modulated rather than suppressed (628) and are influenced by placental cytokine networks (Figure 2); these changes include both proinflammatory and anti-inflammatory profiles (613). In addition the adaptive immune response is downregulated whereas innate immunity is enhanced. As a result, pregnant women are more susceptible to parasitic infections and to severe bacterial and viral infections. This leads to distinct inflammatory pathways with consequences that effect biomarker profiles. These adverse effects are due to a direct effect of the pathogen (viral, bacterial) or are secondary through maternal responses to inflammation/cytokines requires further investigation. Some investigators consider that impaired offspring TLR function is associated with increased susceptibility to infections and to preterm labor (613).

Other chronic pregnancy infections, such as soil-transmitted helminths, contribute to maternal nutritional anemias, which are associated with similar adverse pregnancy outcomes (631–633). Low-grade bacteremia and/or cytokines generated within oral tissues have also been associated with increased risk of preterm birth and neonatal morbidity (634). In the context of low-grade inflammation, regardless of cause, extent, and location, there is evidence for an impact on gastrointestinal morphology and function, which can have nutritional implications (635). Thus, the effects of both acute and chronic infections on nutritional status raise the possibility that nutritional interventions, in addition to infection control, could modulate pregnancy outcomes, especially in developing countries where an underlying prevalence of undernutrition is common and where exposure to pregnancy infections such as malaria is often high (632). Nevertheless, few studies have examined how pregnancy inflammation/infection itself directly modulates nutritional status or biomarker profiles of the mother or the infant. Even the utility of CRP as an indicator of inflammation/infection during pregnancy has been questioned (636). Studies usually describe how infection and inflammation are associated with nutritional deficiencies [e.g., iron, vitamin B-12, folate, and vitamin D for bacterial vaginosis (637–639) and anemia or obesity for stillbirths (640)].

c. Fetal and infant infection. The immunologic responses by the maternal, placental, and/or fetal immune systems can affect fetal development (641) and perinatal survival. The question of whether these adverse effects are due to a direct effect of the pathogen (viral, bacterial) or are secondary through maternal responses to inflammation/cytokines requires further investigation. Some investigators consider that impaired offspring TLR function is associated with increased susceptibility to infections and to preterm labor (613).

Several infections are known to affect fetal growth. An important example in humans is Plasmodium falciparum malaria, which, after placental parasite sequestration, induces specific maternal endocrine, immunologic, and hematologic responses that are associated with fetal growth restriction and preterm birth (642). Infants born to these mothers exposed to malaria in pregnancy have increased infant anemia and mortality risk (643). Another example encompasses the range of gastrointestinal nematodes, which are mostly chronic maternal infections, and which have been associated with stunting in the
Text Box 37  Features of noninfectious inflammatory conditions of pregnancy

- Normal pregnancy may increase serum α1-antichymotrypsin (ACT) (587, 588, 607), and parturition induces an APR (589, 590, 608), with serum ACT concentrations occurring at levels similar to those found in patients with tuberculosis (609).
- Macrophage infiltration of adipose tissue and the placenta is characteristic of established obesity.
- In pregnancy, obesity is associated with an exaggerated inflammatory response with increased macrophage recruitment to the placenta resulting in elevated pronflammatory cytokine production (606).
- Macrophage-associated cytokines linked to insulin resistance include MCP-1, macrophage inflammatory protein 1α (MIP-1α), IL-1, IL-6, and IL-18 (610).
- Obese women with gestational diabetes mellitus release more leptin in response to cytokine stimulation than do those without diabetes (611, 612).
- Pregnancy inflammation (infectious or noninfectious) is often associated with increased risk of adverse pregnancy outcomes, and subclinical endotoxia has been associated with systemic and adipose tissue inflammation in pregravid obese women (606).
- Binding of pathogenic microbes to TLRs, which are widely expressed at the maternal-fetal interface, commonly results in the production of cytokines and antimicrobial factors via a common signaling pathway during pregnancy (613).
- TLRs have also been linked with their expression in the placenta in cases of macrophage-driven inflammation in obesity and intrauterine infection, subsequent chorioamnionitis, and preterm delivery (613, 614).
- An association between in utero markers of inflammation and increased risk of preterm birth has been reported (615, 616).
- A “leaky” placenta has been associated with the pathophysiologic defects associated with inflammation resulting from obesity and/or oxidative stress associated with diabetes (617). These defects include increased vascular endothelial growth factor (VEGF), vascular leakage of albumin, and altered junctional adhesion molecules.
- Changes in placental transfer of lipids (FAs) and cytokines have been noted in obese pregnant women and in those with diabetes (618).
- This “leakage” is one of the suspected side effects of gestational diabetes mellitus and pregestational diabetes.

offspring (644). At least in an animal model, these infections in pregnancy may lead to offspring stunting by causing inflammation, and this has been associated with increased cortisol concentrations and altered cytokine profiles (645).

Infants of mothers with pregnancy inflammation and/or infection have altered systemic immune exposures. A fetal inflammatory response syndrome is described in which infants born after placental infection have elevated inflammatory cytokine profiles (628, 646), despite absence of cultivable microorganisms. Constituents in breast milk help protect the infant from enteric infections (e.g., lactoferrin), whereas inflammatory factors, such as in subclinical and clinical mastitis and which influence postnatal infection transmission via breast milk (e.g., HIV), may directly influence infant mucosal immunity as well as the infant’s microbiome. This is an area for further research.

d. Mastitis. Mastitis, an inflammatory condition of the breast tissues, may or may not be accompanied by infection (647, 648). Milk stasis and infection are the 2 major causes of mastitis (647, 649), but the concept of mastitis as used in contemporary empirical studies remains inconsistent, perhaps due to the disparate views of its etiology (650). The details of the inflammatory response have been best described in cows (651).

In humans, subclinical mastitis (SCM) is usually defined by the absence of external inflammatory symptoms and one or more of the following indicators: reduced milk secretion, increased sodium-to-potassium (Na⁺:K⁺) ratio, elevated IL-8 concentrations, elevated milk leukocyte or somatic cell count, and/or a high bacterial count in a milk sample. Other ancillary tests include the following: milk microbiological cultures, N-acetyl-β-D-glucosaminidase activity, pH, lactose content, electrical conductivity, flow measurements, and quantification of APPs (648, 652). Some suggest that somatic cell and IL-8 counts are more informative indicators of mammary inflammation than sodium content (653). Others suggest microbial identification techniques based on pyrosequencing of the 16S ribosomal RNA gene to obtain a description of the human-milk microbiome (654), as a useful diagnostic tool to assess pathogen persistence (655). Metagenomic and transcriptomic analysis of milk samples from healthy and mastitis-affected women are currently underway. Preliminary results indicate that human mastitis may be characterized by a mammary bacterial dysbiosis, a process in which the population of mastitis agents increases whereas other bacteria, normal or commensal mammary microbiota, decrease (648). How these responses relate to, or result from, maternal nutritional factors is little studied.

Mastitis enhances vertical mother-infant transmission of infections, particularly HIV (656). Prompt diagnosis and treatment prevents lactation failure, recurrent mastitis, and breast abscess (655), but the source of entry of pathogenic bacteria remains uncertain. In contrast to mastitis, systemic inflammation,
although unconfirmed, may be the cause of SCM. SCM may affect the health of the newborn (657), because it may alter milk composition through changes in intramammary inflammation and leakage, changes in the metabolic activity of the mammary epithelial cells, and inflammation-mediated changes in nutrient transport (648, 652).

Mastitis has been associated with oxidative stress (658) and changes in cytokine gene and protein expression associated with adaptive immunity (659). In some conditions, supplementation with vitamins A, D, and E and copper and selenium was protective against mastitis (652), but others reported in HIV-infected women that antioxidant micronutrient supplementation did not lower (660), and might even increase the risk of SCM (661).

e. Polymorphisms and epigenetic effects associated with infection, inflammation, oxidative stress, and pregnancy outcomes. Polymorphisms in the TLR genes have been associated with both increased susceptibility to infections, in particular bacterial vaginosis, and with preterm labor (613). Some superoxide dismutase and catalase polymorphisms have been related to the development of prematurity complications. It was suggested that single nucleotide polymorphisms involved in the generation of ROS and reactive nitrogen species, or free radical scavenging proteins, might be used to identify preterm infants who might benefit from specific antioxidant prevention strategies against free radical–mediated diseases (662). More recently, the emerging role of oxidant molecules in fetal programming was reviewed (663). It is now recognized that genomewide association studies only explain a small proportion of the known heritability of phenotypes. Future studies based on higher definition exome chips that can identify highly penetrant but rare variants, using full genome sequencing to better examine regulatory regions, and studies of genome-epigenome interactions, will better illuminate these issues.

Basic principles of epigenetics were highlighted by WG 1 (Text Box 10). More specifically, in pregnancy, the epigenetic effects of maternal infection, oxidative stress, and nutrition exposures on fetal immune response genes have been little studied (663). Nutritional interactions may be critical because oxidative stress has been associated with epigenesis (663). Changes in methylation patterns can be directed or stochastic in nature. Animal experiments clearly show that changes in maternal methyl-donor supply (choline, methionine, folate, and vitamin B-12) can influence the offspring phenotype (664). Emerging data from humans are confirming such associations and, importantly, indicate that maternal nutritional exposures before and during the earliest stages of pregnancy can be critical (665, 666). Folic acid supplements in pregnancy have been associated with a slightly increased risk of wheeze and lower respiratory infection in children up to 18 mo, which may relate to methyl donors in the maternal diet during pregnancy that influence respiratory health in children, consistent with epigenetic mechanisms (667).

Similarly, the consequences of cigarette smoking in pregnancy on these important aspects of early development may have an epigenetic basis (668), and may influence nutrition in children, including risk of obesity and stunting (669). The periods of gestational susceptibility of the epigenome need to be defined precisely, particularly in relation to peak gestational periods of exposure or infection risk. An example of an infectious disease exposure is the well-established peak P. falciparum malaria prevalence at 13–16 wk gestation in primigravidae living in high malaria transmission areas (670).

f. Profiling nutritional and inflammatory biomarkers in mothers and infants in relation to clinical outcomes. Profiling of nutritional and inflammatory biomarkers in mothers and neonates at birth should be emphasized to allow identification, through longitudinal studies, of baseline characteristics related to subsequent infant immunologic responsiveness, infection risk, nutritional status, and vaccine efficacy. In particular, there is a need for a better understanding of mechanisms affecting iron acquisition of pathogens causing pregnancy and perinatal infections, because this could have implications for maternal iron supplementation (629). Two recent epidemiologic studies showed that iron status predicted malaria risk in very young children. Tanzanian infants recruited at birth and who developed ID during follow-up had significantly decreased odds of subsequent parasitemia (23% decrease; P < 0.001) and subsequent severe malaria (38% decrease; P = 0.04) (671). ID was also associated with 60% lower all-cause mortality (P = 0.04) and 66% lower malaria-associated mortality (P = 0.11) (671). Likewise, malaria risk was predicted by iron status in Malawian preschool-aged children, suggesting that ID protects against malaria parasitemia and clinical malaria in young children (672). Children with ID at baseline had a lower incidence of malaria parasitemia and clinical malaria during a year of follow-up [adjusted HRs (95% CI): 0.55 (0.41, 0.74) and 0.49 (0.33, 0.73), respectively]. Whether these infection risks are definable using birth/neonatal nutritional and/or inflammatory profiling is uncertain. The extent to which invasive bacterial disease is present may also be a risk and unclear (673).

In pregnant women, host iron status may affect maternal and/or neonatal infection risk, potentially contributing to neonatal death (629). Iron acquisition mechanisms of pathogens causing stillbirth, preterm birth, and congenital infection are described but not understood in relation to host iron status. There is in vitro evidence that iron availability influences the severity and chronicity of infections that cause these clinical outcomes. However, in vivo, the risk is unknown because relevant studies of maternal iron supplementation did not assess infection risk (629). Caution with maternal iron supplementation may be indicated in iron-replete women who have high infection exposure, but the challenge in distinguishing iron-replete and iron-deficient women remains. The investigation of infection risk in relation to iron status in mothers and infants and the relevance of nutritional biomarker profiling is certainly an area in need of further research.

VII. Inflammation in specific conditions: drug exposures.

a. Nutrition and pharmacology: overview. In the face of pandemic infection and the explosion of NCDs, the use of single- and multiple-drug regimens will be expected to increase in all settings. Similarly, efforts to ameliorate hunger and more specifically single- and multiple-micronutrient insufficiencies continue to be a high global health priority. The potential clash of these public health interventions demands attention. Numerous examples of the potential for adverse effects of nutrient-drug interactions have been explored previously in the context of conditions such as cancer (674) and HIV (216, 675).

The role of nutrition in all aspects of pharmacology (pharmacokinetics and pharmacodynamics) was being reviewed previously (216). Essentially, nutrients and drugs share common pathways and mechanisms of absorption, metabolism, transport, and elimination. Consequently, the potential exists for either of these to affect the other. The implications of these potential interactions are significant when one appreciates the magnitude and complexity of the global health reality, i.e., that major infectious diseases and NCDs are treated with the available single- (and more often multiple-) drug regimens. As noted throughout this report, these conditions continue to be highly prevalent in LMICs, subject in many cases to the impact of food insecurity and all aspects of the malnutrition continuum,
including exposure to large-scale, high-dose micronutrient interventions. Thus, a need exists to recognize the potential for adverse outcomes consequent to the bidirectional relation between nutrients and drugs.

Aside from the well-established mechanisms of interactions outlined in Text Box 38, recent studies have highlighted another route, via genetic induction of key enzymes within critical pathways of drug metabolism.

For example, 1,25(OH)2D was observed to regulate genes responsible for the production of enzymes (including CYP3A4) responsible for detoxification in the intestine (676). This study, which was followed by numerous others, highlights an important and underappreciated role for vitamin D in drug metabolism through the induction of gene expression of key drug-metabolizing enzymes. This phenomenon should be evaluated closely, particularly in light of the expanding interest in vitamin D supplementation to boost immune function and for use in numerous conditions including HIV and other infections. Several of these types of interactions, including a similar enzyme-nutrient interaction involving vitamin A, were highlighted by WG 1.

The following is a brief coverage of specific aspects of these relations as pertains to inflammation, nutrition, and health.

b. Steroids. Numerous studies in humans have documented effects on inflammation of various drug exposures, although how these changes translate into effects on nutritional status or nutrient status or assessment (i.e., biomarker performance or interpretation) is less well defined. A basic categorization into steroidal and nonsteroidal compounds might be used for considering the influence of drug exposures. One of the most extensively documented compounds is the human glucocorticoid cortisol (or hydrocortisone). Various synthetic glucocorticoids are used in therapy and affect the immune system, with specific clinical consequences. Glucocorticoids antagonize TNF-stimulated lipolysis and reduce resistance to the antilipolytic effect of insulin in human adipocytes (677). The extent to which this occurs may reduce the potentially deleterious effects of excess lipolysis and contribute to fat deposition in obesity, as well as inducing appetite leading to weight gain. Other effects include the inhibition of prostaglandin synthesis at the level of phospholipase A2 and cyclooxygenase isomerase, potentiating the anti-inflammatory effect (678). Glucocorticoids act nonselectively and may impair normal anabolism, leading to negative nitrogen balance, altered amino acid profiles, and muscle breakdown.

c. Nonsteroidal compounds. Several anti-inflammatory drugs fall into this category, including aspirin, statins, and flavones, all of which may have an adjunctive effect on chronic inflammation. Aspirin can attenuate lipid-induced insulin resistance in healthy men, unrelated to changes in inflammatory markers (679). Aspirin is also commonly associated with gastrointestinal bleeding, potentially leading to mucosal injury and ulceration (680), and oxidative stress associated with released iron and inflammation, a scenario that can contribute to altered nutrient/micronutrient absorption and should be considered in clinically assessing nutritional status.

Reduced inflammation is also an effect of statins, which, in the NHANES 1999–2004, were associated with lower CRP and white blood cell (WBC) counts (681). These multiple effects indicate that drug exposures should be considered in the assessment of nutritional homeostasis. A detailed review of these effects is required to improve understanding of the consequences of the potentially wide variety of drug exposures on nutritional biomarkers in various clinical situations.

VIII. Conclusions. Assessing micronutrient status in the presence of inflammation is difficult due to changes in APPs associated with infection and pathophysiological changes in the host. These may involve changes in rates of synthesis and breakdown, plasma volume changes and hemodilution, and tissue sequestration. Improved understanding of the impact of inflammation on nutritional status is essential to correctly assess micronutrient status and to target those with the greatest need.

In this review a framework was presented to enable a structured approach to these assessments. It is essential to have an understanding of acute and chronic stress responses to inflammation and to translate impact in specific risk groups and among those living under different exposure conditions. The variability between infectious and noninfectious exposures is considered. Where possible, a generic approach has been adopted, although specific examples are used to illustrate particular host response pathways. The paradigm of multiple infection exposure is emphasized, and various templates were used to summarize the multiple effects of inflammation on both inflammatory and nutritional biomarkers in a variety of conditions, with an emphasis on obesity, pregnancy and infancy, and chronic infections. These illustrate both the complexity of host profiling and the need for identifying priority biomarkers, and those with functional significance on clinical outcomes. Context-specific examples were considered in relation to gut integrity and to the secondary effects of drug exposures. Nutrients considered in detail include iron, vitamin A, vitamin D, vitamin B-12, zinc, and folate (Supplemental Table 9). Summary statements of evidence that these nutrients play a role in inflammation were presented. The biochemical and functional consequences for the host and implications for biomarker assessment were considered.

IX. Research priorities. Research priorities are highlighted in Text Box 39 and range from basic science to epidemiologic profiling and the identification of risk categories.

d. WG theme 4: translating evidence to practice—approaches to addressing the nutrition and inflammation relations

Objective: 1) Identify clinically and programatically relevant biomarkers of inflammation in the context of acute inflammation/ infection and chronic inflammation/NCDs; 2) explore the impact of inflammation on nutrient biomarkers and summarize key features and challenges in nutrient biomarker performance and interpretation and use in the context of acute vs. chronic inflammation and individuals vs. populations; 3) identify approaches and evaluate options to account for the impact of inflammation on biomarker selection, use, and interpretation in clinical settings/points of care and population-level surveys. WG 4 summary and conclusions can be found in Text Box 40.

I. Introduction. As reviewed by WGs 1–3, our understanding of the interrelations between nutrition, immune function, and the acute and chronic inflammatory response continues to evolve. Coincident with the emergence of new knowledge is the need to translate this evidence to clinical and public health practice. In this section, the clinically and programatically relevant biomarkers of inflammation, the impact of inflammation on nutrient biomarkers, and potential approaches to account for the impact of inflammation on nutrient biomarker interpretation will be addressed. The vernacular with regard to immune function and inflammation is complex, and many of the core concepts were presented in the previous sections (WGs 1–3).

II. APR and APPs. The production of APPs is induced and regulated by the cytokines in response to tissue damage/stress.
The types of APPs are covered in more detail by WG 1. Table 10 summarizes the response of several positive and negative APPs to inflammation. Compared with cytokines that have very short half-lives, APPs remain longer in the blood and can therefore be matched with changes in nutrient biomarker concentrations. The characteristic changes in APPs resulting from the APR have primarily been evaluated in healthy adults undergoing elective surgeries (24, 374, 685, 686).

Ill. Acute vs. chronic inflammation. An inflammatory response can be caused by infections and noninfectious entities, such as trauma, autoimmune disease, and chronic disease. The causes of inflammation can be characterized as acute (lasting days to weeks) or chronic (lasting months to years). There may be exceptions to these categories of inflammation, because certain diseases or conditions do not fit into a single category.

Acute inflammation is characterized by the following features:
- It begins within seconds of a cellular insult by such harmful stimuli as bacteria, viruses, parasites, toxins, or trauma.
- It may initially be covert or subclinical before clinical symptoms appear.
- Macrophages or blood monocytes (24) are the cells most commonly associated with initiating the APR cascade.
- Activated macrophages release cytokines (e.g., IL-1 and TNF), which then trigger the next series of reactions.
- These reactions take place locally and act primarily on the microcirculation at the site of “injury” in a nonspecific response.
- Locally, stroma cells (e.g., fibroblasts and endothelial cells) are activated to cause the release of a second wave of cytokines that include IL-6, as well as additional IL-1 and TNF. These cytokines magnify the homeostatic stimulus and potentially prime all cells in the body with the potential to initiate and propagate this homeostatic response.

Chronic or low-grade inflammation is a critical element of NCDs, including the pathogenesis of atherosclerosis and insulin resistance (687, 688), and is characterized by a 2- to 3-fold elevation in systemic plasma concentrations of several cytokines including TNF and IL-6 as well as CRP (689). Why inflammation does not resolve with a return to homeostasis is not yet understood. Chronic inflammation may be due to loss of a barrier function, a continued APR to a normal nonthreatening stimulus, or infiltration of high numbers of inflammatory cells into areas where they are not normally found (17). The overproduction of inflammatory mediators may amplify the inflammatory response [e.g., oxidants, cytokines, chemokines, eicosanoids, or matrix metalloproteinases (17)] and contribute to the chronicity of inflammation.

IV. Implications of chronic inflammation. The recognition of the profound impact of inflammatory states on health outcomes is just beginning to be recognized. As outlined in Text Box 41, the emerging evidence with regard to the role of chronic inflammation in the elderly offers a good case study of the potential implications of these relations.

Despite the increasing awareness of the association between inflammatory markers and adverse health outcomes in older adults, the integration of these inflammatory markers into clinical practice has been limited. Possible reasons for this include a lack of clear mechanistic understanding, a plethora of inflammatory mediators that can now be measured, and the inconsistent relations of these markers with age-related outcomes. It has been argued that the main impediments to the clinical application of inflammatory mediators are their profusion and the inconsistency of their relation to outcomes (708, 713).

V. Clinically/programmatically relevant biomarkers of inflammation. This section highlights specific biomarkers of inflammation that are most commonly used in clinical and public health settings. These biomarkers may be used to reflect one or more categories of inflammation, namely acute, subclinical, or chronic inflammation. Although serum markers of inflammation are often used to reflect systemic inflammation, they are, in general, not specific for diagnosing individual clinical conditions. However, inflammatory markers are occasionally used clinically for nonspecific diagnosis of serious underlying disease to mark treatment response and to predict clinical outcomes (714). An extensive review of inflammatory biomarkers used in research settings is outside the scope of this review. The most commonly used inflammatory biomarkers, their ranges, and their uses are
Inflammation in specific conditions

- Elucidation of host mechanisms that influence iron acquisition by pathogens, particularly in the context of pregnancy and congenital and perinatal infections
- Nutritional correlates of proinflammatory states secondary to parasitic infection
- Long-term trials of nutritional supplementation, with or without anabolic steroids, on mortality outcomes in COPD
- Data to determine if reduction in inflammation reduces muscle wasting and all-cause mortality
- Trials of micronutrient supplementation in later life to determine effects on asthma exacerbations or severity
- An improved understanding of the pathogenic mechanisms related to environmental exposures may help identify the relevance of these to potential nutritional therapies
- Evaluation of preterm or term human milk, containing a range of hydrophilic and lipophilic antioxidants, for protection against oxidative stress in infants compared with formulas fortified with a few antioxidants
- Systematic review of effects of drug exposures on biomarkers of nutritional status
- Maternal and infant microbiome profiles and mucosal immunity

**Inflammation in pregnancy and nutritional modulation of immune responsiveness**

- Investigation of epigenetic influences on fetal immune responses and relation to nutritional exposures
- Critical periods of susceptibility to the epigenome need to be identified in relation to peak gestational periods of exposure (e.g., gestational timing of period of undernutrition) or for infection; e.g., for *P. falciparum* malaria peak prevalence at 13–16 wk gestation in high-transmission areas
- Longitudinal studies in mothers and infants are required to identify the outcomes of these maternal exposures in their children in terms of clinical outcomes and inflammatory and nutritional biomarkers

**Characterization of nutritional and inflammatory biomarkers of risk**

- Characterization at birth of nutritional and inflammatory biomarkers to identify, through longitudinal studies, their relation with subsequent infant immunologic responsiveness, infection risk, nutritional status, and vaccine efficacy (this approach requires descriptive noninterventional studies and a focus on risk profiling in the first 2 y of life)
- Tests of development and cognition are relevant as additional assessment categories
- Characterization of inflammatory factors in subclinical and clinical mastitis that may influence postnatal infection transmission via breast milk (e.g., HIV) and that may directly influence infant mucosal immunity as well as the infant microbiome
- The role of oxidative stress biomarkers (F2-isoprostanes, oxidized LDL, malondialdehyde, hyperhomocysteinemia, NO, peroxynitrites, 8-oxodeoxyguanosine, reduced glutathione/oxidized glutathione, 4-hydroxy-2-nonenal, tyrosine nitration) and their nutritional modification in relation to pregnancy pathogenesis
- Evaluation of serum citrulline cutoffs in severely undernourished children as a recovery biomarker of the enterocyte cell mass and of fecal calprotectin as a biomarker of EE (calprotectin and other proxy markers should also be further assessed in less severely undernourished children)

<table>
<thead>
<tr>
<th>Text Box 39 Research priorities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammation in specific conditions</strong></td>
</tr>
<tr>
<td>• Elucidation of host mechanisms that influence iron acquisition by pathogens, particularly in the context of pregnancy and congenital and perinatal infections</td>
</tr>
<tr>
<td>• Nutritional correlates of proinflammatory states secondary to parasitic infection</td>
</tr>
<tr>
<td>• Long-term trials of nutritional supplementation, with or without anabolic steroids, on mortality outcomes in COPD</td>
</tr>
<tr>
<td>• Data to determine if reduction in inflammation reduces muscle wasting and all-cause mortality</td>
</tr>
<tr>
<td>• Trials of micronutrient supplementation in later life to determine effects on asthma exacerbations or severity</td>
</tr>
<tr>
<td>• An improved understanding of the pathogenic mechanisms related to environmental exposures may help identify the relevance of these to potential nutritional therapies</td>
</tr>
<tr>
<td>• Evaluation of preterm or term human milk, containing a range of hydrophilic and lipophilic antioxidants, for protection against oxidative stress in infants compared with formulas fortified with a few antioxidants</td>
</tr>
<tr>
<td>• Systematic review of effects of drug exposures on biomarkers of nutritional status</td>
</tr>
<tr>
<td>• Maternal and infant microbiome profiles and mucosal immunity</td>
</tr>
</tbody>
</table>

**Inflammation in pregnancy and nutritional modulation of immune responsiveness**

- Investigation of epigenetic influences on fetal immune responses and relation to nutritional exposures
- Critical periods of susceptibility to the epigenome need to be identified in relation to peak gestational periods of exposure (e.g., gestational timing of period of undernutrition) or for infection; e.g., for *P. falciparum* malaria peak prevalence at 13–16 wk gestation in high-transmission areas
- Longitudinal studies in mothers and infants are required to identify the outcomes of these maternal exposures in their children in terms of clinical outcomes and inflammatory and nutritional biomarkers

**Characterization of nutritional and inflammatory biomarkers of risk**

- Characterization at birth of nutritional and inflammatory biomarkers to identify, through longitudinal studies, their relation with subsequent infant immunologic responsiveness, infection risk, nutritional status, and vaccine efficacy (this approach requires descriptive noninterventional studies and a focus on risk profiling in the first 2 y of life)
- Tests of development and cognition are relevant as additional assessment categories
- Characterization of inflammatory factors in subclinical and clinical mastitis that may influence postnatal infection transmission via breast milk (e.g., HIV) and that may directly influence infant mucosal immunity as well as the infant microbiome
- The role of oxidative stress biomarkers (F2-isoprostanes, oxidized LDL, malondialdehyde, hyperhomocysteinemia, NO, peroxynitrites, 8-oxodeoxyguanosine, reduced glutathione/oxidized glutathione, 4-hydroxy-2-nonenal, tyrosine nitration) and their nutritional modification in relation to pregnancy pathogenesis
- Evaluation of serum citrulline cutoffs in severely undernourished children as a recovery biomarker of the enterocyte cell mass and of fecal calprotectin as a biomarker of EE (calprotectin and other proxy markers should also be further assessed in less severely undernourished children)

summarized in Table 11. The following sections provide some additional details.

**a. WBCs.** Leukocytosis, an increase in the number of WBCs, has long been recognized as a nonspecific marker of systemic infection, tissue damage, allergic reaction, malignancy, or physiologic processes. Leukocytosis is classified according to the component of WBCs that contribute to an increase in the total number of WBCs; types include increased neutrophil count, lymphocyte count, monocyte count, eosinophilic granulocyte count, basophilic granulocyte count, or blastocyte (immature) cells. WBC count is routinely used clinically as an initial screening marker in patients with fever. Although most bacterial infections cause neutrophilia (≥10,000/mm³), the WBC and neutrophil counts alone are not sensitive or specific enough to accurately predict bacterial infection. Automated cell counter analyzers, common in many clinical laboratories, provide precise information on WBC counts as part of a complete blood count profile using only a small volume of freshly collected anticoagulated whole blood. Cutoff values for elevated WBC counts are age-specific and vary greatly (>11,000/µL in adults).

**b. CRP.** CRP is an APP produced in response to acute injury, infection, or other inflammatory stimuli. Because CRP concentration increases within 4–6 h of an insult and is a measure of underlying systemic inflammation, it has numerous clinical uses including detecting bacterial infection, autoimmune disease, and malignancy, as well as measuring response to treatment (714). CRP may also remain elevated in the presence of a continued, chronic inflammatory process [e.g., atherosclerosis, rheumatoid arthritis, and obesity (715)].

Clinically, 5 mg/L originally defined the limit of detection of the method of analysis, and 10 mg/L was accepted as the upper level of the normal range. To identify subclinical inflammation in apparently healthy people in population studies and in research, 5 mg/L has generally become accepted as the upper limit of the normal range (716). CRP is used (in combination with other risk factors) to define risk groups for CVD. The American Heart Association and the CDC defined CVD risk groups as follows: low-risk CRP, <1.0 mg/L; average risk, 1.0–3.0 mg/L, and high risk, >3.0 mg/L (717).

Small differences in normal CRP concentrations have been found relative to race, age, and sex (718–720); however, because CRP responses to inflammation are usually large, and these differences are small, they received little attention until the introduction of the new high-sensitivity CRP assay that allows measurement to concentrations of 0.3 mg/L, compared with 3 mg/L for the modern conventional assay. Population data from NHANES 1999–2002 indicate that concentrations of CRP are higher among women than among men (median: 2.7 vs. 1.6 mg/L, respectively) and increase with age [median: 1.4 mg/L (20–29 y) vs. 2.7 mg/L (>80 y)] but vary less across categories of age, sex, and race.
race or ethnic background (719). Later work by Cartier et al. (720) found that if CRP concentrations are adjusted for subcutaneous adipose tissue, the sex differences disappear, suggesting the greater subcutaneous fat in women to be responsible for the higher CRP concentrations.

The preanalytical stability of CRP in serum or plasma is excellent (11 d at room temperature, 2 mo refrigerated, 3 y frozen at −20°C) (721). No significant difference has been observed between samples collected either while fasting or nonfasting (722) and diurnal variation of CRP is negligible (723). Most CRP assays provide comparable results (724, 725), probably due to the availability of international reference materials and external quality assessment (EQA) programs to monitor the degree of variability and bias in laboratory assays (e.g., UK National EQA Service, US College of American Pathologists).

c. AGP. AGP is a slower reacting positive APP (see Table 10) (24). At birth, concentrations are low and increase slowly, reaching adult values by 10 mo of age (726).

The methods of analysis are similar to those for CRP. There is a certified human serum reference material [ERM-DA470/IFCC (727)] for calibration and since 2008 it has been possible to standardize methods against this. There is an EQA scheme available, which is run by Randox Laboratories Ltd. UK (728).

AGP is not commonly used in clinical situations but is used for assessing longer-term (>3 d) or subclinical inflammation in population studies. With the onset of infection or trauma, changes in plasma nutrient concentrations closely parallel those of CRP. As clinical symptoms disappear, CRP concentrations fall sharply, but nutrient concentrations (e.g., iron, vitamin A) do not respond as rapidly. Therefore, AGP, which remains elevated longer than CRP and may take 3–5 d to reach a plateau, is often used to monitor inflammation during this time period (24).

The combination of CRP and AGP has been used to detect those who have only recently been infected and who are not yet showing clinical evidence of disease (increased CRP only) and those who have recovered and are convalescing (increased AGP with or without an increased CRP). However, as mentioned earlier, the changes in CRP and AGP have been described on the basis of acute tissue injury secondary to surgical procedures, so it is unclear how CRP and AGP act in response to an infectious agent (24).

d. ESR. The ESR is defined as the rate at which erythrocytes suspended in plasma settle when placed in a vertical tube (mm/h) and is a nonspecific measure of inflammation that primarily reflects plasma viscosity. It is often assessed in low-resource settings with the use of an upright tube, but automated analyzers are also available. Despite its wide use, ESR has a number of disadvantages compared with other biomarkers (e.g., CRP), including slow changes in response to treatment and false elevation secondary to...
Concentrations of TNF are 7.5 higher in obese than in lean subjects (739). Increased concentrations have also been observed in smokers; in patients with type 2 diabetes, metabolic syndrome, and atherosclerosis; and in aging (739–741). TNF promotes endothelial activation, increasing vascular permeability; decreases insulin sensitivity; and contributes to the progression of atherosclerosis (742–744). Plasma concentrations of TNF predict the risk of myocardial infarction (745). The most common available methods for TNF measurement are ELISA and radioisotope-labeled immune assays. Cutoffs are not standardized, and the reference range can vary from 0.55 to 2.53 pg/mL (746).

**h. IL-6.** IL-6 has been classified as both a pro- and anti-inflammatory cytokine (747). It inhibits TNF production (748) and also stimulates the production of IL-1 receptor antagonist, IL-10, and soluble TNF receptors, which have anti-inflammatory effects (747, 749). IL-6 is released from contracting muscles during exercise, inducing lipolysis and fat oxidation and is involved in glucose homeostasis (689). The role of IL-6 in insulin resistance remains controversial. IL-6 can be measured by ELISA. Although IL-6 precedes the increase in CRP after exposure to bacterial infection, it has a very short half-life. Cutoff points vary in the literature from 25 to 150 ng/mL (750, 751).

**i. Conclusions.** In summary, numerous biomarkers of inflammation are available to detect acute, subclinical, and chronic inflammation in both clinical and public health settings. Table 11 summarizes the most commonly used biomarkers of inflammation. Text Box 42 contains a summary and some suggestions with regard to the available biomarkers of inflammation.

### VI. Nutrition and Inflammation: Specific Nutrient Perspectives

**a. Overview.** The myriad of causative factors and types of inflammation that need to be considered in the context of nutritional assessment were covered in the previous WG reviews

### TABLE 10 Acute phase proteins in response to an inflammatory event

<table>
<thead>
<tr>
<th>Acute phase protein</th>
<th>Acronym</th>
<th>Normal range</th>
<th>Amount of response to inflammation</th>
<th>Time to maximum response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Positive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>CRP</td>
<td>0.001–10 mg/L</td>
<td>20- to 1000-fold</td>
<td>24–48 h</td>
</tr>
<tr>
<td>α1-Acid glycoprotein</td>
<td>AGP</td>
<td>0.6–1.0 g/L</td>
<td>2–5 times</td>
<td>4–5 d</td>
</tr>
<tr>
<td>α1-Antichymotrypsin</td>
<td>ACT</td>
<td>0.2–0.6 g/L</td>
<td>2–5 times</td>
<td>24–48 h</td>
</tr>
<tr>
<td>Ceruloplasmin</td>
<td></td>
<td>0.3–0.4 g/L</td>
<td>30–60%</td>
<td>4–5 d</td>
</tr>
<tr>
<td>Haptoglobin</td>
<td></td>
<td>0.5–2.6 g/L</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td></td>
<td>1.9–3.3 g/L</td>
<td>30–60%</td>
<td>24–48 h</td>
</tr>
<tr>
<td>Serum amyloid A</td>
<td>SAA</td>
<td>~0.01 g/L</td>
<td>20- to 1000-fold</td>
<td>24–48 h</td>
</tr>
<tr>
<td>White blood cells</td>
<td>WBCs</td>
<td>&gt;11,000/μL (adults)</td>
<td>—</td>
<td>10 h</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>ESR</td>
<td>Age &lt;50 y: &lt;0.5 μg/L</td>
<td>Up to 100-fold</td>
<td>6–24 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Men, 0–15 mm/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women, 0–20 mm/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age ≥50 y: &lt;0.5 μg/L</td>
<td>Up to 100-fold</td>
<td>6–24 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Men, 0–20 mm/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women, 0–30 mm/h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procalcitonin</td>
<td>PCT</td>
<td>≤0.5 μg/L</td>
<td>200-fold</td>
<td>6–24 h</td>
</tr>
<tr>
<td><strong>Negative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transferrin</td>
<td></td>
<td>2.0–3.0 g/L</td>
<td>−30% to 60%</td>
<td>24–48 h</td>
</tr>
<tr>
<td>Albumin</td>
<td>Alb</td>
<td>35–50 g/L</td>
<td>−30% to 60%</td>
<td>1–2 wk</td>
</tr>
<tr>
<td>Prealbumin (transthyretin)</td>
<td>PAB</td>
<td>140–450 mg/L (depending on age)</td>
<td>−30% to 60%</td>
<td>24–48 h</td>
</tr>
<tr>
<td>Retinol binding protein</td>
<td>RBP</td>
<td>&gt;0.7 μmol/L</td>
<td>−26% to 40%</td>
<td>24–48 h</td>
</tr>
</tbody>
</table>

*Data adapted from references 24 and 682–684 with permission.*
and are briefly summarized in Text Box 43. Similarly, basic concepts with regard to the nature of the nutrient-inflammation relations were also covered previously by the INSPIRE WG reviews. The following sections cover the key features and challenges to interpretation presented by the inflammatory response of biomarkers of specific nutrients. The nutrients included below are those that have been addressed in the previous WG reviews, with a particular focus on the 6 nutrients that were covered under the BOND project: iron, zinc, iodine, vitamin A, folate, and vitamin B-12. These nutrients were selected for their public health importance and because the relations described represent the range of issues that the community needs to address when choosing and interpreting a nutrient or nutrients for clinical or population surveillance purposes. Vitamin D and hemoglobin are also covered because of their obvious importance to global health. The emphasis on these nutrients does not imply that similar effects are absent with other nutrients.

**b. Iron.** ID remains the most common micronutrient deficiency in the world, but the distinction of nutritional ID is often obscured by inflammation because the normal control of iron metabolism is disrupted by the primary mediators of the APR (i.e., TNF and IL-1) (752).

As outlined in Text Box 44 and reviewed in detail elsewhere [(753) and BOND iron review], a myriad of biomarkers exist that can be applied to the assessment of iron nutrition.

The BOND iron review can be found on the BOND website (30). The complexity of iron assessment led the WHO/CDC technical consultation on the assessment of iron status at the population level to compare the theoretical advantages for population-based surveys of the following 5 indicators of iron status: hemoglobin, serum ferritin, soluble transferrin receptor (sTfR), ZPP/erythrocyte protoporphyrin (EP), and mean cell volume (MCV) (26). The WHO/CDC consultation recommended serum ferritin as the single best indicator in areas where inflammation is less common and measuring sTfR in areas where inflammation is prevalent.

Hepcidin is a promising iron biomarker, because it is suppressed during ID and anemia but stimulated by inflammation, infection, and iron overload (754). Although hepcidin may be a sensitive marker for iron utilization and absorption, few data are available on hepcidin concentration and its relation to established iron markers in population studies. The relative strengths/weaknesses of other biomarkers of iron were previously reviewed (753).

**Links between inflammation and iron biomarkers: current guidance.** With the use of data obtained from NHANES for women 20–49 y of age, the following associations were reported (755):

- A weak positive association was seen between body iron and CRP (body iron 0.7 mg/kg higher when CRP is >5 mg/L)

- A strong positive association between ferritin and CRP (24% higher ferritin concentrations when CRP is >5 mg/L)

**TABLE 11** Summary of commonly used biomarkers of inflammation

<table>
<thead>
<tr>
<th>Biomarker of inflammation</th>
<th>Normal range</th>
<th>Settings where used</th>
<th>Clinical vs. population use</th>
<th>Use in resource-limited settings</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>4–11,000/µL</td>
<td>Acute inflammation (usually infection)</td>
<td>Clinical</td>
<td>Y</td>
<td>Varies by age</td>
</tr>
<tr>
<td>CRP</td>
<td>0.001–10 mg/L</td>
<td>Acute, subclinical, chronic</td>
<td>Clinical, population</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>AGP</td>
<td>0.6–1.0 g/L</td>
<td>Subclinical</td>
<td>Population</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>ESR</td>
<td>0–30 mm/h</td>
<td>Acute, subclinical, chronic</td>
<td>Clinical</td>
<td>Y</td>
<td>Increases with age and higher in females</td>
</tr>
<tr>
<td>Albumin</td>
<td>30–50 g/L</td>
<td>Acute inflammation (usually infection)</td>
<td>Clinical</td>
<td>N</td>
<td>Decreased during pregnancy</td>
</tr>
<tr>
<td>PCT</td>
<td>≤0.5 µg/L</td>
<td>Acute inflammation (usually infection)</td>
<td>Clinical</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>—</td>
<td>Chronic</td>
<td>Population</td>
<td>N</td>
<td>Use in aging</td>
</tr>
<tr>
<td>TNF-αR1</td>
<td>—</td>
<td>Chronic</td>
<td>Population</td>
<td>N</td>
<td>Use in aging</td>
</tr>
</tbody>
</table>

1 AGP, α1-acid glycoprotein; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; N, no; PCT, procalcitonin; TNF-αR1, TNF-α receptor 1; WBC, white blood cell; Y, yes.
A weak positive association between sTfR and CRP (4% higher sTfR concentrations when CRP is >5 mg/L) (755). Although the first 2 associations remained significant after controlling for certain covariates, the association for sTfR was no longer significant after controlling for age, sex, race/ethnicity, smoking, supplement use, fasting, and estimated glomerular filtration rate (eGFR). Of note, this population had a low prevalence of elevated CRP (~20%) and ID (10–19%); thus, these relations may be not be directly applicable to populations with a high prevalence of these conditions. Text Box 45 contains a summary of suggested approaches to iron assessment for populations.

**Anemia: hemoglobin.** Anemia remains a major and complex global health problem affecting one-quarter of the world’s population, most commonly women and preschool-aged children (756). One of the Global Targets for 2015 by WHO member states is a 50% reduction in the prevalence of anemia among women of reproductive age (757). The causes of anemia include inadequate dietary intake of micronutrients, most prominently iron, increased bodily demand for iron, inherited hemoglobinopathies, and infections (758). Hemoglobin is the main biochemical indicator of anemia and can be easily measured in surveys and in clinical settings by using a portable hemoglobinometer, such as the HemoCue (Radiometer Group) (759).

Although the relation between current or recent illness and anemia, the so-called “anemia of infection,” has been well characterized (760–763), the relation between biomarkers of inflammation and the prevalence of anemia is less studied. Several studies reported statistically significant relations between APP and anemia as shown in Text Box 46.

The current evidence suggests an association between APP and anemia, although the strength of the association appears to be less than that found between APP and other nutrient-specific biomarkers (e.g., serum ferritin). In addition, there may be other factors that may influence the strength of the association of APPs and anemia within a population, such as the overall prevalence of both anemia and inflammation. Although expert groups have provided guidance on adjusting hemoglobin concentrations for altitude and cigarette smoking, no such guidance has been provided on how to account for APPs.

A need exists for more research on the association between inflammation and anemia. In the interim, some authors have recommended that cross-sectional surveys that collect information on anemia and markers of inflammation present the prevalence of anemia both among those with and without inflammation, in addition to the overall prevalence of anemia and the prevalence of inflammation, in order to allow for comparisons between populations (764, 765).

c. **Vitamin A.** VAD remains a significant public health problem, primarily in preschool-aged children and pregnant women (770). The epidemiology of VAD was discussed in the WG 2 review and indicators of vitamin A have been reviewed extensively (BOND review) (30). Text Box 47 provides a summary of currently available biomarkers of vitamin A.

*Influence of inflammation on vitamin A assessment.* As outlined by WGs 1 and 2 and above, RBP is a negative APP (i.e., RBP decreases in the presence of an APR). Because RBP is the carrier protein for retinol, retinol concentrations also decrease in the presence of inflammation. Consequently, inflammation affects the interpretation of serum retinol and RBP.

Thurnham et al. (716) carried out a meta-analysis to calculate factors to adjust serum retinol concentrations for the presence of inflammation using CRP and AGP to define the stage of inflammation. In the presence of elevated CRP concentrations (>5 mg/L), serum retinol concentrations were 13% lower; in the presence of elevated CRP and AGP (>1 g/L), serum retinol concentrations were depressed by 24%, and elevated AGP concentrations alone decreased serum retinol concentrations by 11% compared with the normal (presumably uninflamed) group. Recently, the same factors were used to adjust RBP concentrations because of the good correlation between RBP and retinol. In NHANES data from adults, very similar results were obtained because there was a weak negative association between serum retinol and CRP (~10% lower concentrations of serum retinol when CRP was >5 mg/L) (755). This association was true for crude data as well as after controlling for age, sex, race/ethnicity, smoking, supplement use, fasting, and eGFR.

Although this proposed adjustment seems to work under conditions of nonspecific inflammation, this approach may not be applicable in all settings. For example, in a recent study from a malaria-endemic area, concentrations of RBP, after adjustment for inflammation, showed residual differences of ~0.09 µmol/L between apparently healthy preschool-aged children with and without *Plasmodium* parasites. This seems to indicate that the meta-analysis correction for inflammation may not completely adjust concentrations when malaria, as indicated by malaria parasitemia, is reported (774).

Because human milk has been suggested as a potentially useful biomarker of vitamin A status of women and, by extrapolation, of their children and potentially other groups...
within the population (324), it is useful to explore the potential impact of inflammation on the use of breast-milk vitamin A concentrations and interpretation. To date, limited evidence suggests that human-milk vitamin A is not susceptible to the influence of inflammation (775). However, recent data from a subset of women recruited as part of a national survey in Cameroon indicate that human-milk vitamin A concentrations (casual samples at $1\text{ mo postpartum}$) were associated with CRP, and this association seemed to be explained by a decrease in plasma RBP (776). The overall relation between inflammation, specific biomarkers such as CRP and human-milk vitamin A remains unresolved. In part, the ability to more definitively delineate this relation will be contingent on comparisons between populations of low vs. high prevalence of VAD.

d. Zinc. The importance of zinc to health and, more specifically, the immune system and the APR was described by WGs 1 and 2 and reviewed recently (371). With specific regard to zinc assessment, the current view of the international nutrition community as represented by the International Zinc Nutrition Consultative Group and WHO is that serum or plasma zinc concentration is the primary indicator for use in the assessment of zinc status of a population (375). Potential factors influencing the interpretation of serum/plasma zinc concentrations include age, sex, time of day of the blood collection, and the fasting status of the individual (371). Cutoffs have therefore been established for different age and sex groups and blood sampling conditions (777). In addition to plasma/serum zinc, a number of other biomarkers (listed in Text Box 48) have been identified and are at various stages of viability for either clinical or population-based use. With the exception of plasma/serum zinc, most are not widely used either clinically or for population-based surveillance.

**Influence of inflammation on zinc assessment.** As far as the potential impact of inflammation, it has been reported that zinc is shifted from the bone marrow into the liver during the

---

**Text Box 43 Specific signals that inflammation may need to be considered in the context of nutrient assessment**

- The type of inflammation (acute vs. chronic, clinical vs. subclinical, and etiologies of inflammation) may also be important to consider when evaluating the impact of inflammation on nutrition biomarkers.
- Acute inflammation is most commonly indicated by the presence of the following:
  - systemic bacterial infections,
  - tissue injury, and
  - allergies caused by food and environmental exposures.
- Conditions most often associated with the presence of chronic inflammation include the following:
  - gastrointestinal disturbances such as celiac and inflammatory bowel diseases and environmental enteritis,
  - obesity,
  - arthritis,
  - asthma, and
  - NCDs including diabetes, cancer, and CVD.
- Other individual factors, such as age, socioeconomic status, diet, and breastfeeding may influence the APR and therefore the pattern of inflammation.
- Specific environmental conditions may predict the presence of inflammation, including conditions found in resource-constrained settings/LMICs such as poor sanitation, poor water quality, and food safety concerns.
- In postpartum women, APPs remain elevated for some weeks after delivery.

---

**Text Box 44 Currently available indicators of iron status**

**Iron stores**
- Bone marrow iron
- Ferritin
- Body iron stores or transferrin receptor (TfR):ferritin ratio

**Iron supply**
- Serum/plasma iron
- Total iron-binding capacity
- Transferrin saturation
- EP or ZPP
- Reticulocyte hemoglobin concentration

**Functional iron deficit**
- sTfR
- Hemoglobin
- Hematocrit (or packed cell volume)
- MCV
- Mean cell hemoglobin
- RBC distribution width

**Experimental biomarkers**
- Hepcidin
- Non–transferrin-bound iron
when CRP is >5 mg/L) (755). Plasma total homocysteine, between RBC folate and CRP (374). The most commonly used available biomarkers of vitamin B-12 were also recently reviewed (785) and are summarized in the Text Box 49. The available biomarkers of vitamin B-12 have been inconsistent in the literature. Weak associations between CRP, AGP, and serum or erythrocyte folate have been reported but not consistently. Among adults in NHANES, there was a weak negative association between serum folate and CRP (374, 781). One potential alternative might be hair zinc concentrations, which were observed to be stable during acute infections in a few studies (782).

e. Folate. The role of folate in public health has been reviewed extensively (783). Of the currently available biomarkers, the most commonly used are serum folate, RBC folate, and plasma homocysteine concentrations. Text Box 48 provides a list of available biomarkers for assessing folate.

Influence of inflammation on folate assessment. The reported relation between markers of inflammation and folate biomarkers has been inconsistent in the literature. Weak associations between CRP, AGP, and serum or erythrocyte folate have been reported but not consistently. Among adults in NHANES, there was a weak negative association between serum folate and CRP (~5% lower concentrations of serum folate when CRP is >5 mg/L) and a weak positive association between RBC folate and CRP (~5% higher concentrations when CRP is >5 mg/L) (755). Plasma total homocysteine, which is elevated in deficiencies of folate, vitamin B-12, riboflavin, and vitamin B-6, may also be elevated in chronic inflammation states (784).

f. Vitamin B-12. The role of vitamin B-12 in health and disease was previously reviewed (785, 786). The available biomarkers of vitamin B-12 were also recently reviewed (785) and are summarized in the Text Box 50.

Influence of inflammation on vitamin B-12 assessment. None of the vitamin B-12 specific biomarkers, serum vitamin B-12, holotranscobalamin, and MMA, are correlated with CRP or AGP, even in populations with a high prevalence of acute infection (787). Comments on total homocysteine are the same as for folate in the preceding section.

g. Iodine. Iodine is a trace element required by the thyroid gland to produce thyroxine and tri-iodothyronine, thyroid hormones necessary for multiple processes related to normal growth and development. The biology including a review of all available biomarkers (Text Box 51) of iodine was recently completed (788).

Influence of inflammation on iodine assessment. Limited data exist to suggest an association between inflammation and urinary iodine. In NHANES (adults), a weak positive association was observed between urine iodine and CRP (~8% higher concentrations when CRP is >5 mg/L) for crude data, but the association was no longer significant after controlling for age, sex, race/ethnicity, smoking, supplement use, fasting, eGFR, and urine creatinine (755). Illness, including infection, sepsis,

Text Box 45 Approaches to iron assessment for populations

- The recommendation of the WHO/CDC consultative group for population-based iron assessment was a combination of the following:
  - Hemoglobin (with due recognition that there are other causes of anemia besides ID)
  - Serum ferritin and sTfR, and, where possible,
  - The serum concentration of an APP (e.g., CRP or AGP) (26).
- In places where there is little inflammation, serum ferritin concentrations are recommended as the best indicator of ID.
- If infectious diseases are seasonal, the survey should be done in the season of lowest prevalence.
- Another approach to adjust concentrations of ferritin for the presence of inflammation is to use correction factors based on CRP and AGP measurements, as proposed by Thurnham et al. (272).

Text Box 46 Significant relations between APP and anemia

- In a national cross-sectional survey in Papua, New Guinea, preschool-aged children, the prevalence of anemia was higher among those with elevated CRP, AGP, or both. Similarly, anemia was higher in the incubation and early convalescence stages of inflammation compared to children with no inflammation (764). There was a stronger association between elevated CRP and anemia than between AGP and anemia. Children with inflammation had a prevalence of anemia ~1.5 to 1.7 times higher than those without inflammation.
- A national cross-sectional survey in Nicaragua of preschool-aged children found that children with an elevated AGP were 1.4 times more likely to have anemia, controlling for age and mother’s educational level (765).
- In Marshallese children aged 1–5 y anemia prevalence was significantly higher among those with an elevated CRP or AGP than in those with a normal CRP/AGP (766).
- In a study in HIV-positive post-partum Zimbabwean women, those with an elevated AGP had significantly lower hemoglobin concentrations than those without elevated AGP (767).
- Nonmalarial inflammation (defined as elevated CRP and/or AGP without malaria) was the third most important risk factor for anemia in preschool-aged Kenyan children, after malaria and ID, controlling for multiple nutritional and demographic factors (768).
- Wieringa et al. (357) reported that infants with an elevated AGP had a slightly higher prevalence of anemia, although this was not statistically significant, and there was no association between elevated CRP and anemia.
- Gamble et al. (769) found no association in preschool-aged children (ages 1–5 y) between anemia and a combined marker of inflammation based on TNF-α and AGP.
Text Box 47  Currently available indicators of vitamin A  

- Night blindness: primary functional biomarker  
- Serum retinol:  
  o Retinol in serum measured by HPLC is the most widely used and accepted indicator for vitamin A status.  
  o Concentrations of retinol <0.7 μmol/L in children aged 6–72 mo indicates VAD (770, 771).  
  o Retinol is homeostatically regulated and is not a good indicator of status when there are adequate liver stores of vitamin A (770).  
- RBP:  
  o RBP is more stable than retinol.  
  o It can be measured by using an ELISA technique, which is a much simpler method than HPLC (772).  
  o RBP typically uses the same cutoff as for retinol, although population-specific cutoffs may be advisable because the RBP: retinol ratio is consistently <1:1 (773).  
  o Because it correlates well with retinol, RBP measurements can be used to estimate vitamin A status.  
- Breast-milk retinol (cutoff of ≤1.05 μmol or 8 μg/g milk fat) may reflect recent consumption rather than long-term status (324).  
- Relative dose response (RDR) (cutoff of ≥20%) (771)  
- Modified relative dose response (MRDR; cutoff ratio of ≥0.06)  
  o Both RDR and MRDR are susceptible to inflammation.  
  o MRDR and RDR tend to be used more in research situations rather than in population studies (771).  
- Retinol isotope dilution: although not widely used clinically or programmatically, this is the most sensitive biomarker of vitamin A status to live reserves of vitamin A.

...more text...
a. Considerations for clinical settings/point of care. As reviewed by WG 3, infection and inflammation can affect individual nutritional status through several mechanisms, including suppression of appetite, altered nutrient absorption and excretion, increased caloric requirements through altered metabolism, and nutrient-drug interactions. In a study that estimated the magnitude of the effect of inflammation on plasma micronutrient concentrations of hospitalized patients, for each micronutrient the change in plasma concentrations varied markedly from patient to patient (793). The authors concluded that, in the presence of moderate or severe systemic inflammatory response (CRP >20 mg/L), plasma concentrations of selenium, zinc, and vitamins A, B-6, C, and D were clinically uninterpretable. However, it was possible to interpret these micronutrients if the systemic inflammatory response was less severe: for zinc when CRP is <20 mg/L, for selenium and vitamins A and D when CRP is <10 mg/L, and for vitamins B-6 and C when CRP is <5 mg/L. In clinical settings, it may be best to re-evaluate the nutritional status of individuals when the inflammation has resolved. However, certain chronic disease conditions, such as short gut syndrome, feature a high prevalence of subclinical inflammation as well as rapid transit and malabsorption of nutrients, and thus a high risk of multiple-micronutrient deficiencies (794). Similarly, children in resource-poor settings who are exposed to frequent infections with associated anorexia are at risk of long-standing malnutrition of clinical significance. In such settings, regular, frequent monitoring of micronutrient status is needed and should be assessed with measurements of APPs, such as CRP.

b. Considerations for population-level surveys. Population-level estimates of micronutrient status are important for the implementation, monitoring, and evaluation of nutrition programs, as well as for comparisons between countries. Population-level interventions to address micronutrient deficiencies focus on the prevention of deficiency and shifting the population distribution of a biomarker (or reducing overall prevalence) rather than treating high-risk individuals. The effects of inflammation on population-level estimates of nutrition status are significant and can lead to distorted estimates of micronutrient deficiencies, either overestimating or underestimating the true prevalence, if inflammation is not accounted for in the analysis (357). Furthermore, the extent of the effect likely depends on the prevalence of inflammation and prevalence of the deficiency in the population.

Examples of where accounting for the effect of inflammation on micronutrient prevalence estimates would be helpful include the following:

• A country assesses the prevalence of a micronutrient deficiency, finds the prevalence is high, and implements a population-level intervention program, such as fortification, micronutrient powders, or supplementation. Another survey is performed at a later time to see if the prevalence of the micronutrient deficiency has decreased. If the prevalence of APPs differs between the 2 surveys, this could potentially mask an apparently effective intervention program or make an intervention appear to be successful when in fact it was not.
• In comparing countries or geographic areas within a country, decisions may be made to start intervention programs and/or allocate resources in areas with a higher prevalence of a micronutrient deficiency. If the level of inflammation differs between geographic areas, this may affect the prevalence of the micronutrient deficiency and

---

Text Box 48  Currently available zinc biomarkers/indicators

Plasma/serum zinc
- Most widely used
- May reflect recent meals rather than usual dietary intake
- Affected by inflammation

Potential alternatives
- Hair zinc
  - Potential alternative to plasma/serum zinc because it appears to be unaffected by inflammation
  - Offers technical challenges (sample collection, contamination, etc.)
- Urinary zinc

Emerging biomarkers
- Nail zinc
- Zinc-dependent proteins (e.g., metallothioneine)
- Oxidative stress and DNA integrity
- Zinc kinetics
- Functional biomarkers (e.g., taste acuity, neurobehavioral function)

Not useful
- Erythrocyte and leukocyte zinc (778)
- Zinc-dependent enzymes

Text Box 49  Currently available folate biomarkers/indicators

- Serum folate
- RBC folate
- Plasma total homocysteine
- Urinary folate/folic acid
- Urinary and serum p-aminobenzoylglutamate (pABG) and p-acetimidobenzoylglutamte (apABG); these are catabolites of folate oxidative metabolism.
result in inappropriate program interventions and/or allocation of resources.

Before deciding on approaches to account for inflammation, issues related to biomarker assessment must first be addressed, as follows:

- To assess the prevalence of micronutrient deficiencies, the methods used to collect, store, transport, and analyze the specimens must be performed with high quality. There are generally expert groups that provide guidance on the laboratory tests available, their advantages and disadvantages, laboratory quality assurance programs, and cutoff values to identify abnormal concentrations (e.g., WHO expert groups, International Council for Control of Iodine Deficiency, BOND).

- The quality of CRP and AGP measurements is also important, as is ensuring the quality of laboratory methods. One area that is in need of further investigation is to assess the relation between APPs and micronutrient biomarkers, each on their continuous scale (which may need to be transformed), and determine if there are clear cutoffs for the APP or if alternative methods to account for the APPs that do not rely on cutoffs are needed. Currently, one cutoff is used for CRP and/or for AGP and applied equally to all micronutrient biomarkers thought to be affected by inflammation, but this approach would benefit from further investigation.

- Some surveys measure only CRP, some only AGP, and some collect both. Strategies on how to deal with a variety of approaches based on these APPs from existing surveys are needed. If resources are available, measuring both CRP and AGP is preferred. If limited, either CRP or AGP should be measured, although further investigation is needed to determine, for each nutrient biomarker, whether CRP alone, AGP alone, or some combination of the 2 can account for inflammation.

**c. Review of proposed approaches.** Potential approaches to account for inflammation will be discussed in detail and include ignoring inflammation, exclusion of individuals with inflammation, adjustment of the biomarker cutoff values, correction factors, statistical approaches, and others. Again, the approach will depend on whether applied in a clinical or public health setting and the context or underlying prevalence of inflammation.

**i. Ignore inflammation.** This approach is used if APPs are not measured or APPs are measured but ignored in the analysis of nutritional status. Although this approach is currently used for some biomarkers of micronutrient status, it may result in an under- or overestimate of the prevalence of that micronutrient depending on the biomarker and the context. For the context issue, this would depend on the prevalence of the elevated APP and the strength of the association between the APP and the micronutrient biomarker. If the prevalence of the elevated APP is low, such as in many developed countries, then ignoring the prevalence of an elevated APP would likely have a minimal effect on the prevalence of the micronutrient deficiency. In populations with a high prevalence of elevated APPs, this could have a large impact on the prevalence of the micronutrient deficiency. In comparing 2 cross-sectional surveys within a country, it is often assumed that the prevalence of an elevated APP tends to change little within a country. However, there is little information available about how the prevalence of elevated APPs varies within a country over time. In countries with a low prevalence of elevated APPs, this is probably less of an issue. However, in countries with higher prevalence of elevated APPs, one might expect that the prevalence of elevated APPs may have seasonal variability due to the effect of infectious diseases and perhaps other factors that affect APP concentrations, such as programs to treat infectious diseases. For example, in 4 cross-sectional surveys conducted in preschool-aged children in the same 60 villages in Kenya in 2007–2010, the prevalence of elevated CRP varied from 10.5% to 48.2% (795).

**ii. Exclusion.** In this approach, those with an elevated APP are excluded from the analysis. An important issue is the cutoff used to define an elevated APP. For example, although a cutoff for CRP of >5 mg/L is typically used by investigators to define subclinical inflammation in nutrition surveys (716), a lower cutoff of >3 mg/L is recommended to define cardiovascular risk (796). Furthermore, it is not clear whether APP cutoff values should vary by nutrition biomarkers. The effect of the exclusion approach can be quite variable depending on the prevalence of the elevated APP and the strength of the association between the APP and micronutrient biomarker. In some countries, the prevalence of elevated APPs can be very low and therefore excluding them would have little effect on the prevalence of micronutrient deficiencies. However, in some areas, the prevalence of elevated APPs can be quite high, up to 60% or higher. Excluding those with inflammation can affect precision and, most likely, validity. For precision, in areas with a high prevalence of elevated APPs, the exclusion approach can dramatically lower the sample size and therefore reduce the precision of the prevalence estimate of the micronutrient deficiency.

**Text Box 51 Currently available iodine biomarkers/indicators**
- Urinary iodine concentration
- Thyrotropin
- Thyroglobulin
- Tri-iodothyronine and tetra-iodothyronine
- Goiter

**Text Box 50 Currently available vitamin B-12 biomarkers/indicators**
- Serum/plasma total vitamin B-12
- Serum holotranscobalamin
- Serum/plasma methylmalonic acid (MMA)
- Plasma total homocysteine
deficiency. Concerning validity, individuals with an elevated APP may be systematically different from those with a normal APP. In some settings, it is likely that those with an elevated APP are of lower socioeconomic status (SES), and by excluding them, the estimate of the prevalence of micronutrient deficiencies would be biased. For example, in Laos, the prevalence of elevated CRP in children was significantly different according to maternal education (797). Among preschool-aged children in Papua, New Guinea, those with an elevated CRP, AGP, or both were younger and more likely to be stunted or underweight (764).

iii. Use of different micronutrient deficiency cutoff values for those with and without an elevated APP.

In this approach, one cutoff value for micronutrient deficiency is used for those without an elevated APP and a different cutoff used for those with an elevated APP. For example, for serum ferritin, the cutoff for preschool-aged children is <12 μg/L; however, if the child is known to have inflammation, the cutoff value of <30 μg/L has been suggested (798). This is problematic because it does not account for varying degrees of inflammation (799). Furthermore, having different cutoffs may be confusing, because this does not provide a distinct international standard. One issue with this approach is that the cutoff values may differ by target group and even perhaps the context of the survey—for example, one performed in an area with a high level of malaria vs. a survey performed in an area without malaria—or may differ between developed and developing countries. Therefore, for this approach to be useful, context-specific cutoffs may be needed.

iv. Four-level inflammation correction factor approach.

This approach uses concentrations of CRP >5 mg/L and AGP >1 g/L to create the following 4 inflammation categories (272):

![TABLE 12](image)

### TABLE 12 Summary of key nutrient biomarkers

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Commonly used biomarker/indicators</th>
<th>Magnitude and direction of inflammation effect</th>
<th>Settings where used</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron</td>
<td>Ferritin</td>
<td>+++</td>
<td>Clinical, research, population</td>
<td>sTfR assays are not yet standardized and compare poorly</td>
</tr>
<tr>
<td></td>
<td>stTfR</td>
<td>+</td>
<td>Research, population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemoglobin</td>
<td>-</td>
<td>Clinical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Body iron</td>
<td>+</td>
<td>Research, population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ratio of TfR:ferritin</td>
<td>+</td>
<td>Research, population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TfR index</td>
<td>+</td>
<td>Research, clinical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ZPP</td>
<td>+</td>
<td>Clinical, population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepcidin</td>
<td>0</td>
<td>Research</td>
<td></td>
</tr>
<tr>
<td>Vitamin A</td>
<td>Retinol</td>
<td>-</td>
<td>Clinical, research, population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RBP</td>
<td>-</td>
<td>Research, population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast-milk retinol</td>
<td></td>
<td>Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retinol dose response test</td>
<td></td>
<td>Research</td>
<td></td>
</tr>
<tr>
<td>Zinc</td>
<td>Serum/plasma zinc</td>
<td>-</td>
<td>Clinical, population</td>
<td>Not reliable in clinical settings if patient inflamed</td>
</tr>
<tr>
<td>Folate</td>
<td>Erythrocyte folate</td>
<td>+</td>
<td>Clinical, population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plasma or serum folate</td>
<td>-</td>
<td>Clinical, population</td>
<td></td>
</tr>
<tr>
<td>Vitamin B-12</td>
<td>Serum/plasma total cobalamin</td>
<td>0</td>
<td>Clinical, population</td>
<td>Superior diagnostic performance of holotranscobalamin is controversial</td>
</tr>
<tr>
<td></td>
<td>Serum holotranscobalamin</td>
<td></td>
<td>Research</td>
<td>MMA assay is more expensive</td>
</tr>
<tr>
<td></td>
<td>Plasma/unirine MMA</td>
<td>0</td>
<td>Clinical, population</td>
<td>Elevated in both folate and vitamin B-12 deficiency</td>
</tr>
<tr>
<td></td>
<td>Plasma total homocysteine</td>
<td>+</td>
<td>Clinical</td>
<td>No known association with inflammation</td>
</tr>
<tr>
<td>Iodine</td>
<td>Urinary iodine</td>
<td>0</td>
<td>Population</td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td>25(OH)D</td>
<td></td>
<td>Clinical, population</td>
<td></td>
</tr>
<tr>
<td>Vitamin B-6</td>
<td>Plasma pyridoxal 5-phosphate</td>
<td>-</td>
<td>Research, population</td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>Serum ascorbic acid</td>
<td>-</td>
<td>Research, population</td>
<td>Freshly prepared serum needs to be promptly acidified with meta-phosphoric acid and frozen to stabilize ascorbic acid</td>
</tr>
</tbody>
</table>

1 MMA, methylmalonic acid; RBP, retinol binding protein; stTfR, soluble transferrin receptor; TfR, transferrin receptor; ZPP, zinc protoporphyrin; 0, no change; 25(OH)D, 25-hydroxyvitamin D; –, decrease; +, increase; ++++, major increase.
- Reference: normal CRP and AGP concentrations
- Incubation: CRP concentration is elevated but AGP is normal
- Early convalescence: both CRP and AGP are elevated
- Late convalescence: CRP is normal but AGP is elevated

A number of correction factors can then be derived on the basis of these 4 categories. For example, the ratio of geometric means of reference group (neither CRP nor AGP is increased) to those of the respective inflammation groups is calculated. The correction factor approach groups people with subclinical inflammation into “risk” categories depending on their relation with the time of initial infection and the period of clinical disease. This approach is suitable where the subjects are apparently healthy, that is, they show no evidence of symptoms requiring medical intervention and only demonstrate subclinical signs. For serum ferritin, correction factors calculated as part of a meta-analysis were also proposed (272). Overall, for the studies included in the meta-analyses, inflammation increased ferritin by ~30% and was associated with a 14% (95% CI: 7%, 21%) underestimation of meta-analyses, inflammation increased ferritin by ~30% and was associated with a 14% (95% CI: 7%, 21%) underestimation of ID. When applying the meta-analysis correction factors in an area endemic for malaria, concentrations of ferritin, after adjustment for inflammation, showed a residual difference of +12 μg/L between apparently healthy preschool-aged children with and without Plasmodium parasites. This observation indicated that the meta-analysis correction for inflammation might not completely adjust concentrations when malaria is reported (774). The correction factor approach has raised awareness of the effect of APPs on biomarkers of micronutrient status and has been applied frequently. Advantages of this approach are that it is easy to apply and is preferred in many situations to ignoring inflammation or exclusion. The disadvantages of this approach include the following: 1) the survey must have both CRP and AGP, 2) it does not account for possible effect modifiers and confounders (e.g., age, sex, SES), 3) it is applied assuming the current cutoffs for CRP and AGP are applicable to all biomarkers of micronutrient status, and 4) the net effect of the correction factor is that it results in prevalence estimates of micronutrient status similar to the exclusion approach when internal correction factors are applied. Compared with the exclusion approach, the 4-category inflammation model has better precision but is still subject to the potential biases that may occur when the exclusion approach is applied.

**TABLE 13** Summary of approaches to account for inflammation

<table>
<thead>
<tr>
<th>Approach</th>
<th>Description</th>
<th>Settings where useful</th>
<th>Pros</th>
<th>Cons</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ignore inflammation</td>
<td>APPs not measured or nothing done to account for APPs</td>
<td>1) Nutrient biomarkers that have no association with inflammation,</td>
<td>Easy</td>
<td>Biased estimate of nutrient status</td>
<td>May be ok when comparing 2 surveys in the same setting if concentration of APP is stable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) settings with low prevalence of inflammation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exclusion</td>
<td>Remove individuals with elevated APPs</td>
<td>Settings with low prevalence of inflammation</td>
<td>Easy</td>
<td>1) Relies on concrete APP cutoffs, 2) may lose sample size (precision), 3) may introduce bias (validity)</td>
<td>Need standard cutoffs for APPs; exclude based on which APP? (CRP ± AGP)</td>
</tr>
<tr>
<td>Change nutrient biomarker cutoff</td>
<td>Use different cutoff for nutrient indicator for those with inflammation (e.g., ferritin &lt;30 μg/L)</td>
<td>Single population with fixed effects</td>
<td>Easy</td>
<td>1) Does not account for varying degrees of inflammation, 2) cutoffs may differ by target group</td>
<td>Cutoffs need to be defined</td>
</tr>
<tr>
<td>Four-level inflammation correction factors</td>
<td>Use CRP and AGP to create 4 categories (no inflammation, incubation, early convalescence, and late convalescence)</td>
<td>No demographic differences between those with and without subclinical inflammation</td>
<td>Relatively easy</td>
<td>1) Need both CRP and AGP, 2) does not account for potential confounders and effect modifiers, 3) produces similar estimates as exclusion approach</td>
<td>Individual country CF vs. meta-analysis CF</td>
</tr>
<tr>
<td>Direct standardization</td>
<td>Apply weights to prevalence estimates</td>
<td>Covariates are measured</td>
<td>Accounts for continuous effect of inflammation on biomarkers</td>
<td>Difficult</td>
<td>May allow for comparisons between surveys</td>
</tr>
<tr>
<td>Regression modeling</td>
<td>Linear regression taking into account potential interaction and confounding to produce corrected micronutrient concentration to produce corrected micronutrient concentration that accounts for inflammation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 AGP, α1-acid glycoprotein; APP, acute phase protein; CF, correction factor; CRP, C-reactive protein.
v. Direct standardization. The direct standardization approach is commonly applied to comparing mortality statistics between geographic areas with different age distributions. A similar approach could be applied to the prevalence of micronutrient deficiencies by standardizing on the prevalence of elevated APPs. As with mortality statistics, there could be different standardized weights depending on whether the country is a developing or developed country. In addition, there may be different weights depending on the target group. The approach would be to calculate the prevalence of micronutrient deficiency in those with and without inflammation, then calculate a weighted prevalence estimate by using a “standard” prevalence estimate of inflammation (e.g., 30%). This approach does not correct for inflammation per se but allows for a more valid comparison of surveys over time within a geographic area or in the comparison of different geographic areas. That is, if the prevalence of inflammation was made to be the same in all surveys (taking into account development status and target group), a fair comparison could be made.

vi. Regression modeling. In the analysis of survey data, the relation between the micronutrient biomarker and APPs could be investigated through the use of linear regression. Linear regression is a statistical approach to model the relation between a scale dependent variable y and one or more explanatory variables denoted x. There may be a need to transform the micronutrient biomarker, so that it has an approximately normal distribution. A nonlinear impact of APPs on micronutrient biomarkers can also be accommodated by using generalized additive models. Regression modeling could also take into account potential interaction (i.e., the relation between the micronutrient biomarker and the APP is modified by a third factor) and confounding. The regression model could include, for example, covariates such as age, sex, anthropometry, and SES. Covariates can play 2 different roles in the regression models: they could predict the true nutrient concentration (i.e., nutrient concentrations under no inflammation) and they could modify the effect of inflammation on nutrient concentration. The modeling process would yield an adjustment equation for the micronutrient biomarker and would be applied to those with the elevated APP in order to remove the impact of inflammation. For example, to calculate an adjusted ferritin for the effects of CRP, one would use the slope of CRP from the regression as follows: adjusted ferritin = ferritin – CRP \times \text{slope}.

For anemia, a regression approach is commonly used to adjust individual hemoglobin values to account for altitude (802). This approach is used at the individual level to categorize an individual as anemic or not anemic and at the population level to estimate the prevalence of anemia adjusted for altitude.

Advantages to the regression approach are that it can account for the impact of covariates, and, unlike the correction factor approach, it adjusts for the impact of inflammation in a continuous manner, i.e., the higher the APP, the greater the net correction. It also does not rely on the use of specific cutoffs for APPs. If this approach is promising, it may be possible to derive an equation that would allow for the correction of various micronutrient biomarkers across all surveys, similar to correcting hemoglobin for altitude. A potential challenge is that the relations between CRP and/or AGP and different nutritional biomarkers are nonlinear. AGP increases only slowly after the initial trauma; therefore, AGP is rarely increased between the time of infection and the appearance of clinical signs. Thus, elevated AGP concentrations are only found during convalescence and probably show a reasonably stable (positive or negative) relation with the biomarker concentration. In the case of CRP, the concentration of this protein increases rapidly after infection and biomarker concentrations change in parallel (e.g., ferritin positively, retinol and RBP negatively). During convalescence, the relation is dampened—CRP decreases rapidly whereas some nutritional biomarkers return to normal more gradually. Thus, although AGP may lend itself to regression modeling techniques, the relation between CRP and micronutrients is more complicated because, depending on the point in time relative to the infection, the strength of the association might vary.

---

Text Box 53  Research priorities

- What biomarkers of inflammation should be used in different settings? There is a need to evaluate the utility of composite/aggregate markers of inflammation. In addition, better biomarkers of chronic inflammation and organ/tissue-specific biomarkers need to be developed. Research on the strength of the association between each micronutrient biomarker and CRP and AGP is needed. Some micronutrient biomarkers may change in response to inflammation more like CRP, some more like AGP, and others somewhere in between. What APP cutoffs should be used?
- Investigate the optimal APP cutoff value for each micronutrient biomarker. For each micronutrient biomarker, investigate various cutoff values for CRP and AGP that have the strongest relation with the micronutrient biomarker. This could be through receiver-operator characteristic (ROC) approaches or other approaches. It is possible that for each biomarker of micronutrient status, there could be a different cutoff value of CRP and/or AGP.
- Do the characteristic patterns of change in APPs differ according to inflammation etiologies (e.g., trauma, infection, subclinical infection)?
- Are the type, level, and duration of inflammation important?
- Are there settings where inflammation can be ignored?
- What are potential confounders of inflammation in different settings (age, sex, SES, stunting, malaria, HIV, tuberculosis, etc.)? In assessing the association between micronutrient biomarkers and APPs, it is important to determine if the association is modified or confounded by other factors, such as age, SES, infections, and malnutrition. Ignoring effect modification and confounding could lead to less than optimal ways to account for APPs in assessing micronutrient status.
- What is the role of inflammation on the nutrient content of breast milk?
- Longitudinal studies of otherwise healthy, inflamed individuals (e.g., vaccine response)
- Is a modeling approach feasible and valid to address the inflammation and nutrition association?
- Longitudinal collection of inflammatory and nutrient biomarkers and morbidity data with or without an accompanying nutrient intervention
- Standardization of inflammatory biomarkers
Kung’ et al. (803) used regression modeling to adjust for the influence of APR on iron status indicators. A recent article (804) developed a regression approach to account for inflammation and compared it with the correction factor approach. This study found a similar prevalence of ID by using the 2 approaches. However, these regression approaches did not model the impact of covariates. The regression model formulation and the underlying assumptions for valid adjustment are not clear in these approaches. More work is needed to develop statistical approaches that rigorously model the relation between micronutrient markers and APPs, and the impact of the covariates on them. Such models would possess well-characterized inferential properties (e.g., bias, SE) and transparent assumptions.

To further evaluate approaches to account for inflammation, the CDC, the Global Alliance for Improved Nutrition, and the NICHD have formed a collaborative research group called Biomarkers Reflecting Inflammation and Nutrition Determinants of Anemia, which is conducting secondary analysis from nationally and regionally representative nutrition surveys (805).

VIII. Conclusions and research priorities. In summary, although several approaches to account for inflammation have been proposed in the literature, there is currently no consensus on a single preferred method (Table 13). Nevertheless, the effect of inflammation on nutrient biomarkers cannot be ignored, and we recommend that at a minimum one or more biomarkers of inflammation be measured in assessments of nutritional status in populations with a known or suspected moderate-to-high prevalence of inflammation (as measured by elevated APPs). Although there is no current consensus on which inflammatory biomarker to use, we recommend at a minimum measuring CRP, because it is feasible to measure and data are available on its relation to nutrient biomarkers. The addition of AGP as a measure of longer-term inflammation is probably useful in most settings and should be measured with CRP if resources are available. The ideal cutoffs for CRP and AGP need further investigation and may not be the same in all settings and for all nutrient biomarkers.

In settings with a considerable prevalence of inflammation, the exclusion approach may result in biased prevalence estimates and will reduce precision. The correction factor approach is being more readily used and is relatively simple to apply to data sets. However, it may not be applicable in all settings. Further investigation into regression modeling appears to be warranted, because it is less subject to bias and allows for continuous correction of inflammation, even at levels below traditionally used cutoffs.

Until more work is done to achieve consensus on approaches to account for inflammation (see research priorities in Text Box 53), we recommend presenting data on the prevalence of micronutrient deficiencies in the population overall, and presented separately for those with inflammation and those without inflammation.

Acknowledgments

The INSPIRE Consultative Group includes the following collaborators: Namanjeet Ahluwalia, Tahmeed Ahmed, Lindsay Allen, Melinda Beck, Helene Blanchard, Eleanor Brindle, Kenneth Brown, Philip Calder, William Checkley, Kate Claycombe, Christian Coles, Fabian Esamai, Henrik Friis, Elizabeth Gardner, Steve Grinspoon, Richard Guerrant, Marc Hellerstein, Janet Hunt, Janet King, Kirk Klaping, Bas Kramer, Kristine Koski, Christine Northrop-Clewes, Christine Pfeiffer, Andrew Prentice, Manuel Ramirez-Zea, Patrick van Rheenan, Lothar Rink, Suman Srinivasa, Christine Stabell Benn, Charles Stephensen, Parminder Suchdev, Kevin Sullivan, David Thursham, Ravi Varadhan, Andre van der Ven, Jeremy Walton, and Jeff Xia. The Scientific Steering Committee includes the following contributors: Bernard Brabin, Ian Darnton-Hill, Cindy Davis, Rafael Flores-Ayala, Gilman Grave, Janet Hunt, Klaus Karmer, Simin Meydani, Andrew Prentice, Daniel Raiten, Catherine Ross, Pamela Starke-Reed, Charles Stephensen, Ben Van Omme.

We acknowledge the contributions of the INSPIRE Consultative Group and Scientific Steering Committee. We thank Hal Drakesmith for the material provided. We also acknowledge the contributions of the staff of the Pediatric Growth and Nutrition Branch, including Dr. Gilman Grave, Ms. Alexandra Porter, Ms. Tamika Gillum, Ms. Helene Blanchard, and Ms. Meaghan Jones without whom this project could not have been successfully completed. DJR and FASA were responsible for synthesizing and summarizing the results of the INSPIRE workshop and the WG deliberations; they represent the INSPIRE Project Secretariat and were responsible for the content of this manuscript; ACR and SNM were responsible for reviewing content; HDD, CBS, BJ, PSS, and BvO were responsible for their respective WG contributions; and FASA, ACR, SNM, CBS, BJ, and PSS were responsible for harmonizing content throughout the manuscript. All authors read and approved the final version of the manuscript.

References

42. van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012;18:2018–25.


Schuster GU, Kenyon NJ, Stephensen CB. Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. J Immunol 2008;180:1834–42.


1100S Supplement


633. Imhof-Kunsch B, Briggs V. Antihelminthics in pregnancy and mater-


Goppelt-Streube M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxgenase/PGE isomerase. Br J Pharmacol 1998;99:1287–95.


